[{"article": "Creams containing corticosteroids are also often prescribed to eczema patients, but they come with harsh side effects, and patients usually can't tolerate them for long periods of time.\nExperts say there is more research to be done, but that the goal of the trial is to discover the best combination of bacteria to clear eczema from the skin and then make it available to patients as a prescription cream.\nA new clinical trial is testing a natural treatment that researchers hope will provide a long-term solution for those dealing with the dry, itchy and painful skin that comes with chronic eczema.\n\"There are over 1,000 species of bacteria that all live in balance on healthy skin, some that even produce natural antibiotics.\nResearchers hope that using the bacteria-infused cream will offer a long-term solution where other treatments fall short.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "It\u2019s mentioned that \u201cthere is more research to be done\u201d but it\u2019s unclear whether any people have thus far been tested. The release also alludes to a future safety trial and a larger study \u201cto see if the benefits of bacterial cream can truly provide a permanent solution for eczema patients.\u201d This is a far cry from the claims that this cream \u201crestores the natural balance of healthy skin,\u201d and has the potential to be \u201ca long-term solution.\u201d\nThere\u2019s no indication that any preliminary results have been peer-reviewed, published, or presented at medical conferences. We\u2019re only given the anecdote of one woman, but nothing about her response to the treatment.\nThe news release is clearly jumping to describing a new treatment that sounds beneficial without any evidence at all.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061008/16healthwatch.htm was not found on this server.", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "This story reported on a study that found an association between cola intake and bone mineral density in women but not men. The results of the study do not imply that decreasing cola intake will improve the bone mineral density of an individual. The nature of the data in the study was not specified. The study authors were careful to point out that total calcium intake, a factor well-documented to affect bone mineral density, was lower in women with the highest cola intake. It is valuable for readers to know when observations come from a single study (as in this case) or have been replicated in numerous studies in large groups of people. It would also have been valuable to explain that the association observed between cola consumption and bone mineral density in the group of women studied could have come from other differences between the groups consuming more and less cola.", "answer": 0}, {"article": "For those with this type of IBS, symptoms can include abdominal pain, bloating, and changes in bowel function such as diarrhea.\nThe study looked only at those IBS patients with the non-constipation form, he tells WebMD.\nThat can translate to big changes in the lives of those with IBS, estimated to affect about 15% of adult Americans.\nWith the drug treatment, Pimentel says, those with the IBS ''can enjoy social outings without the worry of having to run to the bathroom and having diarrhea.\"\n''The major finding was that all IBS symptoms improved,\" says Mark Pimentel, MD, director of the GI Motility Program at Cedars-Sinai Medical Center, Los Angeles, who led the clinical trial of the drug at Cedars.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story does an adequate job explaining how the research was done, and had appropriate caveats from an editorial author.", "answer": 1}, {"article": "The decrease we saw was larger than is seen with the currently used medications,\" Lanctot said.\nTUESDAY, July 24, 2018 (HealthDay News) -- The active ingredient in pot that gets you high can calm agitation in people with advanced Alzheimer's disease, a small new study suggests.\nThe study was to be presented Tuesday at the Alzheimer's Association meeting in Chicago.\nMarinol is now being tested for its usefulness in treating Alzheimer's symptoms, Lanctot said.\nHowever, many study patients suffered from sedation due to the drug, noted Keith Fargo, director of scientific programs and outreach at the Alzheimer's Association.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story was clear about the preliminary nature of this trial, and how many patients were enrolled. A source urges the need for a larger trial.\u00a0 We are also glad that HealthDay repeatedly used this sentence, which it often does when reporting from medical meetings:\nThe study was (to be) presented Tuesday at the Alzheimer\u2019s Association meeting in Chicago \u2026 research presented at medical meetings is considered preliminary until published in a peer-reviewed journal.", "answer": 1}, {"article": "Researchers conducted a randomized, double-blind, placebo-controlled study of 40 postmenopausal women ages 45 to 65 with high blood pressure.\nThe lead author, Sarah A. Johnson, a postdoctoral researcher at Florida State University, said she saw no reason for people to radically change their diet, but that if they are not eating blueberries, they might want to try them.\nThe improvement, the scientists write, was moderate compared with that of blood pressure medicines.\nThere were no significant changes in the placebo group.\nThe others consumed an identical-looking and tasting placebo.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story includes reasonable details about who was studied and how, but it includes no language that would clue readers into the significant limitations of this study, particularly the fact that it was very small, of short duration, and looked at a surrogate marker of heart disease risk. It would also have been nice to include some discussion of what the reported reduction in blood pressure might mean in terms of someone\u2019s overall cardiovasular risk.", "answer": 0}, {"article": "\u201cBut it is definitely a breakthrough.\nThe study\u2019s authors noted that patients would need to stay on the drug in order to receive protection against the allergy.\n\u201cOur hope when we started the study was that by treating patients with the equivalent of one peanut per day, many would tolerate as much as two peanuts.\n\u201cReactions from the oral challenges at the end of the study were much milder than prior to treatment,\u201d Tilles said, according to EurekAlert.\nIn addition, the symptoms caused by the 100-fold higher dose at the end of the study were milder than the symptoms on the lower dose at the beginning of the study.\u201d\n\nEXPERTS: CHILDREN AT RISK OF LEAD POISONING IN CHATTANOOGA\n\nWith FDA approval this drug would mark the first treatment available by prescription for peanut allergies.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story notes how many study participants there were and explains this is \u201cnot a cure\u201d and that patients would need to stay on the drug in order to be protected. However, we expect some exploration of the study\u2019s strengths or weaknesses, including caveats such as the degree of commitment needed to comply treatment regime.", "answer": 0}, {"article": "Weekly yoga classes relieve symptoms of low back pain about as well as intense, regular stretching sessions, a new study shows.\nThe study is the largest and most thorough to date to look at whether yoga has an effect on chronic low back pain, a problem that affects millions and has no surefire long-term remedy.\nMore than half of the subjects in each group improved on measurements of function by at least 50 percent, compared with less than a quarter of the controls.\n\u201cCompared with self-care, yoga and stretching class participants were significantly more likely to rate their back pain as better, much better or completely gone at all follow-up times,\u201d the study noted.\nA number of earlier studies suggested that regular yoga classes might benefit back pain sufferers, though most were limited by small sample sizes, short study periods and other flaws.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The article adequately described the randomized controlled trial and its results. However, it did not adequately describe the limitations of this trial\u2014which looked primarily at subjects with mild-to-moderate uncomplicated chronic back pain. It is not clear that the study conclusions apply to individuals with more severe back pain.\n\n\n\n\n\n\n", "answer": 0}, {"article": "Merck suffered a setback last year when its attempts to win marketing approval to sell Erbitux in lung cancer were rebuffed by regulators.\n\u201cThis study clearly opens the field ...\nSales last year were $1.7 billion.\nDr. Fabrice Andre from Institut Gustave Roussy in Villejuif, France, who was not involved in the research, said the results were \u201cextremely important\u201d but echoed the view that the findings now had to be confirmed in larger-scale clinical tests.\nThe Phase II study included 173 women whose cancer had spread and who had received other treatments.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "", "answer": 0}, {"article": "Marie Brown chose to undergo the procedure and credits Orbera for helping her lose over 20 pounds in three and a half months.\nOrbera is not covered by insurance and costs $8,000.\nDr. Prem Chattoo, a New York based gastroenterologist, told FoxNews.com that the balloon is placed it into the stomach through the mouth.\nChattoo said that even if the balloon were to pop, the saline would be absorbed and pose no harm to the patient.\n\u201cWe might be able to prevent young, healthy people from having these chronic diseases like diabetes and hypertension,\u201d Chattoo said.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "Other than one patient\u2019s testimonial, the story offers no evidence that Orbera works at all. That\u2019s about as unsatisfactory as it gets.", "answer": 0}, {"article": "\"A five-millimeter distance will make you either overexposed or underexposed,\u201d he explained.\nAlthough there are no large-scale national results, doctors say studies have shown brachytherapy to be as effective as traditional radiation therapy.\nI think most patients want to get their treatment done as quickly as possible.\u201d\n\nAlgan said he doesn't extol one technique over the others; all are acceptable depending on the patient.\nOU Physicians Radiologist Dr. Ozer Algan said a national study of brachytherapy's effectiveness compared to treating the entire breast is underway, but it will be several years before results are published.\nNot all communities offer radiation treatment, so women often must travel to receive it.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The article presents no evidence about the efficacy or safety of the technique beyond the reports of two individuals who received it and oncologists\u2019 comments about it. \nThe reporter writes, \nAlthough there are no large-scale national results, doctors say studies have shown brachytherapy to be as effective as traditional radiation therapy. \nIt is not clear who these doctors are or what studies they are referring to. This is not satisfactory. \u00a0\nThere are more data avialable on safety and efficacy, though not conclusive. In fact, a reporter for the Pittsburgh Post-Gazette did a story on the same topic a week earlier and found considerable data to report. ", "answer": 0}, {"article": ".\nOn that basis, the authors recommend that techniques such as the Boston modification of Robertson technique should be preferred by surgeons seeking to avoid pseudoptosis.\nThis study provides an anatomical foundation for why our technique may yield better, longer-lasting results.\"\nIn all patients, only one reduction technique was performed per patient.\nThe paper, The Sternum-Nipple Distance is Double the Nipple-Inframammary Fold Distance in Macromastia, is published Ahead-of-Print online in the Annals of Plastic Surgery.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The release presents the broad overview of the research \u2014 the type of study, number of patients involved and the type and frequency of the procedure used in the analysis.\u00a0 The vast majority \u2014 92 percent \u2014 of procedures used the Wise procedure. This provides a very lopsided picture of the outcomes.\nWhile the release may correctly state that the study gives additional support for the idea that the modified Robertson technique may be superior to the Wise method, it doesn\u2019t demonstrate this definitively. The quality of the evidence is not satisfactory in terms of backing up the claims that the procedure is superior. A prospective clinical trial would be needed to prove this.", "answer": 0}, {"article": "\"It's a very important trial,\" added Dr. Angeles Alvarez Secord, associate professor of gynecologic oncology at Duke Comprehensive Cancer Center in Durham, N.C. \"I've been using [the IUD] clinically for several years now for this purpose in patients who desire future fertility and some patients who cannot undergo surgery or who are at high risk for surgical complications.\nBakkum-Gomez has also used the method in her practice and is conducting a study of the IUD, which was originally designed as a contraceptive device, for this purpose.\nNine of the women in the study successfully delivered babies.\nThe IUD was removed at the end of the year if there was no evidence of cancer.\nThe majority of these women have not yet had children, according to background information in the article.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story provides important details about the current study that help the reader evaluate the strength of the evidence. It even emphasizes that the new treatment approach is \"still uNPRoven\". ", "answer": 1}, {"article": "Bladder cancer is the fourth most common cancer in men, but it is less common in women.\nDr. Gupta added that the study provides evidence demonstrating that the robotic approach performs at least as well as the open approach.\nResearchers wrote that the findings \"underscore the need for further high-quality trials to assess surgical innovation before this surgical technique is widely adopted in clinical practice.\"\nBut apart from the RAZOR trial, there have been no prospective, randomized multicenter trials to assess how robotic surgery compares to open surgery in cancer survival.\nThree Loyola Medicine urologists, Marcus Quek, MD, Gopal Gupta, MD, and Alex Gorbonos, MD, are co-authors of the study.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "In a way, the release is satisfactory and yet maddeningly unsatisfactory. It tells readers that the study was a randomly controlled trial with 350 patients, but it buries the most important point: that the ability of these researchers to do this sort of rigorous trial comparing robot-assisted surgery with open techniques highlights how few such trials are done. Deep in the release, the researchers are quoted as saying the findings \u201cunderscore the need for further high-quality trials to assess surgical innovation before this surgical technique is widely adopted in clinical practice\u201d and further that \u201cIt is important to conduct these trials before widespread adoption of technology, as has been the case with robotic prostatectomy (removal of the prostate).\u201d The quality of the evidence should have been the lead.", "answer": 1}, {"article": "A study of more than 20,000 patients with traumatic injuries and at risk of bleeding to death found those who were treated with tranexamic acid were significantly less likely to die than those who got a placebo.\nAnd the result is a life saved.\nThat improvement may not seem so dramatic, but drug is pretty easy to give -- an initial 10-minute infusion within 8 hours of injury, followed by a second infusion over 8 hours.\nIt doesn't cost much.\nAlso, there was no difference in deaths from clots blocking blood vessels in either group, a potential safety concern for the medicine.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story provides the bare essentials noting the outcomes in absolute numbers and in number needed to treat.\u00a0 Unfortunately, several important facts were not\u00a0reported\u00a0including the number of sites involved, the number of countries and other essential attributes of the study. Nonetheless, we\u2019ll give it the benefit of the doubt. ", "answer": 1}, {"article": "\u201cIt may provide more of a one-stop shop.\u201d\nThe developer, Ironwood Pharmaceuticals, said the drug, linaclotide, met all the goals in the first late-stage trial testing it as a treatment for the type of irritable bowel syndrome accompanied by constipation.\nLaxatives can relieve the constipation but often do not help with the pain, said Dr. Chey, who is a consultant to Ironwood.\nIf the drug succeeds in a second Phase 3 trial, with results expected by the end of the year, Ironwood plans to file for regulatory approval next year.\nAn experimental drug can reduce abdominal pain and increase bowel movements in people with irritable bowel syndrome, a condition that affects millions of Americans, the drug\u2019s developer said Monday.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story hit most of the issues\u00a0we wanted to\u00a0see addressed with respect to the study, including\u00a0number of patients,\u00a0the type of intervention, length of follow-up and outcomes measures. But it glossed over the fact that the study results appear to have come directly from the manufacturer of the drug being studied and not from a peer-reviewed journal or even the researchers who conducted the study.\u00a0The drug manufacturer obviously has a strong incentive to present the results in the most positive possible light and avoid any\u00a0critical analysis. It was incumbent on the story to provide some cautionary language about the preliminary nature of the findings and lack of peer review.\u00a0\u00a0 ", "answer": 0}, {"article": "While the study offers insights on managing the disease, there's not enough evidence yet on whether HGH treatments could extend the lives of those with cystic fibrosis.\nThe disease also affects the pancreas, making it difficult for the body to absorb food, which significantly stunts growth and often leads to early deaths.\nThat growth also resulted in larger internal organs, particularly the lungs, making breathing easier.\nThe study, published Monday in the journal Pediatrics, was produced by the UConn/Hartford Hospital Evidence-based Practice Center and was funded by the U.S. Department of Health and Human Services.\nLungs are clogged with a thick mucus, which can lead to lung infections.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "", "answer": 0}, {"article": "The study comes a month after Gov.\nDr. William Zoghbi, director of Methodist Hospital's Cardiovascular Imaging Institute, said the cancer risk numbers reported in the study are actually fairly low compared to other tests that take X-rays of the chest area, such as a regular CAT scan or coronary angiography.\nThey say the test's value is limited because it doesn't identify which plaque are stable and which could rupture and cause a heart attack.\nOne Houston doctor said that there was just one scanner in Houston in the mid-'90s, and now the $1 million machines are all over the city.\nThe study offers the most definitive estimate yet of the cancer risk from the radiation exposure that comes with increasingly popular CT scans, which provide pictures of the heart's arteries and quantify the risk of heart attack in people without symptoms.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "\n\n\nThe story does a good job of summarizing the results of this study of potential cancer risk from CT screening. In addition, it outlines the positions of experts and organizations on the broader body of evidence on the use of CT scans to identify people who may have plaque buildups in their heart arteries.\nIt would have been better if the reporter stated that the estimate was based on several assumptions, that it wasn\u2019t a definitive point estimate, but just the center of a range, and that it was higher than earlier estimates. Readers still got the point that there is a cancer risk which needs to be considered.\u00a0 ", "answer": 1}, {"article": "Jean-Charles Sanchez says.\nYet 90% of these patients will be able to return home safely, as no trauma has been detected.\nHis team has developed a rapid diagnostic test (POCT) called TBIcheck, inspired by the principle of pregnancy testing: by placing a single drop of blood on the well of a small 5cm plastic case, the patient knows within 10 minutes whether there is a risk of mild trauma, namely whether or not his H-FABP level is higher than 2.5 nanograms per millilitre of blood.\n\"Biomarkers are a mine of information on patients' state of health, it is up to us to decode them,\" concludes the Geneva researcher.\nThese results, patented by UNIGE and awarded the Prix de l'Innovation Academy in December 2017, will be marketed from 2019 by ABCDx, a start-up founded four years ago by Jean-Charles Sanchez of UNIGE and Joan Montaner of Vall d'Hebron Hospital in Barcelona, co-authors of this study.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "There was no data on the accuracy of this test. How often does it falsely give a negative result? And how often are people referred for further testing or evaluation when they don\u2019t have an injury? The news release didn\u2019t say.\nMore importantly, it doesn\u2019t appear that this test has been studied in a randomized clinical trial, so there\u2019s no evidence that patients who use it would have better outcomes or reduced costs compared with patients who are treated using current practices. That wasn\u2019t explained in the news release.\nThe published study provides the sensitivity and specificity of the test but these results are only hinted at in the news release.", "answer": 0}, {"article": "Scientists have used a form of stem-cell therapy to improve survival rates for the most severely sick lupus patients, a group that usually has no remaining treatment options.\n\nLupus is an autoimmune disease that attacks an individual's own organs, causing symptoms that range from swollen joints and skin rashes to severe damage to kidneys, lungs and other parts of the body.", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The article explained that the study it reported on was small and that the results were \npreliminary and did not contain a control group for comparison.", "answer": 1}, {"article": "So patients are caught in the middle.\"\nIn an editorial accompanying the new paper, another addiction and pain specialist, William C. Becker, Ph.D. of Yale University and the Connecticut VA, notes that the new results are even more impressive because ImPAT was compared with another psychosocial approach.\nAnd the study's authors note that the ImPAT approach has the potential to be easily and inexpensively adopted by addiction treatment centers and groups worldwide, through team members trained in standard psychological techniques.\nANN ARBOR, Mich. -- It's a Catch-22 with potentially deadly consequences: People trying to overcome addiction can't get treatment for their pain, because the most powerful pain medicines also carry an addiction risk.\nThe newly published study did show that one in five veterans randomly assigned to ImPAT or the comparison approach did not actually attend any sessions - likely because of delays in getting the sessions going.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The release makes a good effort at describing the study, though the language is a little confusing. Altogether, there were 129 patients in the study. The release tells us that half were in the ImPAT group, while the other half had conventional group therapy. The release describes ImPAT and offers an overview of patient demographics. The information is distributed throughout the release, which is what makes it confusing. However, it appears to be a good-faith attempt to describe the work openly for readers, so we\u2019ll give it a Satisfactory rating.", "answer": 1}, {"article": "\u201cI was exhausted all the time, from the time I woke to the time I went to bed,\u201d says Turner.\nFor Kothare, the out-of-pocket expense for the device, the risks of surgery, plus the potential for the mechanism \u2014which moves the tongue forward \u2014 to break, doesn\u2019t make it a viable option for everyone.\nWhat's more, a recent study in the New England Journal of Medicine found that the bulky CPAP machines \u2014 standard treatment for many patients with sleep apnea \u2014 doesn't help prevent heart attacks or stroke, although it does help patients sleep better and improve mood.\n\u201cAnd then the doctors looked piece by piece, and realized that what I have is sleep apnea.\u201d\n\nTurner\u2019s nightly interrupted breathing increased her chances of heart attack or stroke by three to four times, according to Dr. Robson Capasso, associate professor of Otolaryngology Head and Neck Surgery at Stanford University.\nI thought since I'm older so that's what it is.\u201d\n\nIt wasn\u2019t until a mother-daughter vacation that Turner\u2019s daughter noticed something interesting when her mother slept.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The evidence underpinning this implantable technology should have a fairly high bar, given that it is invasive, expensive, and there are already a range of\u00a0effective ways to treat sleep apnea\u00a0that helps many people. There is, however, no information about how reliable the\u00a0assertions of this new technology are and the details on the quality of evidence expressed in this story is minimal. From what we can tell, there are a handful of studies on this new device.", "answer": 0}, {"article": "Actinic keratoses are typically red, scaly skin lesions that can over time develop into a type of skin cancer.\nThe new study was funded by Picato manufacturer LEO Pharma.\nThe short duration also makes people more likely to stay the course, another advantage, according to the study's authors.\n\u201cThe shorter application period is what makes ingenol mebutate a breakthrough in the treatment of actinic keratosis,\u201d researcher Mark Lebwohl, MD, says in a news release.\nHalf got the new gel and the other half received an inactive placebo.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "In providing information on how the gel performed versus placebo, the story failed to note anything about how this evidence stacks up against other available topical treatments. We did appreciate that the story provided some quantification of the purported benefits of the gel. But without context about the study\u2019s design and limitations, those numbers can be very misleading to readers. Is two months an adequate time to measure the effects of a treatment like this? How was the trial controlled? With the consultation of even one independent expert, the story could have filled in many of these gaps.", "answer": 0}, {"article": "Uterine fibroid embolization (UFE) is a less invasive option that involves injection of an embolic agent, typically made up of very small beads, into the uterine arteries to block the blood supply to the uterus and fibroids.\nThe researchers are continuing the treatments and compiling data.\nThe procedures had a clinical success rate of approximately 79 percent for fibroid-related symptoms.\nFor the new study, Dr. Pisco and colleagues assessed pregnancy rates in 359 women with uterine fibroids who were unable to conceive and who underwent either conventional or partial UFE.\nIt was the first pregnancy for more than 85 percent of the women who gave birth.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "There is little in the news release describing what kind of study was undertaken. A reading of the original research article reveals that the findings are based on a retrospective, observational cohort study (one that establishes a link between risk factors and health outcomes but can\u2019t establish cause and effect). It isn\u2019t until the last line of the news release that we learn the researchers next plan to conduct \u201ca randomized study comparing the results of partial and conventional UFE.\u201d", "answer": 0}, {"article": "\"Although we do not know why the men who took saunas more frequently had greater longevity (whether it is the time spent in the hot room, the relaxation time, the leisure of a life that allows for more relaxation time, or the camaraderie of the sauna), clearly time spent in the sauna is time well spent,\" Redberg wrote.", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story included more than one statement by scientists saying essentially \u201cWe don\u2019t understand\u201d the results, and that additional study is needed. We want to praise this transparency, as it\u2019s certainly true that this study can\u2019t establish that saunas cause the health benefits that were observed. In fact, we would have liked much more information about why confounding variables might muddy the conclusion. Men who have the leisure time and social connections to take a sauna more often may have other reasons for good health besides the heated 14 minutes they spend during an average visit.", "answer": 1}, {"article": "BLOOMINGTON, Ind.\nSpecifically, the researchers mined the data to identify people with ADHD whose records showed periods of ADHD medication use and periods without ADHD medication use -- as well as one or more visits to the emergency room due to drug or alcohol use.\nOf the nearly 3 million people with ADHD in the study's database, about 57 percent experienced periods in which they were and were not prescribed medication to treat the disorder.\n\"This study contributes to growing evidence that ADHD medication is linked to lower risk for many types of harmful behavior, including substance abuse,\" said Patrick D. Quinn, a postdoctoral researcher in the IU Bloomington College of Arts and Sciences' Department of Psychological and Brain Sciences, who led the study.\nThe majority of the ADHD medicines used in the study were stimulants such as Adderall, an amphetamine, and Ritalin, or methylphenidate.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The release briefly described how the study was conducted, but didn\u2019t offer any analysis on what the methods meant for the quality of the evidence. The release didn\u2019t mention any limitations of the study. One thing that could have used more clarification was the term \u201csubstance use,\u201d and how it was defined. The study looked at trips to the emergency room because of drugs or alcohol, but there are many substance users that don\u2019t go to the emergency room. Emergency room visits were used as a surrogate marker of general substance abuse, but the release made no mention of that.\nFurthermore, the researchers collected data from a database of employee health insurance coverage, meaning everyone in their sample was employed and had commercial insurance. This automatically leaves out anyone who is unemployed, has personal insurance, or paid for their emergency room trip via cash or other methods.\nOther limitations that should have been mentioned: the fact that this was an observational study so it is unable to prove causality, and the fact that the researchers did not have enough data to calculate long-term benefits among the women of the study.", "answer": 0}, {"article": "They have.\nThere's no official policy from the American College of Cardiology, but officials say most members support screening student athletes.\nThe severity of this and the other two problems that turned up as a result of the abnormal EKGs are reason enough, Debauche says, to screen all school athletes nationwide.\nAfter the abnormal EKG result, however, Debauche told Anthony and his parents to closely monitor the asthma.\nFor other students who had abnormal EKG results, some received medication for blood pressure and others were treated for abnormal heart rhythms.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>1clip_themedata.thmx\" rel=\"themeData\"/>1clip_colorschememapping.xml\" rel=\"colorSchemeMapping\"/>\n\n\n\n\nThe story cites data from an uncontrolled short-term study of 2000 high school athletes which found that about 10 percent of the students had an abnormal EKG. There is no discussion of any of the many limitations that are inherent in this kind of study. The suggestion is that this testing uncovered real heart problems that required medical attention, but it is likely that many of these abnormal results were harmless false positives, and the story should have pointed this out. It also should have mentioned that because there was no control group, this study is very likely to have overestimated the benefits of screening with EKGs. Finally, the story did not disclose that this study was presented at a scientific meeting and had not yet been subjected to the scrutiny of other heart specialists via the peer review process. \u00a0\u00a0\n", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070513/21sunscreen.htm was not found on this server.", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The news story fails to comment on the quality of evidence to support its contention that special ingredients unique to a select group of sunscreens protect people from the harmful consequences of ultraviolet rays. Does the evidence match the hype? Did researchers arrive at this conclusion after comparing the incidence of melanoma in a population of high-risk individuals randomly assigned to slather up with either \u201cnew\u201d formulations or \u201cold\u201d ones, then follow them for many years? Or did they study mice in a laboratory, as in one recent Australian experiment? (Br J Dermatol. 2006;155(2):408-15.)", "answer": 0}, {"article": "An estimated 170 million people worldwide suffer from age-related macular degeneration (AMD), a serious eye condition marked by the death of light-sensitive cells in the retina.\nBut Dr. Grazia Pertile, director of ophthalmology at the Sacred Heart Don Calabria in Negrar, Italy and one of the Italian researchers, said in a written statement that her team's device could be \u201ca turning point in the treatment of extremely debilitating retinal diseases.\u201d\n\nShe\u2019s not alone in that assessment.\nThe devices are only experimental prototypes with many years of additional research and development likely before they might be ready for commercial use.\nBut, he says, \u201cThose are things that can be easily worked out and can be done in the coming future.\nRelated: This Revolutionary Gene-Editing Tool Could Change the World\n\nWhen the prosthesis was tested in rats, the animals' pupils constricted in response to exposure to light.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story takes a gee-whiz tone with the new devices, quoting one independent source who called them \u201cgame changers.\u201d But the details of how the game has been changed are quite limited. The Italian technology is wholly contained in the implant, unlike the current FDA-approved version that relies on an external camera. The Californian technology uses \u201csilicon nanowires,\u201d which certainly sounds cool. We wish the reporter had told us why these materials might improve functionality, beyond a vague assertion that they\u00a0would. Also, additional details about the rat model finding would be helpful.", "answer": 0}, {"article": "A growing number of doctors are offering an expensive laser procedure they say zaps away a common fungus that causes ugly, discolored nails. Published data on laser treatment for nail fungus is scant, but early results suggest it is a reasonable option for people who don't want the side effects of oral medications.\n\nOnychomycosis, or fungal infection of nails\u2014most often on the toes\u2014affects about 12% of Americans, according to the American Academy of Dermatology. Some people are genetically prone to it. Others, including swimmers...", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "At a broad, overview level, the column does an adequate job.\u00a0 Language used is important;", "answer": 1}, {"article": "Professor Tim Newton from the Dental Institute at King's College London and lead author of the study said: \"People with dental phobia are most commonly given sedation to allow them to become relaxed enough for a short period of time to have their dental treatment performed.\nThe latest study, published in the British Dental Journal, looked at the characteristics of 130 patients (99 women and 31 men) attending a psychologist-led CBT service and the outcomes of their treatment.\nA recent study published in the same journal, co-authored by Professor Tim Newton, showed that more women than men reported dental phobia in the 2009 Adult Dental Health Survey.\nThe average number of CBT appointments required before a patient received dental treatment without sedation was five.\nNearly all patients (94%) reported a knock-on effect from problems with their teeth, mouth or gums on their daily living and quality of life.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The release does a relatively thorough job of describing the study itself \u2014 the number of patients (130), the degree of dental fear, the methods used to test and score dental phobia. etc. What\u2019s missing in the release (but not in the published study results) is that the most common fear among patients with dental phobias are fear of dental injections and the dental drill.\nIn addition, an important limitation to the research not mentioned in the release is that this was essentially a case series \u2014 a very low level of evidence. There was no comparison or control group, which would\u2019ve made the findings more robust. And the study only looked at patients with dental fears who are willing to take advantage of CBT services. Do the results apply to the community of people with dental phobias so severe that they would not take part in a study that required them to follow-up with dental treatment? For severe phobias, avoidance is key.\nA final issue is that the patient outcomes were gathered post-therapy via patient questionnaires. Service evaluations are not as reliable as actual clinical trials.", "answer": 0}, {"article": "\"The treatment I received on the trial changed my life.\nWith such an approach we should be able to achieve a significantly higher remission rate than in the trial and send nearly all low-risk localised prostate cancers into remission.\nThe research, published in The Lancet Oncology, found that around half (49%) of patients treated with VTP went into complete remission compared with 13.5% in the control group.\nAt the moment, men with low-risk prostate cancer are put under 'active surveillance' where the disease is monitored and only treated when it becomes more severe.\nIn the trial only 6% of patients treated with VTP needed radical therapy compared with 30% of patients in the control arm who were under active surveillance.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The news release describes the scope and methodology of the study, including the number of patients and treatment sites. But it does not discuss some important limitations described in the study, including the fact that more research is needed to determine the long-term efficacy of tissue-preserving therapies such as VTP in controlling prostate cancer.\nAs pointed out in the accompanying editorial, applying more rigorous criteria to define low-risk cancer would likely identify men who clearly would not benefit from any active treatment. Moreover, one of the outcomes reported in the release \u2014 the need for radical prostate surgery, which the researchers say is lower with VTP \u2014 is problematic because neither the release nor the article say how it was determined that additional treatment was needed. One reason that men switch from active surveillance to surgery is that they are uncomfortable not treating their cancer. In this study, the men in the intervention group may have been more comfortable not aggressively treating their cancer because they were getting the VTP. The cancer progression reported in this study is actually much higher than has been reported in other studies.", "answer": 0}, {"article": "Robison, 58, is autistic.\nIt didn\u2019t occur to me that most of the news out there, most of the emotion, is, if not bad, at least not all good.\nYet it is more than a linear account of a life transformed by cutting-edge medical technology.\nStill, for all the positive changes described in \u201cSwitched On,\u201d Robison\u2019s fourth book, there were negatives he was forced to deal with.\nBut his book does illustrate that the consequences can be long-lasting, and detrimental.\u201d\n\nRobison remains optimistic that as research continues, the potential benefits will outweigh the risks.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "There is no evidence provided except for\u00a0anecdotes. If there isn\u2019t any substantial research on this topic, the story could have said so. At the very least, the story could\u2019ve described the larger results of the study that Robison took part in.", "answer": 0}, {"article": "The average age of people in both groups was 73.\nAlthough there are no drugs available yet to prevent or delay the onset of Alzheimer's disease, identifying those at high risk of developing dementia within the next few years could still be beneficial, the researchers said.\nWhen the researchers focused on specific parts of the brain most likely to show damage, the accuracy rose to 95 percent.\nThe findings, presented Sunday, Nov. 25 at the Radiological Society of North America meeting in Chicago, suggest that doctors may one day be able to use widely available tests to tell people their risk of developing dementia before symptoms arise.\nThe researchers found that people who went on to experience cognitive decline had significantly more signs of damage to their white matter.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "To its credit, the news release rightly explained in the lead that this is a \u201csmall study.\u201d\nIt also gave details about how the study was conducted \u2014 first by identifying disproportionate white matter damage that had occurred in 10 people in their 70s with significant cognitive decline compared with those who did not decline, and then measuring \u201cwhite matter integrity\u201d of a separate sample of 61 people.\nFinally, it quoted a researcher explaining that what\u2019s needed is to \u201cget more control subjects and develop computerized tools that can more reliably compare individual patients\u2019 scans to a baseline normal standard.\u201d\nHowever, the news release didn\u2019t explain that this was not a randomized trial that could measure how well MRI brain scans actually do work at predicting Alzheimer\u2019s.", "answer": 1}, {"article": "Like any screening test, iFOBT does have a risk of false-positive results, which leads to unnecessary invasive testing in some people.\nPositive results on the screen prompt a follow-up colonoscopy to investigate the source of the blood.\nImmunochemical FOBT is now largely replacing the older test.\nA screening colonoscopy averages around $3,000.\nAdvances in the stool tests in recent years have made them more effective.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "Thorough analysis of how the study was done, including easy to understand discussion of sensitivity and specificity.", "answer": 1}, {"article": "Do you realize that color brings joy into your life?\"\nTwo studies out Wednesday in the New England Journal of Medicine report on patients given monthly injections for two years.\nThere's a catch: it's expensive \u2014 about $2,000 per injection \u2014 although Medicare and most insurance companies cover most of it.\nThere are some rare side effects, including severe inflammation, infection and detached retina.\nAnd patients may need to continue treatment.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "Although the story mentions two studies, this is not enough information on the strength of the available evidence. Specifically, there have been no studies comparing the effectiveness of Lucentis compared to Avastin, another drug that is commonly used off-label to treat AMD.", "answer": 0}, {"article": "Viagra is one of three licensed drugs to treat erectile dysfunction, Davies explained. The other two are Cialis and Levitra. They can take from half an hour to several hours to work, and they're not for everyone: Men who've had a stroke or heart attack are told to use the drugs with caution, reports the Daily Mail. Even those without medical issues simply don't like the wait.", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story explained the cream was tested in rats, and that human trials may not begin for another two years.\nThe story said \"The cream succeeded in 9 out of 10 cases with the rats.\"\u00a0 \nThere was no discussion of:", "answer": 0}, {"article": "For more information, see www.scripps.edu.\nThe next step in this research is to design a way to synthesize the modified vancomycin using fewer steps in the lab, as the current method takes 30 steps.\n\u201cMaking this molecule is important, even by the current approach, if the failure of antibiotics continues.\u201d\n\nIn addition to Boger, authors of the study, \u201cPeripheral modifications of [\u03a8[CH2NH]Tpg4]vancomycin with added synergistic mechanisms of action provide durable and potent antibiotics,\u201d included first author Akinori Okano and Nicholas A. Isley, both of TSRI.\nThe antibiotic has been prescribed by doctors for 60 years, and bacteria are only now developing resistance to it.\nThe new study shows that scientists can make a third modification\u2014which interferes with a bacterium\u2019s cell wall in a new way\u2014with promising results.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The release tells readers only that the new form of vancomycin was tested against both vancomycin-resistant Enterococci bacteria and Enterococci that are not resistant to the drug. Was the study done using an in vitro model? In vivo testing in an animal model? How large was the n, or sample size? Based on the paper, the modified vancomycin was tested solely in an in vitro model. That would be useful context to provide for readers.\nThe drug needs to be tested in humans before it\u2019s approved and judged to be of clinical relevance.", "answer": 0}, {"article": "For more about stroke, visit the National Stroke Association.\nBut clinical trials have shown that the risk of brain bleeding for people who received tPA and then went through mechanical clot removal is no greater than for people who just receive the blood thinner, Powers said.\nBut when those drugs don't work, doctors now can turn to a new catheter-based device that will physically remove the blood clot, said Dr. William Powers, lead author of the updated AHA guidelines and chair of neurology at the University of North Carolina at Chapel Hill.\nThe guidelines provide added incentive to quickly transfer stroke victims from a local hospital to a major stroke center capable of advanced treatment, said Powers and Dr. David Kandzari, director of interventional cardiology and chief scientific officer for the Piedmont Heart Institute in Atlanta.\nThe major risk of using the device is that it could tear an artery and cause bleeding in the brain, particularly since it will be used on people who have already received very potent blood thinners, Kandzari said.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "This story is about a set of guidelines and not about a single research study. The guidelines are themselves based on six different randomized trials described elsewhere as of high-quality.\nGuidelines like these are very carefully considered by a committee. The quote from the story is: \u201cThe outcomes were uniformly positive in all of the trials,\u201d he said. \u201cIt\u2019s really, really good evidence.\u201d The story also notes that the guidelines have been endorsed by other medical societies. In addition, there is discussion of limitations insofar as the story addresses\u00a0how narrowly one must filter patients in order for them to fit these new guidelines.\nWe think the discussion of evidence is sufficient to convey the quality of the research, but we wouldn\u2019t have minded some additional detail. For example, the related news release issued for the guidelines says:\n\u201cThe evidence backing this new recommendation received the highest rating based on the scientific evidence reviewed, and suggests the benefits substantially outweigh the potential risks in these patients.\u201d\nand further:\n\u201cEvidence-based guidelines are based on clinical trials, which tell you that if you have a patient with the same characteristics of those in the trials, on average they will do much better with the treatment than if you treat them another way,\u201d Powers said.", "answer": 1}, {"article": "(Sunlight stimulates production of vitamin D for people in sunnier climes.)\nBut somehow we've arrived at a point when some physicians are prescribing large doses of Vitamin D supplements for their patients in the hope of preventing cancer, cardiovascular disease, diabetes, autoimmune disorders and other maladies, despite a lack of evidence that this works, according to a new commentary in the Journal of the American Medical Association.\nI think there's a general perception that if some is good, more is better.\nOver the past 15 years, those studies \"have looked promising, and very often they've been reported by the media as suggesting that vitamin D has these benefits.\nYou should consume modest amounts in your diet, if possible (and for most people that is quite possible), or in the form of supplements if you can't get enough via food and drink.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story was prompted by a perspective piece by Dr. Manson, a leading expert in vitamin D and health outcomes. The main topic of the commentary is the lack of evidence supporting high-dose vitamin D supplementation. The story conveys that message first by stating that \u201cphysicians are prescribing large doses of Vitamin D\u2026in the hope of preventing cancer\u2026and other maladies, despite a lack of evidence that this works.\u201d To back this up, the story relies on a quote that \u201cthere\u2019s been a disconnect between the observational studies and the randomized clinical trials to date.\u201d This is all correct, but admittedly a bit vague and potentially confusing for readers. How is an observational study different from a randomized trial, and which one provides stronger evidence? \u00a0Which studies have fallen short of showing positive health effects? Which health effects were those studies evaluating? Is this an area that may be affected by the bias against publishing negative results?\nA bit more detail and explanation would have been welcome here. But since the overall message of the story is consistent with the evidence on this topic \u2014 i.e. the story clearly \u201cgrasps the quality of the evidence\u201d \u2014 we\u2019re inclined to rule this satisfactory.", "answer": 1}, {"article": "About half of the patients undergo the procedure to control chronic throat or ear infections.\nAccording to the paper, which was published yesterday in Pediatrics, it has been known that children with sleep disorders often have behavior problems.\nCompared with the control group, the children scheduled for adenotonsillectomy were more likely to be hyperactive by their parents' estimates and more likely to experience behavior problems and sleepiness at school.\nTwenty-two of the adenotonsillectomy patients, but only 2 of the controls, had a diagnosis of attention-deficit hyperactivity disorder.\nBut no cause-and-effect relationship has been established.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story does not accurately represent the strength of the available evidence that adenotonsillectomy is effective for ADHD. The opening line of the story refers to \u201cstrong evidence,\u201d which is really an overstatement. Although it is true that this is a randomized clinical trial, there are several limiting factors that are not adressed in this story. Specifically, this was a small study and the psychiatrists who assessed the children were not blinded to surgical status, potentially biasing the results. Furthermore, this story does not mention that sleep disturbance at baseline and at one year follow-up did not correlate with behavioral outcomes. This suggests that either there are problems with how sleep disturbance or behavior was measured in this study or that there is some other mechanism other than sleep that is mediating the relationship between the treatment and behavioral outcomes. These issues are not discussed in the story.", "answer": 0}, {"article": "Autism is a spectrum disorder that includes repetitive behaviors and impairments in language, communication and social skills.\nFor one, this study was done in school-aged children, many of whom were actually teenagers, so it is impossible to know if these differences in neuroimaging would also be found in younger patients, Adesman pointed out.\n\"It is possible that children who have delayed language but not autism would also show the same pattern.\n\"There are questions about how this varies across the severity of autism.\nHowever, if this test could be done in really young children, it might help identify autism so that treatment can begin early, Lopez-Alberola suggested.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story notes the limitations of the study several times and in several ways. For example, it says, \u201cFor one, this study was done in school-aged children, many of whom were actually teenagers, so it is impossible to know if these differences in neuroimaging would also be found in younger patients, Adesman pointed out.\u201d\u00a0 We would have liked more details about the correlation between clinical symptoms and the fMRI findings.", "answer": 1}, {"article": ".\nInstead, these results show that endoscopic sleeve gastroplasty is another possibility that patients and health-care providers should consider when discussing options.\nDr. Sharaiha noted that these findings do not suggest that endoscopic sleeve gastroplasty will replace the two surgical treatments as weight-loss interventions.\nWhen examining cost, researchers reported endoscopic sleeve gastroplasty resulted in the lowest-cost, with an average institutional procedure cost of $12,000, compared to $22,000 for laparoscopic sleeve gastrectomy and $15,000 for laparoscopic banding.\nAt one-year follow-up, patients who chose laparoscopic sleeve gastrectomy surgery achieved the greatest percent total body weight loss at 29.28 percent, compared to 17.57 percent for endoscopic sleeve gastroplasty patients and 14.46 percent for laparoscopic banding patients.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The release does an adequate job of describing the study. However, there are two things that could have made the release significantly better. First, there could have been some information about the patients involved \u2014 including age, sex, and other characteristics that could potentially affect outcomes. (e.g., the conference abstract notes that a lower age was a predictor for weight loss at six months.) Were there any factors that informed physicians to choose one procedure over another? Since this was not a randomized trial, the release could have noted that factors other than the treatment itself likely played a role in how much weight was lost.\nSecond, while the release notes that \u201cpatients went to an academic bariatric center of excellence as part of their treatment,\u201d it could have made it clear that changes to diet and exercise are an important factor in determining the outcome of medical interventions for weight loss.", "answer": 1}, {"article": "At 12 months in patients receiving torcetrapib, there was a 72 percent increased in good cholesterol and a 24.9 percent decrease in bad cholesterol.\nThe study said there were still many unanswered questions about Pfizer's pill, torcetrapib, the first in a new class of heart medicines known as a CETP inhibitors, which raise HDL, or good cholesterol, and lower LDL, or bad cholesterol.\nIt was unclear what the mixed bag of data presented at the American Heart Association's Scientific Session in Orlando would mean for CETP drugs under development by Merck and Roche, and another candidate in early-stage development by Pfizer.\nA long-awaited postmortem released this morning of Pfizer's (NYSE: PFE) failed heart drug held out hope for the discovery of a safe version of the revolutionary heart pill.\n\"It is still possible that CETP inhibitors without off-target effects of torcetrapib could be viable as a therapy for cardiovascular disease,\" said an editorial published in today's edition of the New England Journal of Medicine, which concluded: \"It is possible that CETP inhibition might be better suited to certain subgroups of patients, such as those with impaired clearance of LDL cholesterol or low levels of HDL cholesterol at base line,\" the editorial said.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "Although the story accurately describes the ILLUMINATE study presented at the meeting, the story repeatedly exaggerates the claims that there is a future for HDL-targeted therapeutics. Starting with the headline and throughout the story, the possibility that other drugs targeting HDL could be viable is consistently overhyped in this story. At this point there is no evidence that targeting HDL will be an effective strategy and hopes that a more \"clean\" version of the drug will not have the harms of the failed drug is nothing but conjecture. ", "answer": 0}, {"article": "Women.\nData on aspirin and other NSAID usage came from the women\u2019s responses on questionnaires.\n[Certain adults should take a daily baby aspirin, expert panel says]\n\nWho may be affected?\nThe researchers analyzed data on 57,164 women, most in their early 60s, who had no history of breast cancer.\nOver seven years, 1,457 women got a breast-cancer diagnosis.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "As noted above and in our review of the news release, observational studies like this one can only identify correlations. These studies can\u2019t prove a causal relationship \u2014 i.e., that the action (taking aspirin) caused the result (reduced risk of breast cancer). The story does not address that head on. The story also doesn\u2019t address whether other factors \u2014 such as age or weight \u2014 may have contributed to the difference in breast cancer rates. The story does, however, address hormone therapy and alcohol use among study participants, and explains why those factors are important. That\u2019s a plus. Lastly, the story notes that most of the study participants were white, but doesn\u2019t explain to readers why that is relevant.\nAnother omission in the story is that more than 4,100 women who had developed breast cancer before the 10-year follow-up were excluded from the study. This should have been mentioned as a limitation. We wonder how these women who were excluded differed in their low-dose aspirin intake from those who developed breast cancer later on. ", "answer": 0}, {"article": "The findings are published in TheJournal of the American Medical Association.\nIn the study, Freeman found the antidepressant reduced both the number and severity of hot flashes compared to placebo.\nThe new study findings suggest Lexapro can provide an option for women reluctant to take hormone therapy.\nPrevious studies of other antidepressants have yielded mixed results, according to Freeman.\n''We believe escitalopram provides an option for treating moderate to severe hot flashes that are disrupting people's lives and quality of life,\" says study researcher Ellen Freeman, PhD, a research professor in the department of obstetrics-gynecology and psychiatry at the University of Pennsylvania School of Medicine, Philadelphia.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story includes\u00a0enough details about how the study was conducted and what the researchers observed to earn a satisfactory. It notes that this was a randomized, double-blind, placebo-controlled study \u2014 the \u201cgold standard\u201d of medical evidence. It explains that outcomes were based on women\u2019s\u00a0records of how often and how severe their hot flashes were \u2014 a relevant clinical endpoint.\nAlthough the story notes that women in the study took\u00a0the drug for 8 weeks, it could have explained that 8 weeks\u00a0isn\u2019t long\u00a0to meet FDA criteria for a hot flash treatment; the FDA requires\u00a0that benefits be maintained for 12-weeks.\u00a0The study also should have explained that we have no idea how well these drugs will work over the longer term (menopause symptoms can last for years) or whether problems might occur with longer use (more on\u00a0this in the Harms\u00a0criterion).\u00a0Lastly, it would have been useful to have\u00a0some discussion of how the treatment affected general health-related quality of life; this would have helped readers\u00a0understand the importance of the observed benefit on hot flashes when considering overall health/function.", "answer": 1}, {"article": "Air is suctioned through the side channels to emulate breathing.\n\u201cBiology is very complex.\u201d\n\nIncorporating the chips into drug testing could save millions of dollars and years of time on research.\n\u201cAnything you can ask at the molecular level, we could do in our chips.\u201d\n\nIn 2008, the team built and tested its first \u201corganoid\u201d chip to mimic the mechanical function of human lungs.\n\u201cThey\u2019ve told us if they are as good as animals that they would consider accepting data provided by a drug company from one of these models rather than an animal model.\u201d\nOf course, the chips have limitations.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "As noted above under \u201cBenefits,\u201d it\u2019s not possible for these systems at present to replicate the dynamic processes of the human body, and the story doesn\u2019t alert readers to that limitation. But we\u2019ve already dinged the story for that concern, and the story does mention some other limitations, including that researchers can\u2019t mimic consciousness or compression on a joint.\u00a0It\u2019s also clear from reading that this is still a technology that isn\u2019t yet available or proven. The story does a reasonable job of describing what has been done so far and what needs to be done in the future. We\u2019ll rate this Satisfactory.", "answer": 1}, {"article": "After doing it for so long, it's not hard to do.\"\nThe study, known as DPPOS, puts science behind Mr. Held's success.\nHis results do not surprise researchers.\nThe prevalence of diagnosed diabetes has more than doubled in three decades due in large part to an upsurge in obesity, the study states.\nBut those who did undergo lifestyle changes showed such notable results that Pitt offered to enroll all 159 participants, including Mr. Held, in a lifestyle modification program.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The study on which the story is based is riddled with caveats. Some findings baffle the researchers.\nHowever, the reporter twice makes the mistake of saying the story \"proves\" certain benefits. The study suggests, or demonstrates a link, but it does not prove anything.\nBy using the word \"proves\" the reporter over-interprets the findings, exaggerating the quality of evidence. Therefore the story earns an Unsatisfactory rating under this criterion.", "answer": 0}, {"article": "For more information on asthma, visit the U.S. National Library of Medicine.\nHowever, the study authors and an outside expert stressed that these are early findings and much longer, larger clinical trials are needed.\n\"This is a good foundation to design a trial where you would look at Spiriva plus steroids versus doubling the dose of steroids in a large number of asthmatics who are poorly controlled and then you follow them long-term,\" Shafazand said, but right now there is no data on long-term efficacy and safety.\nSUNDAY, Sept. 19, 2010 (HealthDay News) -- For asthma patients whose condition is not controlled with standard inhaled steroids, the addition of Spiriva -- a medication already approved for lung disease -- appears to improve breathing, a new study finds.\nHowever, at this stage there is no definitive answer whether Spiriva should or shouldn't be used in asthma, she said.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "From the article\u2019s headline to its last sentence, it firmly emphasizes the preliminary quality of this research. We give it a shout-out for\u00a0prominently\u00a0establishing the study\u2019s early stage, providing wonderful context about the small sample size and follow-up period, identifying why future research is needed, and bringing those caveats home by concluding that right now there are no definitive answers and these new results do not constitute an all-out recommendation for its use in asthma.\nAs with the AP article, this story could\u2019ve been clearer about the importance of randomization, blinding, and placebo controls, and there\u2019s no explanation of the crossover design, obscuring the study\u2019s duration and who received what when. However, the HealthDay article is not misleading about the duration, unlike the AP story that presents 14-week data on a 52-week timescale without acknowledging that an extrapolation was done.", "answer": 1}, {"article": "Open and laparoscopic surgeries were still more common than robotic surgeries for kidney repairs and removals.\nThe analysis, which appeared in the Journal of Urology, compared increasingly common robotic surgery with two other techniques for the same surgery and found that direct costs can be up to several thousand dollars higher for the robotic type.\nThe trade-off was the cost, with robotic prostate removal costing about $10,000 on average, roughly $700 more than laparoscopic surgery and $1,100 more than open surgery.\nDavid Penson, a surgeon at Vanderbilt University Medical Center who was not part of the study, said more consideration should have been given to the state of patients afterwards.\nHu and his team analyzed surgery data from a national government database to see if the costlier robotic surgeries were cost effective with extra benefits over older techniques.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story nodded in the direction of the accompanying editorial, but we wish it had captured the important points as written by the editorialist:\nWhile this study provides some important information that will help patients, providers and policy makers make these value judgments, it fails to capture 3 important elements. First, as the authors note, the costs estimates do not include the capital investment of purchasing a robotic system or the indirect economic benefits of patients\u2019 early return to work and increased productivity. Second, the analysis fails to capture the human cost of the learning curve. In other words, as providers learn new surgical techniques, outcomes are often worse for patients early in the learning curve as hypothesized by Hu and others. Finally, and perhaps most importantly, the study fails to capture patient reported outcomes such as postoperative pain, return to baseline functional status and health related quality of life, all of which are highly germane to the procedures under study here. It is difficult, if not impossible, to assess the costeffectiveness of minimally invasive technologies without including these critical outcomes. Future comparative effectiveness studies of these techniques must include patient reported outcomes as the primary end point if they are to inform the debate regarding the value of our interventions.", "answer": 0}, {"article": "MayoClinic: Find out more about melanoma\n\nOne study presented at the American Society of Clinical Oncology's (ASCO) conference on Sunday focused on the experimental drug vemurafenib.\nNearly 90% benefited from this new targeted drug, Schuchter said.\nYervoy takes a while to work, and some patients may not have that time, study author Chapman said.\n\"This is an unprecedented time of clinical options -- it is truly practice-changing,\" said Dr. Lynn Schuchter, who heads the Melanoma Center at the University of Pennsylvania and is not involved with the research.\nThis is very unusual in the world of drug development, he said.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "Adequate explanation of the evidence. Interestingly, both this story and the one from Reuters provided information from the ASCO meetings and neglected to tell readers that both studies have been published in a peer reviewed journal. The NY Times provided both sources.", "answer": 1}, {"article": "\"These are very basic facts, concerning simply who lived and died,\" he noted.\nThe study authors noted that the observation is somewhat surprising, given that some of the patients not enrolled in structured studies have already experienced a cardiac event and are therefore prescribed such devices to prevent a recurrence.\nTUESDAY, Nov. 23, 2010 (HealthDay News) -- Implantable devices designed to control heart rhythm and efficiency while preventing sudden death among heart failure patients are as effective at ensuring patient survival in real-world situations as they are in controlled study environments, new research suggests.\nDr. Eric N. Prystowsky, cardiologist and director of clinical electrophysiology at St. Vincent Medical Center in Indianapolis, said that the findings are \"good news,\" but cautioned against over-interpreting the data.\nBut, Prystowsky continued, \"this analysis does show two impressive things: one, that patients who are not super-selected for a trial do well with these devices from a mortality standpoint; and two, that patients who had home-monitoring had better outcomes.\"\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story starts out with a very confusing lead. \u201cImplantable devices designed to control heart rhythm and efficiency while preventing sudden death among heart failure patients are as effective at ensuring patient survival in real-world situations as they are in controlled study environments, new research suggests.\u201d But then, quickly, it raises an interesting red flag, saying, \u201cThe study authors noted that the observation is somewhat surprising, given that some of the patients not enrolled in structured studies have already experienced a cardiac event and are therefore prescribed such devices to prevent a recurrence.\u201d We have read this sentence multiple times and still don\u2019t know what it means. The rest of the story meanders through various numbers that appear to be differentiating between the devices, and then, suddenly, the story takes a sharp turn into a discussion of remote monitoring, claiming, \u201cthat patients whose implants were monitored remotely, on a continual basis, by a health facility network were about half as likely to die as patients who only had intermittent in-person assessments.\u201d None of this evidence is carefully examined. Also, the study was observational and used existing datasets to determine patient outcomes. There are a number of limitations to this study design, including a lack of randomization and a lack of specific information for each patient in the dataset. The story does not provide the reader with these important provisos to the study results. The study was accompanied by a well written and thoughtful editorial that could have provided the reporter with a useful context for the story.", "answer": 0}, {"article": "Co-authors are: Leslie Donato, Ph.D.; Sandra Bryant; Grant Spears; Peter Berger, M.D.\n\u201cOur research suggests that evaluating ceramide levels in patients who are not at immediate risk for coronary artery disease events may help cardiologists decide who could benefit from proactive and preventive treatment, such as statins, or lifestyle changes to prevent a serious cardiac event down the road,\u201d says Jeff Meeusen, Ph.D., a clinical chemist, co-director of Cardiovascular Laboratory Medicine at Mayo Clinic and the study\u2019s lead author.\nBut when researchers examined cardiovascular disease in this population by ceramide scores, people with the highest levels of ceramides were four times more likely to have an event compared with those with the lowest (7.8 vs. 2.2 percent, respectively).\nThe study found that individuals with the highest levels of blood ceramides were found to have a 3- to 4-times greater risk of having a cardiovascular event compared with those with the lowest ceramide score, regardless of their LDL cholesterol level or the presence of a blockage in the heart\u2019s arteries.\nBut the risk of having an event became higher as ceramide level increased; for each 1-point increase in the ceramide risk score, the risk rose by 9 percent.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The news release wasn\u2019t clear about what this study cannot tell us, which is that we don\u2019t know if the results of the blood test would make doctors change how they treat patients. Given that most patients are already on medication to treat their cardiac risk factors, measuring ceramide levels might not lead to any treatment and would just increase costs. Moreover, it\u2019s not clear whether any changes in treatment would actually produce measurable benefits for patients who are at increased risk according to the test.\nAnother concern here is that the research discussed in the news release was being presented at a scientific conference and had not yet gone through the peer review process for journal publication. Research findings may change when a study report is published in a journal, and for this reason, journalists often are cautioned against building stories around conference reports. In this case, the association between ceramide levels and heart disease has been documented in other research. However, the news release\u2019s contention that those with low LDL but high ceramide levels are four times as likely to have a heart attack, stroke or other cardiovascular event would still be considered a preliminary finding, given the lack of rigorous peer review.", "answer": 0}, {"article": "\"It was the end of our world and we didn't know why, because this child was a perfectly normal healthy child, Never had a problem,\" Miller says.\nFDA said it is reviewing a handful of reports involving mood changes, suicidal behavior and suicide in patients who have taken the popular allergy and asthma drug.\nFDA said it asked the company to dig deeper into its data on Singulair for evidence of possible links to suicide.\nMerck officials stressed that the FDA's inquiry is based on reports, not clinical studies - which are the standard tool for evaluating drug safety.\nMerck said it recently added reports of suicide to Singulair's label, which already listed suicidal thinking and behavior as reported side effects.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The segment is based on an FDA investigation and labeling changes that follow post-marketing reports of four suicides and mental disorders. This is adequate evidence on which to base this news report. ", "answer": 1}, {"article": "While insulin is typically associated with type 1 diabetes, many patients with type 2 eventually see their disease progress to the point where they need insulin.\nBut the data from the Phase II, 180-patient trial represents a major milestone.\nOramed said it plans to publish more detailed data from the study once it has had time to analyze the full results.\nThe positive results must be replicated in a larger Phase III trial before the drug, known as ORMD-0801, can be submitted for approval.\nThe result is likely to surprise many skeptics who did not believe insulin could be delivered orally because they doubted it could survive the onslaught of digestive juices so it could have the intended effect.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story tells us this was a randomly chosen, blinded study of 180 people over 28 days, and considered a Phase II trial.\u00a0The story also mentions that stage III trials still need to be done, which is when the drug might be considered for approval. These are important details.\nBut, because it\u2019s an unpublished study, no one outside of the company has taken a look at the evidence. This story should have had a stronger signal that this is potentially straying from the realm of science and into marketing.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070520/28diet.b.htm was not found on this server.", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The news brief says some women \u201cwere given\u201d vitamin supplements and other women placebo, hinting that the study was a randomized controlled trial. Given the extraordinary size of the population enrolled\u2014more than 36,000 women\u2014readers would be better able to evaluate the quality of the study if the story clarified this. The story also failed to mention that the new study is an analysis of data from a trial initially designed to find out whether calcium and vitamin D reduce the risk of hip fractures or colorectal cancer in postmenopausal women.", "answer": 1}, {"article": "The average age of children in the study was 7.\nThe findings suggest that a sniff test could be quite useful in the clinic, although the researchers emphasize that their test is in no way ready for that yet.\n\"This raises the hope that these findings could form the base for development of a diagnostic tool that can be applied very early on, such as in toddlers only a few months old.\nThey also want to find out how early in life such a test might be used.\nThe researchers now plan to test whether the sniff-response pattern they've observed is specific to autism or whether it might show up also in people with other neurodevelopmental conditions.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The release clearly describes the study, including the study size, the use of a control group, and the composition of the study participants. The release could have been even stronger, however, if it had placed that information in context for readers. For example, the study evaluated 18 children diagnosed with ASD and 18 children without ASD. Is that a robust sample size for a study of this kind? Most readers likely won\u2019t know. In addition, the symptoms of autism can range from mild to severely debilitating. Where were these children on that spectrum, and what does that say about the test\u2019s usefulness for differentiating between normal children and those with mild impairment?\u00a0The release tips toward a Satisfactory rating with its emphasis on the fact the test is not ready to be used clinically. \u00a0\u201cThe findings suggest that a sniff test could be quite useful in the clinic, although the researchers emphasize that their test is in no way ready for that yet.\u201d Well said.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070225/5laser.htm was not found on this server.", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story provides little evidence about the success rate (i.e. how many people report 20/40 or 20/20 vision following either LASIK or PRK), or what is the incidence of lasting negative outcomes from the surgery? After 10+ years of the procedures\u00a0being performed,\u00a0there is published data\u00a0 examining the efficacy and safety of Lasik vs PRK for correction of myopia.(Cochrane Database Syst Rev. 2006 Apr 19;(2):CD005135) of clinical trials\u00a0\u00a0The story would have been improved with inclusion of some of the available data.\u00a0", "answer": 0}, {"article": "Grocers shelves add new coconut-water products regularly.\nI was meeting with a cardiologist recently, and he said he doesn\u2019t advise (coconut oil) for any clients.\u201d\n\nThe fat issue is complicated by the types of fatty acids found in coconut, versus other saturated fats.\nIn the past couple of years a couple of brands have figured out the right angle \u2014 electrolytes and hydration.\u201d\n\nCraven estimated the coconut-water market at about $100 million annually right now, but companies are doubling their sales year after year.\n\u201cIf you focus on coconut oil, you lose out on the fiber and you are focusing on a concentrated source of calories.\nIt\u2019s the whole coconut that needs to be talked about.\u201d\n\nEntrepreneurs are talking about the whole coconut these days.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "It is not clear from this story that there is any evidence to evaluate about coconut products, but we presume that coconuts or coconut derivatives have been studied. The story also spends considerable space talking about electrolytes, fat, cholesterol without quantifying the benefits (or harms) of any of them or analyzing the claims being made in any meaningful way. For example, in discussing coconut oil, it starts out by saying that it has received \u201cmixed reviews\u201d and quotes a Denver dietitian who says that coconut oil contains saturated fat that \u201cclogs your arteries and is not good for heart health.\u201d We\u2019re not sure she is the best source on heart health, but this is good information nonetheless. Then the story muddies the waters, though, by saying that coconut oil fats are composed of \u201cmedium-chain fatty acids\u201d that are \u201cmore healthy\u201d and that they are \u201chigh in lauric acid, which many believe acts as an antimicrobial, helping prevent viruses, fungi and parasites.\u201d\u00a0 By comparing well established, proven medical evidence on cholesterol to spurious, unfounded claims about what \u201cmany believe\u201d the story provides readers no hierarchy of evidence. Marketing and true science slosh around in this story like a mug full of coconut milk.", "answer": 0}, {"article": "Sen. Edward Kennedy was diagnosed with the disease last week.\nThe time of survival was also up significantly from the previous average of 14 months, said Sampson, who declined to reveal the exact number until he presents the data June 2 at the American Society of Clinical Oncology meeting in Chicago.\nGilbert cautioned that the study results are preliminary.\nFor one patient in the study, the Temodar-vaccine combination by itself has worked fine.\nUnder the trial protocol, some patients received Temodar for the first five days of the month, and some received it for the first 21 days.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "It is important to focus on the type of study this was: a trial of two different durations of the vaccine drugs, not a trial of the vaccine versus no vaccine.\u00a0 The lead paragraph states that the finding was that the combination of chemotherapy plus a new vaccine prolonged survival.\u00a0 This is misleading because there is no arm of the study without the vaccine.\u00a0 The prolongation is compared to historical controls, and this is not a robust comparison.\u00a0 The study participants were, as the story commendably explains, \"cherry-picked\" for the study and may not be comparable to the historical controls.\nFurther, there was some information provided about the results of the trial (i.e. time to tumor recurrence) and that the trial itself was a pilot study and the results would need to be replicated. \u00a0That said, the story mentioned the data about time to recurrence in the same paragraph as it discussed time to patient death (data not available at the time the story was written). \u00a0It is likely that readers will fail to appreciate the difference between these two end points (time to cancer recurrence and time to death); the story should have provided some insight for readers about how meaningful the end point of time to recurrence really was (the sample size may have been too small for a difference of 2.6 months to be statistically different).\u00a0 Was it statistically different and/or clinically significant?", "answer": 0}, {"article": "Platelets are tiny blood cells that circulate in the body, helping wounds to clot.\nThat, say the researchers, makes testing for raised platelet count a valuable tool, and could speed up cancer diagnosis by at least three months for thousands of patients a year.\n\u201cMeasuring platelet count in patients who don\u2019t otherwise warrant a blood test is not necessarily a good idea.\n\u201cThis is an excellent study that demonstrates the potential for a commonly used blood test to identify some patients with cancer earlier,\u201d he said.\nFor about a third of cases of lung and colorectal cancer in patients with thrombocytosis, there had been no other symptoms that raised the suggestion of cancer.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The article clearly explained where the data originated, how the study was done, and (with the use of quotes) some of the limitations of the findings.\nWe do think there was a limitation worth noting, though. Usually when you conduct a matched case-control study, you have the same number of controls per cases or more controls matched per case (which strengthens the power to detect differences). The lack of controls in this study may have produced inflated results.", "answer": 1}, {"article": "In many countries, the rate drops to less than 10 percent.\n\u201cAlthough antidepressants are of proven benefit\u2014as this study shows,\u201d she said, \u201cno doctor wants their patients to become reliant on medication.\u201d\n\nCarmine Pariante, a professor at the UK\u2019s Institute of Psychiatry, Psychology and Neuroscience and spokesperson for the Royal College of Psychiatrists, said the study \"finally puts to bed the controversy on antidepressants.\"\nPooling data from 522 trials including nearly 120,000 patients, researchers found all drugs analysed were more effective than placebos in the treatment of adults with acute depression.\nSome drugs more effective than others\n\nThe researchers analyzed existing studies of 21 different drugs, and found some were much more effective than others.\nThe results add up to a complex treatment picture for what authors called \u201cone of the most common, burdensome, and costly psychiatric disorders worldwide in adults.\u201d\n\nAntidepressants do not improve symptoms in about 40 percent of people, study author Andrea Cipriani of Oxford University told a press briefing.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story does include information suggesting how large the analysis was \u2014 522 drug trials with nearly 120,000 subjects reviewed \u2014 and that it was the \u201cmost comprehensive evidence currently available,\u201d according to the authors.\nBut the story doesn\u2019t mention any limitations, including the fact that the analysis didn\u2019t examine how patients respond based on age, sex, severity of symptoms, or duration of illness.\nThe authors of the study also noted weak evidence for some drugs and the potential for unintentional errors in their complication of data.\nFinally, they noted also noted that \u201csome of the adverse effects of antidepressants occur over a prolonged period, meaning that positive results need to be taken with great caution, because the trials in this network meta-analysis were of short duration.\u201d", "answer": 0}, {"article": "\"The data set is massive.\nWhile the study findings indicate that there is a consistent signal present in circulating blood cells of children with spastic CP that remains from early childhood to the teenage years, the researchers say they need to further study samples from different age groups, including teenagers, toddlers, and infants from birth to 2 years.\nIn the study, the research team profiled blood samples collected in a blinded study from children and adolescents 9-19 years to explore whether patients with spastic CP showed differences at the cellular level that routine orthopedic patients (needing ACL repairs, spinal fusions or other surgeries) did not.\nThe researchers identified a strong set of methylation markers, or patterns, that indicate differences in the genome between children with spastic CP and those without it.\nIf successful, the researchers say the type of blood test in development also may be useful for other disorders, such as infant leukemia.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The release doesn\u2019t tell us how many samples were analyzed in the studies. It also relies on \u201ca strong set of methylation markers, or patterns, that indicate differences in the genome between children with spastic CP and those without it\u201d as an indication of the likelihood of CP. It doesn\u2019t offer readers any details on what the differences were between children with CP and controls, or how they were measured.", "answer": 0}, {"article": "\"It took quite a bit of time to get approval,\" Mithoefer says.\nThe resulting sense of euphoria and emotional warmth seems to help patients connect with their therapists, says Michael Mithoefer, M.D., the lead author of the study and a Mount Pleasant, South Carolina-based psychiatrist who specializes in PTSD.\nTwo months later, 10 of the 12 people who took MDMA had improved to the point where they no longer met the diagnostic criteria for PTSD, and three participants whose condition had prevented them from holding down a job were able to return to work.\nThis was the first clinical trial to explore the therapeutic potential of MDMA since the drug was outlawed in 1985, and the researchers required the permission of the National Institutes of Health, the Food and Drug Administration , and the Drug Enforcement Administration.\nThe study, which appears in the Journal of Psychopharmacology, included 20 people with PTSD stemming from traumas such as sexual assault and combat stress.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "No attempt was made to evaluate the quality of the evidence in this story. The press release actually offers more caveats than the story, saying, \"The authors caution that the study does have limitations \u2013 for example they did not look at gender and ethnic factors in their sample selection. Another important limitation was that most participants and trial investigators guessed accurately whether they were in the treatment or the placebo group. The placebo had no psychoactive effect and investigators could detect raised blood pressure and other symptoms in the MDMA group. A long-term follow-up to the study just published, evaluating subjects an average of about 40 months post-treatment, is underway.\" So, if the participants in the study knew that they were taking\u00a0a placebo, what would that do to their mindset during therapy? Conversely, those taking drugs knew they were taking drugs and may have responded in a positive way to please the researchers, a very real response. On the plus side, the story didn\u2019t use percentages, which would have been even more misleading. Instead, it just gave readers the raw numbers, which to anyone who has read more than a few medical studies or health stories would be underwhelming.", "answer": 0}, {"article": "Contributing authors Dr. Farid Saad is a full time employee of Bayer Pharma.\nTo date, there are limited studies comparing the effects of long-term TTh in hypogonadal men who were treated or remained untreated with T.\n\nResearchers at Boston University Schools of Medicine (BUSM) and Public Health (BUSPH), along with researchers in Germany, established a registry to assess long-term effectiveness and safety of T in men.\nIn the absence of large, prospective, placebo-controlled clinical trials of longer duration, substantial evidence regarding the safety and risk of testosterone therapy (TTh) with regard to cardiovascular outcomes can only be gleaned from observational studies.\nAccording to the researchers, long-term TTh in men with hypogonadism appears to be an effective approach to achieve sustained improvements in cardiometabolic function and reduces the risk of CV events.\nFor this study, they sought to compare its effects on a host of parameters (obesity, cholesterol levels, diabetes, liver function) considered to contribute to cardiovascular disease.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The release does a nice job of describing the study and reflecting on the relative value of an observational study compared to more rigorous clinical trial designs. That comparison should serve as a signal to journalists to explain these differences in more detail. For example, patients are not randomly assigned to study conditions in observational studies such as this; rather, they end up in one or another treatment arm by choice, thus opening the door for confounding variables to play a role in the outcome. The study did statistically control for a number of possible confounds, and a mention of that in the news release would have been useful.\nIt\u2019s because of the study\u2019s large risk for confounding that leads to uncertainty that we rate this unsatisfactory. The control group (those not taking testosterone therapy) had more prevalent cardiovascular disease and more cardiovascular risk factors. \u00a0Even with the statistical adjustment used in the study, the validity of the results is highly questionable. The other measures\u00a0that were addressed \u2014 including diabetes and lipid levels \u2014 are surrogate endpoints and were likely confounded by factors other than testosterone replacement. \u00a0The comment that testosterone has a \u201cprotective effect\u201d is an egregious misstatement given the important limitations of the study design. \u00a0Randomized controlled trials have addressed this issue and found there does not necessarily appear to be a risk from testosterone, but there is certainly no indication of a protective effect.", "answer": 0}, {"article": "\"We're on the verge of something here that's going to transform lives,\" he says.\nBut they have relied entirely on vision to know whether the arm is going in the right direction or grasping an object with the proper amount of force.\nAt the moment, they are still too expensive, too bulky and too finicky to be used outside a laboratory setting.\nOf course, mind-controlled robots are still years away from consumer applications, McLoughlin says.\nStill, the ability to receive touch sensation from a robotic arm has the potential to help not only thousands of people who are paralyzed, but also people with a wide range of physical disabilities, McLoughlin says.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story does make clear this is a laboratory result for a single man. But:\u00a0How exactly did researchers measure what was gained by the patient? What are the limitations? And, as we explained in the benefits criterion, the story could have done a better job stressing how preliminary these findings are, perhaps by more thoroughly explaining the future steps this kind of research requires before it\u2019s a mass-market device, and how similar technologies created similar excitement early on but never came to pass. Bottom line: It was a case study, not a controlled trial, and the multiple limitations inherent in a case study needed\u00a0more\u00a0mention.", "answer": 0}, {"article": "Miner continued.\nThe results of this study showed that two mesothelioma-specific ENOX2 protein transcript variants were detected in the serum of asbestos-exposed individuals 4-10 years prior to clinical diagnosis of malignant mesothelioma, an exciting sign of progress in the cancer detection field.\nIn this study, the serum presence of a mesothelioma-specific form of the ENOX2 protein (a recently identified marker of malignancy) was found within the serum of asbestos-exposed individuals an average of 6.2 years in advance of clinical symptoms by using the ONCOblot tissue of origin cancer detection test.\nSerum samples that were collected from asbestos-exposed individuals prior to the development of mesothelioma as part of a cancer surveillance program were tested for ENOX2 protein presence to determine how long in advance of clinical symptoms that the mesothelioma-specific ENOX2 protein transcript variants could be detected.\nDallas, Texas -February 4, 2016 - MorNuCo Laboratories of West Lafayette, Indiana, and their ONCOblot\u00ae Test recently completed a retrospective clinical trial focusing on the early detection of malignant mesothelioma, with the exciting results that the ONCOblot\u00ae test detected a molecular marker that is indicative of the presence of mesothelioma, 4-10 years in advance of clinical symptoms appearing.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The release fails to mention how many people were included in the study: just 17 cancer patients and 15 people who were exposed to asbestos, but had not been diagnosed with cancer.\nAlthough the release notes near the top that the study was \u201cretrospective\u201d (it looked back at stored blood samples taken from people exposed to asbestos, some who had been diagnosed with mesothelioma and some without known cancer), there is no mention of the long years of work needed before anyone will be able to say the test would be useful to people who have been exposed to asbestos. The journal article notes, \u201cAs with all biomarker studies, these observations require validation in a larger, independent cohort of patients and should include prospective as well as retrospective sampling.\u201d The release should have noted that there is an important difference between finding that people who have cancer carry a certain biomarker and what people really want to know: that the biomarker can predict who will or won\u2019t develop cancer, and even more importantly, whether starting treatment earlier makes any difference.", "answer": 0}, {"article": "There may also be other benefits linked to omega 3 fatty acids for the fetus as well, in helping nerve development \u2014 that\u2019s why many prenatal vitamins include forms of omega 3 fats.\n\u201cOur study shows that there may be some relationship between dietary factors and things like egg quality so one idea may be recommending supplementation with omega 3s to improve fertility.\u201d\n\nExactly how the healthy omega 3 fatty acids are helping the ovary to produce better quality eggs isn\u2019t clear yet.\n\u201cWe hope in the future to have more answers to be able to say firmly that yes, omega 3 fatty acids are the way to go [for women hoping to get pregnant,]\u201d she says.\nNow, according to scientists at the University of Colorado, there is even evidence that the healthy fat can boost your chances of getting pregnant.\nMore studies need to replicate and confirm the role that omega 3 fatty acids might play in fertility, but for now, Skaznik-Wikiel says that there isn\u2019t much harm in consuming more omega 3 fats.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The Time story acknowledges in the second paragraph that the study involved only mice and notes that more research will be needed to determine whether increasing omega 3 consumption will have any effect on human fertility.\u00a0But the story provides no sense of what\u2019s involved, or just how challenging it will be, to translate these results to humans.\u00a0So why report it now when there\u2019s no evidence? We don\u2019t know.", "answer": 0}, {"article": "\"(But) we used aspirin long before we knew how it worked.\n\"That's huge,\" said lead author Fran Weaver, a researcher with the Hines VA Hospital in Hines, Ill.\n\nShe said the best drugs provide only one to two hours of added improvement, or \"on time.\"\nThere also was one death related to the surgery involving a patient who had bleeding in the brain, went into a coma and died several days later, she said.\nThose who got the therapy also had significantly more improvement in other measures of symptoms, according to the study that will appear today in the Journal of the American Medical Association.\nThe hospital has done about 300 of the procedures since 2005, said Brad Hiner, an associate professor of neurology at the Medical College of Wisconsin and neurologic director of the hospital's deep brain stimulation program.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The news article is based on a randomized controlled trial published in the Journal of the American Medical Association. \nThe study is fairly small and some key outcomes, including the most dramatic, are based on self-reports. It was only six months long, and the efficacy of the treatment over time is still unknown. \nThe story should have reported these caveats. On balance, however, the story earns a \"satisfactory\" rating under the \"evidence\" criterion.\u00a0\u00a0 ", "answer": 1}, {"article": "Vitamin D is found in certain foods and beverages such as fortified milk and cereals, and fatty fish such as salmon.\n\"The risk of MS among daughters whose mothers consumed four glasses of milk per day was 56% lower than daughters whose mothers consumed less than three glasses of milk per month,\" Harvard researcher Fariba Mirzaei, MD, says in a news release.\nIt revealed that women born to mothers who had the highest intake of vitamin D had a much lower risk of developing MS as an adult.\nSunlight is one of the most important sources of vitamin D.\n\nResearchers will present their findings in April at the American Academy of Neurology's 62nd Annual Meeting in Toronto.\nThe study involved more than 35,000 female nurses whose mothers answered questions about their diet habits during pregnancy.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "This story failed to point out the limitations of having the mothers answer questions about their diets during pregnancy many, many years after the fact. The story also should have emphasized that only daughters were included the study, and it\u2019s unclear whether this same protective effect would be seen in males. \n\u00a0\n\n\nFurthermore, the story mentions that the researchers will present these findings at the upcoming American Academy of Neurology\u2019s meeting, but does not explicitly state that the research has yet to be published in a medical journal. Unlike published articles, this study has not gone through a rigorous review process. \n\n", "answer": 0}, {"article": "The U.S. National Institutes of Health has more on insomnia.\nThat means, theoretically, fewer side effects and perhaps less of a tendency to be habit forming, Thorpy explained.\nExperts note that findings from animal studies do not always hold up in human trials.\nBut many questions remain: Do the drugs truly have fewer side effects?\nMore than 30 million Americans struggle to get a good night's sleep, and about one-third of these use drugs to help the process, the study authors pointed out.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "Although there are qualifiers late in the story \u2013 (\u201cBut many questions remain: Do the drugs truly have fewer side effects? Will they be habit forming? And will they change the quality of sleep in any way? Those questions will only be answered with more testing and use in humans.\u00a0 Experts note that findings from animal studies do not always hold up in human trials.\u201d) \u2013 the overall impression is that the data generated in rats and monkeys are transferable to humans.\u00a0 A bit of restraint in the early statements would have provided a much more concise and informative story\nAnd, as noted above, this story misstates the question that researchers investigated.", "answer": 0}, {"article": "Briakinumab works by dampening the immune system response that causes psoriasis, said Bruce Bebo, director of research and medical programs for the National Psoriasis Foundation, based in Portland, Ore.\n\nMore serious infections were seen in people taking briakinumab (2.6 percent) vs. those taking methotrexate (1.8 percent).\nFor people living with psoriasis, Bebo said the message from this study is that \"dramatic progress has been made from where we were just five years ago.\"\nThe study lasted one year.\nWEDNESDAY, Oct. 26, 2011 (HealthDay News) -- An experimental psoriasis treatment performed significantly better than the commonly prescribed medication methotrexate in a new clinical trial.\n\"Cancer risk is extremely hard to define, and this study was not powered to detect any difference in the risk of developing a malignancy,\" said Bebo.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "Adequate job explaining the study.\nThe ending \u2013 with quote from the National Psoriasis Foundation spokesman \u2013 was apt:\u00a0 \u201cFor people living with psoriasis\u2026the message from this study is that \u2018dramatic progress has been made from where we were just five years ago.\u2019 \u201d\nWe like that;\u00a0 it was measured and responsible and didn\u2019t go beyond the limits of what this study means.", "answer": 1}, {"article": "Toxins produced by bacteria, such as salmonella, can severely harm the digestive system by damaging nerves critical to healthy gut function.\nThe tests, created by Mark Pimentel, MD, director of the GI Motility Program and Laboratory, confirm when a patient has developed IBS because of food poisoning, a major cause of the disorder.\nFor more information on IBS and the new blood test for the disorder, watch this video:\n\nFirst Ever Blood Test for IBS\n\nCedars-Sinai has entered into an exclusive license agreement with Commonwealth Laboratories for several patent applications covering the blood tests, developed by Pimentel to detect both anti-CdtB and anti-vinculin antibodies in the diagnosis of irritable bowel syndrome and inflammatory bowel disease.\nNew blood tests will speed up diagnosis for the most common GI disorder\n\nLOS ANGELES (May 14, 2015) - Millions of people afflicted by irritable bowel syndrome can now be diagnosed quickly and accurately with two simple blood tests developed by a Cedars-Sinai gastroenterologist.\nThe blood tests identified the two antibodies associated with IBS -- anti-Cdtb and anti-vinculin -- with greater than 90 percent certainty.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "While the release does note the overall size (\u201cnearly 3,000 people\u201d) and general outlines of the study, it\u2019s characterization of the evidence is misleading. First, this isn\u2019t a test for IBS in general. It is a test for patients with chronic diarrhea \u2013 or IBS with diarrhea as the primary component. The release is simply wrong to use the general term \u201cIBS\u201d to describe this subgroup of IBS patients. Second, the release doesn\u2019t describe that while the IBS population is large, there were only 43 control patients. It is hard to know how specific the test is without testing in more controls. In addition, the study reported (but the release didn\u2019t mention) that the test wasn\u2019t as good for differentiating IBS from celiac disease, and that\u00a010-15% of inflammatory bowel disease patients (especially Crohn\u2019s disease) also have IBS, so there\u2019s no perfect test for these patients. Finally, such a study needs to be repeated in a new population. Tests and their thresholds are never quite as good when applied to new populations \u2014 something that wasn\u2019t done here.", "answer": 0}, {"article": "For example, a normal-weight woman should gain between 25 and 35 pounds, while an overweight woman should gain between 15 and 25 pounds.\nWhile the new study generally did not show fewer complications in the diet and exercise group, Dr. Loralei Thornburg told Reuters Health that it\u2019s good that there was no increase in complications.\nAfter including the new studies, the new review found \u201chigh-quality evidence\u201d to show diet, exercise or both can reduce the risk of excessive weight gain during pregnancy, write the researchers in The Cochrane Library.\nThere was no clear benefit among the women in the diet and exercise groups when the researchers looked at other complications, such as cesarean delivery, but it did look like there may be some benefit, they write.\nThe review incorporates dozens of new studies to update a previous review that did not find enough evidence to support the use of diet and exercise during pregnancy.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "Another close one. The story states that \u201cthe researchers examined data from 65 randomized controlled trials, which are considered the \u2018gold standard\u2019 of medical research. They were able to combine data from 49 trials involving a total of 11,444 pregnant women.\u201d Good. The story also says \u201cthe new review found \u2018high quality evidence'\u201d \u2014 not as good. The story never defines what it means by \u201chigh-quality evidence,\u201d and we think that description could be somewhat misleading, since the paper notes that 20 of the studies it looked at were \u201cat moderate-to-high risk of bias.\u201d The paper also differentiated between findings for which it had \u201chigh-quality evidence\u201d (those studies found \u201cno clear difference\u201d on excessive birth weight) and those for which it had \u201cmoderate-quality evidence\u201d (those studies found that women in diet or exercise programs had less weight gain) \u2014 a distinction the story didn\u2019t address.\nWith that being said, we acknowledge that it would have been difficult for the story to get into the details that would have clarified these issues, and we think the coverage is generally on target. We\u2019ll give the benefit of the doubt here and award a Satisfactory.", "answer": 1}, {"article": "Further,Dr.\nCrucially, this woman was in good health, suggesting that therapies aimed at blocking PCSK9 would not only be effective, but also safe.\nDr. Cohen, Professor of Internal Medicine and with the McDermott Center, holds the C. Vincent Prothro Distinguished Chair in Human Nutrition Research.\nThis woman had stunningly low levels of LDL cholesterol.\nWhile anything below 100 is considered good, her LDL cholesterol level was just 14.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The release shares incomplete information on one patient\u2019s experience. That is not satisfactory.", "answer": 0}, {"article": "Dr. William Nelson, co-vice chair of the SU2C Scientific Advisory Committee and director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland, said:\n\n\"Understanding the link between prostate cancer and DNA repair mutations is incredibly important for patients and their families.\nMost of these men, who all had terminal prostate cancer with limited treatment options, had disease control lasting much longer than expected in this group of patients.\nThe trial is a milestone in cancer treatment as the first to show the benefits of 'precision medicine' in prostate cancer - with treatment matched to the particular genetic characteristics of a man's tumour.\nThe next trial includes only men with these mutations in their tumours, with the aim of proving that olaparib is highly effective for them.\"\nThis is partly because the disease is so hard to treat once it has spread around the body.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "Summaries of studies need qualifiers. The trial was a controlled clinical trial (not observational) in that the researchers selected the subjects and decided what to treat them with. But it wasn\u2019t randomized or blinded which made it ripe for potential biases.", "answer": 0}, {"article": "Dr Allan Pantuck, the lead clinician of the study, added, \"With fixed dose therapy, patients are often switched to other drugs when they no longer respond to treatment.\nOur clinical study has shown that dosing can profoundly affect the efficacy and safety of treatment.\n\"The implementation of CURATE.AI represents a game-changing shift in the way that combination therapy can be optimised at the single patient level, and we have shown that N-of-1 medicine can be a reality.\nHowever, CURATE.AI has shown that patients can still respond to the therapies that have seemingly stopped working by continuously identifying the patient's optimal dosing parameters.\"\nEven a single patient's response to therapy can vary substantially over the course of treatment.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The release makes clear that it is focused only on one patient\u2019s treatment. But that\u2019s not good enough. The release should make clear that, while this patient\u2019s results were promising, there are severe limitations on the extent to which the patient\u2019s results can be extrapolated to a larger population. Instead, the release does just the opposite, calling a single case a \u201cbig step forward.\u201d In addition, as noted above under \u201cExplain Harms,\u201d this patient was part of a clinical trial, and there are other clinical trials under way. Are they phase 1 trials? Phase 2? Phase 3? How many patients are involved? What are the study designs? The release raises more questions than it answers.", "answer": 0}, {"article": "\"Normally when you make drugs, it's hard to say 'attack only that protein.'\nThe precision of the process is crucial to limiting side effects, the researchers said.\nThey did not inject directly into the tumor as many other researchers have done.\nAnd unlike conventional gene therapy -- where the offending gene is replaced by a new one or overridden -- this therapy is reversible, said Adams.\nThe experiment proceeded just as planned, as biopsies later showed.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "\u00a0The story stated that this was an \"early phase clinical trial\" but didn\u2019t explain how early \u2013 that tissue samples of only three patients were tested.\u00a0 In addition, the results have not been subject to peer review, something the story didn\u2019t mention. The story also crossed a line when it stated, \"The experiment proceeded just as planned, as biopsies later showed.\"\u00a0 This would suggest that the study was in fact completed and the results were completely as expected.\u00a0 However, a more careful review of the letter does not support that view.", "answer": 0}, {"article": "It\u2019s easy to get into the habit of popping a pill to have a good night\u2019s sleep. Insomnia, which affects a third of adults, becomes more common as we age.\n\nBut as evidence has mounted about the risks of drugging the brain to induce or maintain slumber, more doctors are steering patients away from sleep aids, including over-the-counter medications, and are offering innovative behavioral-change solutions.", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "This story is not focused on one specific study, but it notes that the American College of Physicians reviewed 15 years\u2019 worth of scientific evidence before issuing guidelines recommending that drugs should be used to treat insomnia only if cognitive behavioral therapy has failed. More could have been said about how thorough the review was that contributed to the guidelines, and if there were any notable gaps in research that limit the findings.", "answer": 1}, {"article": "Inc.\n\nFor more on multiple sclerosis, visit the U.S. National Library of Medicine.\nAnd I see no major advantage of this drug versus that older drug.\nWhat's more, to date the treatment appears to be safe.\nAnd all this new drug is attempting to do is replicate the same that rituximab already does.\nWhat's more, relapse rates were much lower among those taking the new drug, in contrast to those taking a placebo.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "What does an 89 percent drop in lesion count mean?\nRelapse rates may have been a more helpful indicator, but we\u2019re only told they were \u201cmuch lower.\u201d\u00a0 How much lower?\u00a0 What does that mean to patients?\nAnd if the Mayo expert says that a competing drug has been in early trials for years \u2013 why not provide the evidence from those trials?\nAll in all, the story didn\u2019t provide a meaningful context for readers.", "answer": 0}, {"article": "In coherent breathing, the goal is to breathe at a rate of five breaths per minute, which generally translates into inhaling and exhaling to the count of six.\nThe research was presented in May at the International Congress on Integrative Medicine and Health in Las Vegas.\nWhile the study was small and lacked a control group, Dr. Streeter and her colleagues are planning a randomized controlled trial to further test the intervention.\n\u201cThey show that a behavioral intervention can have effects of similar magnitude as an antidepressant.\u201d\n\nControlled breathing may also affect the immune system.\nThe researchers found that the breathing exercise group\u2019s saliva had significantly lower levels of three cytokines that are associated with inflammation and stress.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "This was a tough call. The story rightly alludes to the need for more research. \u201cHow controlled breathing may promote healing remains a source of scientific study,\u201d it says, describing a \u201ctheory\u201d that controlled breathing can change the response of the body\u2019s autonomic nervous system, which controls unconscious processes such as heart rate and digestion as well as the body\u2019s stress response.\nBut more skepticism is warranted. For example, when it comes to the description of a \u201csmall study\u201d at Boston University of patients with major depressive disorder, who experienced fewer depressive symptoms and increased levels of a brain chemical with calming and anti-anxiety effects after they did 12 weeks of daily yoga and breathing exercises. The story mentions the lack of a control group and plans for a randomized control trial \u201cto further test the intervention,\u201d but nevertheless quotes the researcher\u2019s assertion that the findings \u201cshow that a behavioral intervention can have effects of similar magnitude as an antidepressant.\u201d That\u2019s quite a leap.\nAnd the story doesn\u2019t challenge an statement by a psychiatry professor who wrote a book about breathing and has a private practice teaching breathing workshops, that he has \u201cseen patients transformed by adopting regular breathing practices.\u201d It\u00a0should have cautioned on the limitations of such anecdotes and noted that the professor clearly has a strong vested interest in this approach.\n", "answer": 1}, {"article": "Immunotherapy moves to the front lines in fight against lung cancer\n\nThe cancer death rate has dropped again.\nThe trial that grabbed much of the spotlight Monday is a randomized effectiveness study that involved more than 600 untreated patients with advanced nonsquamous non-small cell lung cancer \u2014 a common type of the disease.\nAnd he said the trial showed that \u201ctumor mutational burden\u201d is a reliable way to predict who will benefit from the medications.\nExperts said it was especially significant that the study showed that patients benefited from the Keytruda-chemo combination regardless of the levels of a protein, called PD-L1, found on their cancer cells.\nThe studies simultaneously were published by the New England Journal of Medicine on a day that some experts called the \u201cSuper Bowl of lung cancer immunotherapy.\u201d\n\nThe reports underscore the increasingly important first-line role that immunotherapy, which unleashes the immune system to destroy cancer cells, is taking against the deadliest cancer.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story tempers the positive news, stating: \u201cRoy Herbst, an oncologist at Yale Cancer Center said that most lung cancer patients now will be offered immunotherapy in some form much earlier than before. Still, he said, the approach was not a cure and there is a lot of room for improvement.\u201d That is information we wish the TIME story had included, too.\nIt also states that it\u2019s unclear whether Keytruda will work alone, without chemo. And it notes that it\u2019s too early to know whether two other treatments will translate to benefit that matter to patients.\nHowever, the story lumps together survival and progression-free survival \u2014 or non-worsening of the cancer \u2014 into the same group without explaining that progression-free survival may not translate into overall survival.\nAlso, the story doesn\u2019t go into the remaining unknowns about the studies and these treatments. How many years will these patients survive? And will they have to take these drugs indefinitely?", "answer": 0}, {"article": "And conditions in which the body makes too little insulin or is resistant to its effects \u2014 diabetes, prediabetes, even untreated high-blood pressure \u2014 are associated with an increased risk of Alzheimer\u2019s.\nBut, she added, if her study goes forward, many will be able to participate in it.\nThat led to the current study, lasting four months.\nAnd patients would need a special device to get it deep into the nose.\nIt is too soon to say if the treatment is even safe, she said.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story provided a reasonably detailed and accurate description of the study, with appropriate attention to limitations.\u00a0It cautioned readers about the small size of the study and the preliminary nature of the\u00a0data in several places, including high up in the piece. We liked that it referenced\u00a0previous experience showing that early findings\u00a0such as this\u00a0\u201coften fall apart\u201d in larger, longer tests.", "answer": 1}, {"article": "\"And a well designed instrument will push back.\"\n\"The people who had 24 lessons had gone down from about 21 days of pain that the usual care group reported to about 3 days in pain,\" says Little.\nHe cautions though that it may be something else entirely that accounts for the apparent success of the Alexander Technique.\nHe's about to start a new study that involves giving chronic back pain sufferers lessons in the Alexander Technique and exercises, and then measuring how far their spines can twist and the size and strength of their deep lumbar muscles \u2013 which Little thinks might work poorly in people with chronic low back pain.\nHe led a study of some 460 patients who were given Alexander lessons, massage, or the usual care of pain killers and exercise.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The journalist did not adequately characterize the quality of evidence supporting the Alexander Technique. The evidence supporting the Alexander Technique is thin.\u00a0 It comes from a single clinical trial with some distinct methodological limitations.\nFor instance, the study compared up to 24 sessions of Alexander Therapy with only six sessions of massage. The exercise program employed in this study has never been adequately tested in a clinical trial. Given the way the study subjects were selected, it is not clear if this technique can be applied in usual clinical practice with the same results.\nAnd the article did not mention that the Alexander Technique has never been compared to other standard treatments for chronic back pain in clinical trials.\nSo pending further research, it is not clear if this constitutes a treatment advance or merely one more option that provides a modest benefit. \n", "answer": 0}, {"article": "Drinking cow\u2019s milk produced at night may be a treatment for anxiety and insomnia, suggests an animal study in the Journal of Medicinal Food.\n\nA glass of milk at bedtime has long been touted as a sleep aid. But the study found that milk collected at night, or night milk, had enhanced sedative effects in mice compared with milk produced during the day. Night milk significantly decreased the rodents\u2019 physical activity, balance and coordination and increased sleep time compared with day milk, the research showed.", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story earns points for declaring up front that the study was conducted in animals and including a caveat at the end that the study can\u2019t be generalized to humans. This is an excellent practice that helps counterbalance some significant concerns we had with other aspects of the piece.\nSpecifically, the statements\n\u2026 the study found that milk collected at night, or night milk, had enhanced sedative effects in mice compared with milk produced during the day.\nand\nNight milk significantly decreased the rodents\u2019 physical activity, balance and coordination and increased sleep time compared with day milk, the research showed.\nare misguided. The underlying study never directly compares night milk to day milk. Rather, the treatment arms\u00a0of 1) day milk at three doses, 2) night milk at three doses, and 3) diazepem\u00a0are each compared to the treatment arm corresponding to the control group,\u00a0which consists of mice who only received distilled water.\nWe think the confusion may stem from the fact that the study also reports one-way ANOVA results. (Just fancy statistics jargon for comparing treatment effects between multiple groups.) A significant ANOVA result allows one to\u00a0conclude that not all of the treatment\u00a0arms are the same, i.e. there exists at least a pair of comparisons amongst the treatment arms that are significantly different from each other. ANOVA used in this way simply tests an omnibus hypothesis that is not very interesting in its own right, in that it is not a procedure that identifies which two experimental arms are different.\nWe acknowledge that the study itself is not clear on this point, making it difficult for journalists to analyze the results. Inclusion of an independent source might have helped with the evaluation.", "answer": 0}, {"article": "And now, a real pill for your unreal illness.\nThe study found that hypochondriacs who got cognitive behavior therapy, which encourages people to challenge the validity of their disabling beliefs, also improved -- as much as those given the drug.\nMen who had only daughters were more likely to have developed the disease than those who had at least one son, researchers found, and the relative risk of prostate cancer decreased as the number of sons increased.\nIn the first controlled study that compared a group of hypochondriacs given the drug with a group that got psychological talk therapy and another group that received sugar pills, the medication significantly reduced people's fears about imaginary illnesses.\nScientists report that the antidepressant Paxil helped hypochondriacs be less fearful about getting sick.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story did not adequately describe the size, design, duration or outcomes of the trial. \nAlthough the story did not explicitly mention that the study was a randomized controlled trial, it did explain that Paxil was compared to a sugar pill (placebo) and to cognitive behavioral therapy for effectiveness in helping people affected by hypochondria.\u00a0 However, the story did not accurately represent the results of the study.\u00a0 The story said \"the medication significantly reduced people's fears about imaginary illnesses.\" But, in fact, only when you compared the three groups (Paxil, cognitive behavioral therapy, and sugar pill) did one find that there were significant differences among the groups.\u00a0 A back of the envelope comparison only\u00a0between those taking Paxil and placebo finds that the difference between these two is not statistically significant.", "answer": 0}, {"article": "The procedure, called a prostatic urethral lift, does not improve flow as much as surgery, in which a physician cuts away some of the inside of the prostate to allow better flow. But the lift procedure and recovery are much quicker, with no hospital stay and fewer complications. And patients who get the sutures can always come back for surgery later.", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The procedure was studied in a prospective, 5-year randomized trial but those details were not included in the story.", "answer": 0}, {"article": "There are three types of omega-3 fatty acids: a-linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).\n\"There is evidence that both omega-3s from plants and marine sources are protective against cancer and we wanted to determine which form is more effective.\"\n\"This study is the first to compare the cancer-fighting potency of plant- versus marine-derived omega-3s on breast tumour development,\" said the professor in the Department of Human Health and Nutritional Sciences.\nThe next step is to investigate the effects of omega-3s on other forms of breast cancer.\n\"The mice were exposed to the different omega-3s even before tumours developed, which allowed us to compare how effective the fatty acids are at prevention,\" said Ma.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "Not until the fifth paragraph does this news release mention that this is a study of mice with an unusual form of breast cancer, not healthy humans. It doesn\u2019t explain how those limit the usefulness of the results.", "answer": 0}, {"article": "Cancer cells remain elusive and tough to locate, but a new crop of nuclear-imaging tests promises to lead to more accurate prognosis and treatment.\n\nThe tests use imaging agents that combine radioactive isotopes with targeted molecules that can spot cancer at the cellular level. The ability to accurately locate the cancers helps physicians make better and earlier diagnoses\u2014and may eventually make possible targeted nuclear-medicine therapies that identify and kill cancer cells, but not the surrounding healthy cells.", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "This was a somewhat tough call, because the article is not, strictly speaking, describing the research behind the newly approved tests. But the article needed at least some indication about the strength or weakness of evidence for the use of these tests; who the best candidates are for the test; how widely they should or could be used; and their limitations.\nAlso, a\u00a0big issue for prostate cancer screening is finding tests that better identify aggressive cancers\u2013finding more cancers is not helpful given concerns about over diagnosis\u2013especially low-risk cancers when PSA is <5. \u00a0We found some of the discussion misleading: \u201cProstate-specific antigen, or PSA, is the common way to screen for the disease. But it isn\u2019t entirely reliable because the PSA protein count also rises with age and disease of the prostate like inflammation, and it doesn\u2019t help to determine the location of the tumor. That can be crucial in deciding on treatment.\u201d\nWhen PSA is elevated and/or the prostate exam is normal, cancer will be found through a biopsy performed with ultrasound (or more recently in some centers with MRI). Yes, PSA has false positives, but you can determine that only by performing biopsy\u2013not an imaging study. Depending upon the PSA level, the digital rectal finding, and the biopsies, clinicians have a reasonable idea of whether the cancer is confined to the prostate\u2013potentially curable\u2013so the added value of the new imaging in this scenario is quite unclear.", "answer": 0}, {"article": "Fibromyalgia is a syndrome marked by widespread pain \u2014 including discomfort at specific \u201ctender points\u201d in the body \u2014 along with symptoms such as fatigue, irritable bowel and sleep problems.\nThe study is only the first clinical trial to test affective self-awareness for fibromyalgia, and it had a number of limitations, including its small size.\nPart of that, according to the researchers on the new study, may be because standard treatments do not specifically address the role psychological stress and emotions can play in triggering people\u2019s pain.\nThat is important because it is possible for patients to benefit from simply receiving attention from a healthcare provider, or being part of small-group sessions with other people suffering from the same condition, for example.\nThe study, of 45 women with fibromyalgia, found that those who learned a technique called \u201caffective self-awareness\u201d were more likely to show a significant reduction in their pain over six months.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story does a relatively\u00a0thorough job of\u00a0explaining the study and\u00a0included key information such as the number of patients, a description of the intervention, and the length of follow-up. It could have done a better job of pointing out strengths of the research, including the fact that the evaluators were blinded to the treatment status of the subjects.\u00a0Moreover, the story didn\u2019t comment on the the fact that the therapy was provided only in the first month of the study (and was limited to\u00a0the\u00a0initial evaluation followed by three two hour group sessions),\u00a0and yet\u00a0the positive\u00a0effect on pain was noted at 6 months\u2013evidence of a durable effect of the treatment.\nImportantly,\u00a0the story drew attention to\u00a0several limitations such as the\u00a0small sample size and the fact that the control group was on a wait list and didn\u2019t receive as much\u00a0attention as the intervention group.\u00a0The latter point is important, the story points outs, because patients tend to get better when they are\u00a0seen by health care professionals,\u00a0regardless of whether any effective treatment is provided.\u00a0Accordingly, the improvements seen with affective self-awareness\u00a0therapy might\u00a0be due in part to the increased number of office visits these patients\u00a0made\u00a0rather than any specific effect of the treatment.\u00a0", "answer": 1}, {"article": "Minimally invasive procedures increased to 31 percent of all radical prostatectomies in 2005 from 12.2 percent in 2003.\nThe study, published on May 10 in The Journal of Clinical Oncology, examined a sample of 2,702 Medicare patients undergoing radical prostatectomy, the complete removal of the prostate, from 2003 to 2005.\nThe widely advertised procedure is becoming more popular, said Dr. Jim C. Hu, the lead author of the study and an instructor in surgery at Harvard.\nBut the surgery increases the chance for longer term problems that require further therapy, the research says.\n\u201cThis paper,\u201d Dr. Hu said, \u201cdemonstrates that there are hidden risks for patients who opt for laparoscopic or robotic surgery.\u201d\n\nIn laparoscopy, a surgeon inserts instruments through small cuts in the skin instead of making large incisions to expose the organs.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The article is based on a retrospective study of outcomes in a large population, conducted by university researchers and published in a major peer-reviewed journal.\nHowever, there have been no head-to-head randomized trials comparing open vs. laparoscopic prostatectomies. Since outcomes in observational studies are subject to selection bias, the article should have plainly indicated this. \u00a0\n\u00a0", "answer": 0}, {"article": "\"Transfer between hospitals takes a lot of time,\" said Turner.\nThe researchers hope that the device will save valuable time -- especially important in stroke where time is brain -- when it is deployed with emergency medical personnel in the field.\nThe VIPS device requires very little training to operate compared to that required to learn standard emergency examination skills, thereby reducing the possibility of human error during emergency diagnosis.\nIn the study, the VIPS device was deployed with emergency medical personnel in regions served by five Comprehensive Stroke Centers equipped with the endovascular capabilities to treat large-vessel occlusions that underlie severe stroke.\nIt is also not clear how the device would work for patients with cranial implants, as metal interferes with the device's operating radio frequencies.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The study compares this device to a standard clinical diagnosis. However, the gold standard in stroke care is a CT scan which determines if a patient is a candidate for clot busting drugs like tissue plasminogen activator (tPA), which opens blocked vessels after a stroke, or endovascular therapy. The real comparison would be comparing this device to CT scans given that mobile CT scanners are increasingly being used in ambulances.", "answer": 0}, {"article": "\u201cIf screening is going to work, you\u2019ve got to keep at it.\u201d\nThis latest study, published in the journal Lung Cancer, looked at death rates in a different, smaller population of heavy smokers, and estimated that those who received up to two CT scans would have between a 36 and 64 percent lower risk of dying, compared to those who went unscreened.\nFor instance, to compare death rates, the researchers tracked how many people died among those who were screened, then pulled out all the people with similar underlying characteristics in the other two groups and looked at their death rates, Hanley explained.\nIn the current study, funded in part by manufacturers of CT scanners (along with government and other sources), Henschke and her colleagues compared outcomes for nearly 8,000 smokers and former smokers who volunteered to undergo CT scans to outcomes in two sets of people with smoking histories who were not scanned.\nThe results are in keeping with those of a much larger study published last month, which showed that these 3-D X-rays, or CT scans, reduced the death rate among 53,000 current and former heavy smokers by 20 percent compared with screening using regular chest X-rays.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "\n\n\n\n\nThis criterion is of critical importance given the controversies over lead researcher Claudia Henscke\u2019s long-standing advocacy of CT screening of smokers and criticism of some of her earlier publications on this topic. This latest study raises a number of questions about the methods used to compare lung cancer deaths in three different groups of people. The screened group was made up of heavy smokers living in New York who were recruited by Henschke and her team specifically for a study of CT screening. There was no control group, so in this study statistics from two other unrelated studies are used. One group (CPS-II) was made up of people who reported being smokers as part of a large nationwide study of cancer in general. The second group (CARET) was a subset of smokers who took part in the control group of a trial of drugs to prevent lung cancer.\nThe story takes note of earlier controversies involving Henschke and points out that this study attempts to compare groups of people with important differences and then calculate estimates of the number of lung cancer deaths would have been expected in the first group if they had not been screened. \nAlthough the headline, lead and concluding lines of this story don\u2019t incorporate these and other concerns, we give the story credit for attempting to address challenging questions of scientific and statistical methods.", "answer": 1}, {"article": "Botulinum toxin type A is sold under different brands, but it\u2019s best known by the Allergan brand-name Botox.\nOne is how long the benefits of repeat Botox injections might last: this study tested the effects of just one Botox treatment over three months.\n\u201cThere are several questions that need to be answered by doing larger and longer-term studies,\u201d Dr. Anneke van der Walt, a neurologist at Royal Melbourne Hospital in Australia, said in an email.\nLarger studies, van der Walt said, should look at whether Botox is more effective for some tremors than others.\nRight now, there\u2019s no good way to treat MS arm tremors, said Nicholas G. LaRocca, vice-president of healthcare delivery and policy research at the National MS Society.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "Good context provided.\u00a0 Example:\n\u201cThis study is fairly preliminary, and it had a small number of patients,\u201d LaRocca said. Larger studies, of more-diverse groups of MS patients, are needed, he said.\nThe study\u2019s lead researcher agreed on the need for more work. \u201cThere are several questions that need to be answered by doing larger and longer-term studies,\u201d Dr. Anneke van der Walt, a neurologist at Royal Melbourne Hospital in Australia, said in an email.\nOne is how long the benefits of repeat Botox injections might last: this study tested the effects of just one Botox treatment over three months.\nIn real life, the injections would have to be repeated every few months, or possibly every six months for some people, according to van der Walt. Another question is whether the side effects change over time.", "answer": 1}, {"article": "They form when the skin is rapidly stretched, such as during puberty, pregnancy, and rapid weight gain, says Joshua Zeichner, MD, director of cosmetic and clinical research at Mt.\nThe study, funded by Merz Pharmaceuticals, which makes the cream, was presented at the annual meeting of the American Academy of Dermatology.\nNew stretch marks were also softer and smoother in 54 women who used the cream for three months, says Zoe Draelos, MD, a consulting professor of dermatology at Duke University Medical Center in Durham, N.C. \"The stretch marks did not go away,\" she tells WebMD.\nOnions contain flavonoids, a type of antioxidant, that have anti-inflammatory properties, Draelos says.\nThe new product also contains pennywort, a plant found in Asia, Africa, and the Americas that has anti-inflammatory properties and is widely used in Indian naturopathic medicine for ulcer healing, she says.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The design of this study was such that the onion cream treatment was almost guaranteed to come out ahead, but\u00a0the story offers no cautionary notes regarding the generally poor quality of the evidence. It is a well-established fact that patients often will perceive benefits from a treatment regardless of whether\u00a0the therapy\u00a0is objectively effective (the placebo effect). So one has to question why this study didn\u2019t use blinded observers to grade the effects of the cream instead of relying on the unblinded participant reports.\u00a0Moreover, instead of comparing the onion cream to no treatment, why not compare it with one of the many other moisturizing creams that claim to reduce stretch marks? This would have provided a more useful\u00a0test of the onion extract\u2019s\u00a0\"anti-inflammatory\" properties. The story just didn\u2019t pose any questions about the evidence. ", "answer": 0}, {"article": "That's the concern.\"\nAlthough the companies that make the CT machines have been developing new protocols designed to minimize radiation exposure, particularly for children, everyone agrees that the most prudent thing to do is to eliminate unnecessary use.\nBut researchers have estimated the risk based on what is considered the best information available about the health effects of radiation -- data collected from survivors of the atomic bombings of Hiroshima and Nagasaki, as well as exposure of nuclear plant and medical workers.\nBecause it would take decades to follow a large number of patients who have undergone CT scans to determine the exact risks posed by the exams, there are no direct data demonstrating the danger.\nSome question the estimates, saying the risk of exposure from radiation from multiple CT scans may not be the same as from radiation from an atomic bomb.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story does a good job of describing the available evidence that CT scans are harmful. The story details that the risk associated from\u00a0CT scans is extrapolated from radiation exposures at Hiroshima and Nagasaki and from industrial situations.\u00a0 One study cited in the story used a simulation (dummies receiving radiation in\u00a0CT scanners.) The critics and proponents of the methodology are both given voice.\u00a0 The story mentions that studies using more definitive methods are ongoing.\u00a0 This is excellent detail and balanced analysis.", "answer": 1}, {"article": "\"This is not a colossal risk,\" Rippon said.\nExperts said the findings could make doctors think twice before prescribing the standard hormone treatment to men with prostate cancer, particularly if they are at risk of heart disease.\nStill, these risks were low in absolute terms: researchers estimated the hormone therapies would cause an extra 10 heart problems \u2013 like chest pain or a heart attack \u2013 a year for every 1,000 prostate cancer patients.\n\"What we can do with these results is to raise a flag with hormone treatments,\" said Mieke Van Hemelrijck, a cancer epidemiologist at King's College in London and the study's lead researcher.\nPrevious studies have found hormone therapy given to prostate cancer patients with a history of heart disease increases their chances of dying.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "\n\n\n \nAlthough this study used data on a very large number of patients with prostate cancer, its results don\u2019t justify the headline claim that \u201cprostate cancer treatment may spark heart problems.\u201d\nBy its very nature, this sort of observational study can only point out associations, not causation. While this analysis meshes with hints from earlier reports that raised questions about whether eliminating or blocking testosterone might have some effect on the hearts of patients, it leaves huge questions unanswered.\nFor example, the reporter failed to address an important concern about the design of the study: that it compared prostate cancer patients who received hormonal therapies to people in the general population. \nBy not comparing prostate cancer patients who received hormonal therapies to other prostate cancer patients who did not receive hormonal therapies, the researchers left open the possibility that men with prostate cancer have a higher risk of developing heart disease in general\u2026 and that at least some of the hormonal therapies may not actually be associated with additional heart disease risk.\nIn addition, while this story reported that \u201c[p]revious studies have found hormone therapy given to prostate cancer patients with a history of heart disease increases their chances of dying,\u201d it failed to tell readers that this latest study found that men with a previous history of heart disease had a less pronounced increase in risk of an event. ", "answer": 0}, {"article": "Guyuron, chair of plastic surgery at University Hospitals Case Medical Center in Cleveland, went on to identify four common \"trigger sites\" and publish studies showing that, in selected patients, surgical decompression of nerves in one or more of these sites provides lasting migraine relief. He has also taught 250 plastic surgeons around the world (none in the Philadelphia area) to perform the outpatient operation, which costs an average of $10,000 and is not covered by many insurers.", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "One of the first mistakes the story makes is conflating cosmetic procedures to marshal evidence behind surgical treatment for migraines. It says that the surgery \u201cidea was unorthodox, but not far-fetched. Botox, which paralyzes muscles by blocking nerve signals, was then being tested for migraines. In 2010, the U.S. Food and Drug Administration approved it for prevention of chronic migraines, the frequent, relentless headaches that afflict 3 percent of \u2018migraineurs.\u2019\u201d Botox is not surgery. As the story explains, it blocks nerve signals temporarily. It does not permanently rearrange a person\u2019s facial structure. Then the story says that \u201cGuyuron, chair of plastic surgery at University Hospitals Case Medical Center in Cleveland, went on to identify four common \u2018trigger sites\u2019 and publish studies showing that, in selected patients, surgical decompression of nerves in one or more of these sites provides lasting migraine relief.\u201d Where were those studies published? How many patients were involved? None of these questions are answered. Later it says, \u201cNeurology journals have declined to publish Guyuron\u2019s submissions.\u201d That casts even more doubt on the underlying evidence for these procedures.\nFinally, the story does not adequately frame this one small RCT from the group of \u201ctrue believers\u201d. While these results are intriguing, it doesn\u2019t provide adequate proof that this treatment is safe and that it works.", "answer": 0}, {"article": "Claudia Kawas, a geriatric neurologist at the University of California, Irvine, said a patient strode into her office soon after the FDA approved the procedure and asked for the \"Alzheimer's test.\" In one hand, he held an article about the approval of Amyvid. In the other, he had a document from a right-to-die group. If the test was positive, he told her, he would get his affairs in order and kill himself within 60 days.", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story reported: \u201cRecent studies involving Amyvid, which is made by Avid Radiopharmaceuticals, an Eli Lilly & Co. subsidiary, have shown that a surprising number of patients thought to have Alzheimer\u2019s didn\u2019t. A paper in the October issue of Annals of Neurology noted that 12 of 53 patients diagnosed with Alzheimer\u2019s by expert physicians had negative PET scans for amyloid.\u201d\nBut the story\u2019s narrative displayed healthy skepticism and a concern for evidence throughout:\nThat section, as well as any we\u2019ve seen in many recent news stories, showed an appreciation for the value of accurate, balanced and complete news stories on sensitive subjects like Alzheimer\u2019s testing.\u00a0 We will point to this part of the story with praise for some time to come.\nKUDOS to the reporter and to the paper!", "answer": 1}, {"article": "The most common form of breast cancer uses oestrogen to grow.\nThis discovery may, in future, help reduce these concerns for some patients, by allowing doctors to test if their cancer is likely to return, and tailor treatment accordingly.\u201d\n\u201cThis early study raises an interesting question of whether cholesterol-reducing treatment, such as statins, could help lower the chances of breast cancer returning for some women who have developed a resistance to hormone therapy,\u201d said Jane Murphy, clinical nurse specialist.\nOur study also demonstrates that statins could be a valuable addition to breast cancer treatment, and that this warrants investigation in clinical trials.\u201d\n\nThe research has not yet been tested in humans.\n\u201cThis study breaks new ground in uncovering how some breast cancers continue to survive without oestrogen and suggests that women could benefit from adding statins to standard anti-hormone treatments.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story acknowledges in the fourth paragraph that this is \u201cearly research \u2014 most of it still in the lab.\u201d Further down it says, \u201cThe research has not yet been tested in humans.\u201d\nIt should have gone farther by pointing out that lab studies are often poor indicators of how cells behave in the human body. Further, it would take years of clinical trials to generate data to support the use of statins for breast cancer. Such caveats would help to temper a researcher\u2019s puffery that the study is \u201chugely significant.\u201d", "answer": 0}, {"article": "His own previous research indicates that cannabis was used as early as 1800 B.C.\nThe study was a randomized, double-blind, placebo-controlled human trial, which is considered the gold standard test for any new medicine.\n\"No one study decides an issue; the sample size is still relatively small (because this is a rare syndrome and so hard to study large numbers of cases) and the duration of treatment so far has been relatively short,\" Hall, who was not involved in the research, wrote in an email.\nShe added that the new study is \"critically important\" for the epilepsy community, which believes a CBD-based medical product would be a first-in-class therapeutic option.\nHe noted that generating more evidence of effective use is \"a good thing.\"\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story gives a fairly good description of the trial. It also provides appropriate context and caveats. It says, for example, \u201cThe study was a randomized, double-blind, placebo-controlled human trial, which is considered the gold standard test for any new medicine.\u201d And it also\u00a0includes a good quote saying, \u201cNo one study decides an issue; the sample size is still relatively small (because this is a rare syndrome and so hard to study large numbers of cases) and the duration of treatment so far has been relatively short.\u201d", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070520/28healthwatch.lede.htm was not found on this server.", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story provided evidence of increased risk only in relative terms, not absolute.\u00a0 See our primer on this issue. Without knowing how common advanced or fatal prostate cancer are, it is not possible to understand what 32% and 50% increases represent.\u00a0 ", "answer": 0}, {"article": "The apolipoprotein gene is inherited from each parent and when a patient inherits the ApoE4 variant from one parent they have a three times greater risk of developing Alzheimer's disease, whereas a patient who inherits ApoE4 from both parents is eight-to-12 times more likely to develop the disease.\n\"Higher FT4 or TSH Below the Normal Range are Associated with an Increased Risk of Dementia: a Meta-analysis of 10 Studies\" (A-180)\n\nSession Information \n\nRegistration for the AACC Annual Scientific Meeting is free for members of the media.\nReporters can register online here: https://www.xpressreg.net/register/aacc0716/media/landing.asp\n\nScientific Poster B-124: Development of a New Biochip Array for ApoE4 Classification from Plasma Samples Using Immunoassay Based Methods \n\nWednesday, August 3\n\n9:30 a.m. \u2013 5 p.m. (presenting author in attendance from 12:30\u20131:30 p.m.)\n\nScientific Posters A-118, A-119, A-135, and A-180\n\nTuesday, August 2\n\n9:30 a.m. \u2013 5 p.m. (presenting author in attendance from 12:30\u20131:30 p.m.)\n\nAll scientific posters will be on display in the Terrace Ballroom at the Pennsylvania Convention Center in Philadelphia.\nTo verify the accuracy of the biochip test, 384 samples were analyzed and results compared to those from a standard molecular diagnostic test.\nResearchers from Randox Laboratories collaborated with research colleagues at the Medical University of Vienna and found that results from the two tests were in 100% agreement.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "Both the release and the study abstract on which it was based offer little information about the characteristics of the participant population whose blood samples were used, or how the participants were recruited and from where. We would also have liked to see it mentioned that the study data have not yet been peer-reviewed or published.", "answer": 0}, {"article": "Surgeons sometimes fly blind when operating on hard-to-reach anatomical parts or hard-to-see conditions. For visual references inside the brain or body, they often rely on images and scans taken before an operation.\n\nA growing number of hospitals are equipping operating suites with magnetic resonance imaging, CT scanners and other technology that enables surgeons to scan a patient in real time, without having to move them from the operating table.", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The only quantifiable evidence the story presents is that \u201cin 40% of cases, brain surgeons will modify what they are doing based on an intraoperative MRI scan.\u201d However, it\u2019s not clear where that number comes from, making it difficult to assess the quality of the evidence. Moreover, surgeons\u00a0modifying what they are doing does not mean that the patient\u2019s outcome is necessarily going to be better.\u00a0Otherwise, the story relies on one lengthy anecdote and qualitative discussions of why these real-time imaging techniques make sense. Some analysis of the existing literature on these techniques would have been valuable.", "answer": 0}, {"article": "Commenting, Professor Andreas Meyer-Lindenberg, Central Institute of Mental Health, Mannheim and member of the ECNP executive board, said: \"This work builds on previous studies that have shown a critical role of excessive activity of subregions of the temporal lobe in the generation of voice hallucinations in schizophrenia.\nTo move this into treatment, controlled trial such as the one by Dollfus and coworkers are important.\nThe French research team worked with 26 patients who received active TMS treatment, and 33 as a control group, who received sham (placebo) treatment.\nThis is the first controlled trial to show an improvement in these patients by targeting a specific area of the brain and using high frequency TMS.\nWhile response rates were moderate, TMS is a welcome addition to the therapeutic repertoire especially for patients who do not respond to medication.\"\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The release does a good job of explaining the size of the trial and the study design. The release would have been stronger if it had noted that it\u2019s not clear how long the benefits lasted beyond two weeks.", "answer": 1}, {"article": "The thought never crossed my mind.\nStudies show that for kids' ear infections, antibiotics work better than waiting\n\nBeing a parent these days sometimes entails this hypocrisy: Yes, I know overuse of antibiotics is creating superbugs that may soon conquer the universe.\nNow two new studies (bolstered by an accompanying editorial) in the New England Journal of Medicine demonstrate what we parents have suspected for years: When it comes to ear infections, antibiotics are in order.\nBoth of the studies, in contrast to earlier research on which the \"watchful waiting\" approach has been based, are considered well-designed, even if they are on the small side.\nInterestingly, antibiotics were no more effective at reducing pain, as reported by parents or children, than placebos.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "Among several deficits in this blog\u2019s characterization of the evidence, the most glaring is its failure to qualify what kind of children were included in the studies being discussed. Both of the trials involved children\u00a0that were by and large between 6 months and 2 years of age and who doctors were absolutely certain had ear infections.\u00a0Contrary to the story\u2019s assertions, these are children\u00a0which current U.S. treatment guidelines say\u00a0should be treated\u00a0immediately with\u00a0antiobiotics.\u00a0The story\u2019s claim\u00a0that these studies contradict current practice is simply not true.\u00a0The \u201cwatchful waiting\u201d option mentioned in the story is recommended only for older children (>2 years),\u00a0or for\u00a0young children when the doctor\u00a0can\u2019t\u00a0be sure if there is an ear infection or not.\u00a0Young children with an uncertain diagnosis remain a challenging group of kids to treat and there are no clear cut answers provided by these studies.\u00a0In the everyday world, doctors may have a tougher time identifying\u00a0ear infections than in these studies because they have less time to get a screaming infant or toddler to sit still for an ear exam.\u00a0Doctors may also be\u00a0less experienced than these experts and\u00a0have a tougher time\u00a0distinguishing ear infections from other kinds of infections \u2014 such as viral colds \u2014 that can cause similar symptoms. So, the benefits of antibiotics are still unclear for kids when there is uncertainty about the diagnosis, because kids with other types of infections probably won\u2019t benefit from treatment but will be\u00a0exposed to\u00a0potential harms. And these studies tell us\u00a0very little about the value of antibiotics\u00a0for treating children older than two (or the author\u2019s\u00a017-year old daughter for that matter), and so the\u00a0story\u2019s blanket assertion\u00a0that \u201cantibiotics are in order\u201d and \u201cwork better\u201d\u00a0for ear infections in all\u00a0children is\u00a0unfounded and is contradicted by considerable evidence.", "answer": 0}, {"article": "Cognitive behavioural therapy (CBT) is a talking therapy that can help a person manage problems by changing how they think and behave.\nThe study, one of the largest randomised control trials to be held in the developing world, followed women diagnosed with depression mid-pregnancy in 40 communities in rural Pakistan.\n\u201cThis is an important study for the impact on mothers with depression but there are global implications for the treatment of all human beings suffering from depression.\n\u201cThese findings on the longer-term benefits at seven years post-treatment are really exciting,\u201d Bhalotra said.\nThe NHS website explains that it is \u201cbased on the concept that your thoughts, feelings, physical sensations and actions are interconnected, and that negative thoughts and feelings can trap you in a vicious cycle\u201d.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story does provide some important details on the initial study:\nThe study, one of the largest randomised control trials to be held in the developing world, followed women diagnosed with depression mid-pregnancy in 40 communities in rural Pakistan.\nHowever, it doesn\u2019t give us adequate information about the follow-up study on maternal outcomes. It states that it is based on research led by Sonia Bhalotra, of the Institute for Social and Economic Research, ISER, at the University of Essex, and that\u2019s about it.\nWe could not find any publication of this presumably new research by Bhalotra.\u00a0What we did find was a media briefing\u00a0indicating that this research was recently presented at a conference\u2013which indicates it should be considered preliminary until published. This point should have been stressed in the news story.", "answer": 0}, {"article": "So the jelly may ooze a little bit, but it will not run out like an oil,\" says Schulman.\nBut now the Food and Drug Administration has evaluated the safety of the second generation of silicone implants and the results are mixed.\nSid Wolf of the nonprofit watchdog group Public Citizen is among critics who point out that the data in the FDA report sample just a fraction of the nearly 400,000 women who receive breast implants each year.\nAlthough the long-term effects of silicone in the body are still uncertain, many plastic surgeons don't see the leaking of modern implants as a health concern.\nStill, there are plenty of satisfied customers among the nearly 400,000 women who receive breast implants each year.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "Missing is reference to the actual FDA- published information on post-approval studies describing:\nConflicting implications of silicone leakage are anecdotal, rather than evidence-based.\n", "answer": 0}, {"article": "Specific means that the test is unlikely to be positive if cancer isn\u2019t really present.\nThe company that developed the test, Gen-Probe, helped to pay for the study, and several authors said they had a personal financial interest in the technology.\nThe two tests together appeared to generate both sensitive and specific results.\nBased on the levels of PCA3 and TMPRSS2:ERG detected, the men were given numerical scores that were classified as being high, medium, or low.\nNow that the researchers have validated the test, further studies in larger, more diverse populations will be important to understand how it is best used.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story did a fair job explaining the study reported on, including mention that additional studies are necessary to validate the results of this study, larger groups of men need to be studied, and more diverse populations need to be tested in order to better estimate the utility of this test. \u00a0However \u2013 the story does not report the PSA range of the men who where included in the study.", "answer": 1}, {"article": "Visit the Mayo Clinic News Network.\nWhile twice-daily injections of low-molecular-weight heparin has been the traditional treatment of choice for cancer patients who suffer a venous clot, Dr. McBane notes that there are numerous limitations to this therapy.\n\"More recently, a number of new blood thinners called 'direct oral anticoagulants' have become available,\" says Dr. McBane.\nFinally, Dr. McBane says there isn't is a good antidote for this medication should a bleeding problem arise.\nTheir findings were presented at the annual meeting of the American Society of Hematology by Robert McBane II M.D., a Mayo Clinic cardiologist.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The news release said next to nothing about how the study was actually conducted. The only details we get are that it was a 6-month study, and that participants took monthly quality of life surveys. But how many participants were there? Was this study randomized? Nothing else is noted in the news release. The conference abstract once again sheds some light: 287 patients with different types of cancer were involved and randomized to receive either apixaban or heparin for 6 months. While this may have been a robust study, we get no sense of that from the news release.", "answer": 0}, {"article": "Diseases like Alzheimer\u2019s start years, even decades, before the first symptoms of memory loss shows up.\n\u201cIf we had a simple blood test, a cholesterol test for Alzheimer\u2019s disease, that would help,\u201d says Dr. Ronald Petersen, director of the Alzheimer\u2019s Disease Research Center at the Mayo Clinic, \u201cbut we don\u2019t.\u201d But Petersen has a potential solution, and according to a new paper released Wednesday in the journal , his Alzheimer\u2019s test has promise.\n\u201cBut what\u2019s nice about it is that it\u2019s a nice non-cognitive, motor factor so it\u2019s looking at another aspect of brain function.\u201d\n\nMORE: This Alzheimer\u2019s Breakthrough Could Be a Game Changer\n\nPetersen suggests that every physician should get this information on their patients at age 65; that way, they can have a baseline against which to compare any changes as their patients age.\nMORE: New Test May Predict Alzheimer\u2019s 10 Years Before Diagnosis\n\nWhile his test is a possible solution to that problem, he acknowledges that the results need be repeated before it\u2019s recommended on a wide scale to physicians across the country.\nFor now, even if doctors identify patients around age 65 who might be at higher risk of developing cognitive impairment, there isn\u2019t much they can do to interrupt the process.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "We are on the fence on this one, but we\u2019ll give the story the benefit of the doubt.\nThe story does give an effective description of how the study was done, and it points out that the tests described are a \u201cpotential\u201d solution and that confirmatory studies need to be performed. \u00a0It also points out that the only way to truly diagnose Alzheimer\u2019s is through examination of spinal fluid or expensive imaging.\nBut the story headline, \u201cA Simple 3-Part Test May Predict Alzheimer\u2019s,\u201d and its sub-head suggesting there\u2019s \u201ca new test that any physician can perform in their office\u201d give an over-optimistic and inaccurate representation of the research and its implications. The 3-part testing process involves detailed patient histories, a psychiatric evaluation, a test of motor skills and a blood test to identify the presence of a specific gene associated with Alzheimer\u2019s Disease. That\u2019s not exactly \u201csimple.\u201d\nWe\u2019re also concerned that the story allows an expert to suggest \u201cthat every physician should get this information on their patients at age 65; that way, they can have a baseline against which to compare any changes as their patients age.\u201d \u00a0Even though the story later knocks that statement down, why even suggest it if the research isn\u2019t yet ready for prime time? We\u2019ll flag the story for this below in the Disease Mongering section.", "answer": 1}, {"article": "Not a single cancer was undetected that became palpable,\" she said.\nHowever, with breast cancer remaining a major cause of cancer death in women, there is good reason to pursue the search for improved screening methods, according to the study's lead author, Christiane Kuhl, M.D., chair of the Department of Radiology at RWTH Aachen University in Aachen, Germany.\nAccording to Dr. Kuhl, the results suggest that MRI can serve as a useful supplemental screening tool for women at average risk, especially those with dense mammographic tissue, and that MRI is superior to supplemental ultrasound for this purpose.\nThe new study showed that, consistent with previous research, breast MRI can depict these rapidly growing cancers with high reliability.\nBreast MRI detected 60 additional breast cancers, including 40 invasive cancers, for an overall supplemental cancer detection rate of 15.5 per 1,000 women.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The release provides a nice summary of the study protocol, noting that:\n\u201cBetween 2005 and 2013, Dr. Kuhl and colleagues studied breast MRI\u2019s impact on 2,120 women, ages 40 to 70, with less than a 15 percent lifetime risk of breast cancer. The women had normal screening mammograms and, in the case of those with dense breast tissue, normal screening ultrasound. Breast MRI detected 60 additional breast cancers, including 40 invasive cancers, for an overall supplemental cancer detection rate of 15.5 per 1,000 women. Of the 60 cancers detected in the study group over the observation period (7,007 screening rounds), 59 were found only using MRI, one was found also by mammography, and none by mammography or ultrasound alone.\u201d\nUnfortunately, the release isn\u2019t clear about the limitations of the study. The study doesn\u2019t show that MRI offers benefits that women really care about such as longer life and better quality of life. The only way to prove such benefits would be in a large-scale controlled trial that follows groups of women (those who do and don\u2019t receive breast MRIs) for many years. The release also fails to mention the risk of over-diagnosis and over-treatment. Finding more cancer at an early stage is not always a good thing, because some cancers don\u2019t progress to a point where they would cause harm. While the release suggests that many of the cancers that were found were aggressive in nature, it doesn\u2019t say how many, nor does it caution that some of these cancers might never have caused a problem. It also doesn\u2019t warn that some particularly aggressive cancers might not respond to treatment despite early detection.\nThe published research noted that the screening studies were read by specialized breast radiologists and that the results \u201cmay not be transferrable to a community level until more radiologists gain practical experience in reading breast MR screening studies.\u201d That would have been a useful addition to the release as well.", "answer": 0}, {"article": "ET.\nA limitation of the study is that the researchers did not assess the effects of untreated erectile dysfunction, or conversely, the effect of having an active sex life without taking erectile dysfunction drugs.\nThe study, which retrospectively tracked more than 43,000 men for an average of 3.3 years, found that men prescribed phosphodiesterase-5 (PDE5) inhibitors--the type of erectile dysfunction drug sold under the names Viagra, Levitra, Cialis and others--after their first heart attack were 33 percent less likely to die from any cause.\nAlthough the results provide evidence that PDE5 inhibitors may benefit heart health, the retrospective study design makes it impossible to ascertain direct cause and effect, Andersson noted.\nFilling more prescriptions for PDE5 inhibitors appeared to be associated with a greater benefit, although Andersson said that trend should be interpreted with caution because the study was not large enough for a definitive dose-response analysis.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The release provides sufficient information on the study goals, design and outcomes. The readers is told the study was retrospective, and tracked more than 43,000 men for an average of 3.3 years.\nThe release includes several important caveats. It notes as a limitation that \u201cresearchers did not assess the effects of untreated erectile dysfunction, or conversely, the effect of having an active sex life without taking erectile dysfunction drugs.\u201d\nAnd it included an indirect reminder that observational studies do not prove cause and effect: \u201cAlthough the results provide evidence that PDE5 inhibitors may benefit heart health, the retrospective study design makes it impossible to ascertain direct cause and effect.\u201d\u00a0 What was it about the retrospective study design that made it impossible to ascertain cause and effect? The fact that it\u2019s observational.\nIt is possible that using erectile dysfunction drugs simply indicates a more active sex life, which could itself contribute to, or be a marker of, a heart-healthy lifestyle overall.\nBut the study did not demonstrate a reduced risk of myocardial infarction associated with ED drug use.", "answer": 1}, {"article": "\u201cI didn\u2019t want to take two to three years on adults, and then go back and do children,\u201d he said.\n\u201cThere\u2019s a lot that still needs to be worked out.\u201d\n\n[Here\u2019s what you need to know about immunotherapy]\n\nComplications can be lethal; one clinical trial was briefly halted in July after three young adults died of brain swelling.\n[For a 6-year-old with cancer, a future staked on medicine\u2019s hottest field]\n\nThe clinical trial already has treated nearly two dozen leukemia and lymphoma patients through age 30.\nIn the past few years, however, breakthroughs have led to the development of two types of immunotherapy \u2014 checkpoint inhibitors and CAR T cells \u2014 that are generating enormous excitement.\n[Brain cancer now the leading cause of cancer deaths in children]\n\nAt a six-month checkup, tests showed that the leukemia was back again.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story makes clear that immunotherapies in general, and CAR T-cell therapies in particular, are garnering a great deal of attention in the medical research community. However, while we understand that the story is trying to get its arms around a large and growing number of clinical trials related to the therapy, it doesn\u2019t offer much information about those trials.\nReaders learn that trials involve adults and children (which is an excellent point, and we\u2019re glad the story makes it). And readers learn a little bit about the number of participants in one particular trial (as noted above, under Quantify Benefits). But readers don\u2019t know how many relevant trials have been completed or how many are underway \u2014 much less any real detail about any given trial. The story is focused more on providing human faces to the fight against the disease. That can make for good storytelling, but it makes the story less valuable for those trying to learn more about the treatment itself, and what the limitations are of research like this where children\u2019s lives are at stake.", "answer": 0}, {"article": "Hyperbaric wound treatment, often for diabetics, is booming.\nOften, Efrati and others say, injured brain cells don't die, but may persist for years or decades, alive but hobbled.\nOf course, such anecdotes are not the same as rigorous scientific research.\nA few studies besides Cifu's have looked at humans.\nEfrati and others argue that it probably works through several biological pathways.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story mentions a mixed bag of studies, but doesn\u2019t give us a sense of how authoritative the studies were. For example: Were they randomized and controlled? Or observational? Etc.", "answer": 0}, {"article": "In addition, Drs.\n\u201cWe hope that the breath analysis can serve as the primary screening tool for cancer recurrence and a CT scan ordered only if the breath test suggests that there has been a change,\u201d said Dr. van Berkel.\n\u201cThe great potential with breath analysis is detecting lung cancer at any point, both as a primary screening tool and to follow patients after disease has been treated,\u201d said Dr. van Berkel.\nDr. Schumer said those grim statistics underscore the need for early detection, \u201cWe hope that breath analysis will allow us to diagnose patients with primary or recurrent lung cancer long before they suffer from symptoms, when we have more options for treating them, giving them the best chance for cure.\u201d\n\nCurrently, lung cancer patients are followed after surgery with chest computed tomography (CT) scans, which can be inconvenient, expensive, and expose the patient to radiation.\nThe pump is reusable; the balloon, microchip, and lab test together cost around $20, all supporting the increasing acceptance of breath tests as a cost-effective, easy-to-perform, non-invasive, and rapid option for the diagnosis of lung cancer.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "All we know from the release is that VOC levels dropped after surgery and were comparable to levels in controls. The study provided no data on how well this test would perform for cancer surveillance \u2014 which would require prospectively evaluating the breath test against the standard CT tests to determine its predictive values. The news release might have more appropriately stated that the breath test is being evaluated as a tool to monitor for disease recurrence \u2014 not being used as a tool. ", "answer": 0}, {"article": "They work by promoting the release of dopamine, which is impaired in ADHD and other disorders characterized by executive function problems.\n\"Although we observed that short-term use of LDX was well tolerated and effective in several subjective and objective areas, long-term studies of menopausal women receiving LDX are needed, similar to those conducted for ADHD patients,\" said Epperson.\n\"Reports of cognitive decline, particularly in executive functions, are widespread among menopausal women,\" said lead author, C. Neill Epperson, MD, professor of Psychiatry and Obstetrics and Gynecology at the Perelman School of Medicine at the University of Pennsylvania, and director of the Penn Center for Women's Behavioral Wellness.\n\"There are approximately 90 million post-menopausal women living in the US alone, and with the average age of onset occurring at 52, the great majority of those women will live in the postmenopausal state for at least one-third of their lives.\n\"It is also important for clinicians to confirm that a woman's complaints of worsening memory are in the executive function domains, are temporally related to the transition to menopause, and are not indicative of some other pathological cognitive impairment before prescribing a trial of LDX.\"\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "This release does identify the nature of this trial, pointing to the randomization of the participants and that they served as their own control group as crossovers in the study. It also comments on the short duration of the study, noting that \u201clong-term studies of menopausal women receiving LDX are needed.\u201d However, the study only involved 32 women, and the original study paper recommends testing the hypothesis with a much larger cohort.\u00a0 Moreover, in the paper itself, the researchers state: \u201cWhile these findings are compelling, there are several aspects of the study design that limit our ability to generalize these data to all women with cognitive complaints during the menopause transition.\u201d \u00a0(For example, women with mood problems were excluded from the study.) Both the lede of the story and its headline could have better represented this caveat by referring to \u201csome menopausal women.\u201d We\u2019ll give the benefit of the doubt here with suggestions for improvement for next time.", "answer": 1}, {"article": "When dealing with opioid users who are addicted, doctors and policymakers also need to ensure that addiction treatment is available.\nFor one, the reviewed studies generally looked at the results of tapering, when patients are slowly weaned off opioid painkillers \u2014 a process that, Stanford psychiatrist Anna Lembke told me, can take months or even years.\nSeveral of the studies were done in pain centers where they have expert programs, and those just are not widespread.\u201d\n\nIn fact, the lack of access to non-opioid strategies may be one big reason that doctors resorted to opioids in the first place.\nHe added, \u201cI want patients and their doctors to use caution in applying this.\u201d\n\nA few pain patients will still benefit from opioids\n\nOne of the study\u2019s implications is that opioids actually aren\u2019t a good treatment for chronic pain.\n\u201cOne day in June, in my inbox were 42 deaths.\u201d\n\nThe findings show the balancing act of opioid policy: Even if doctors need to pull back opioids, they must be careful to ensure patients suffering from debilitating pain and other problems can still meet their other care needs.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "This article does a thorough job of laying out the study\u2019s design, discussing what it found, and what its flaws might be. The author, in fact, dedicated several paragraphs to hedging the study\u2019s conclusions by walking readers through its hang-ups, including its reliance on small studies with sometimes poor methodologies. The self-selecting nature of the subjects in those studies is also described\u2014 i.e. only those who volunteered to taper off opioids were studied, not people who didn\u2019t want to go off opioids.", "answer": 1}, {"article": "\u201cI\u2019m amazed,\u201d she said.\nIt\u2019s no miracle cure \u2014 only about 20 percent of patients with gliomas were helped \u2014 but some are alive six years later, the team reported in the New England Journal of Medicine.\nIt\u2019s not clear why just one in five patients benefits, said Dr. Annick Desjardins, who worked on the study team.\n\u201cThe average survival rate for all malignant brain tumor patients is only 34.7 percent,\u201d the group says.\n\u201cSimilar to many immunotherapies, it appears that some patients don\u2019t respond for one reason or another, but if they respond, they often become long-term survivors,\u201d Desjardins said.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story did some things right on this score, but we wish it had refrained from cause-and-effect language and the inclusion of a single \u2014 extremely positive \u2014 patient anecdote.\nTo its credit, the story stated in the second graph that this is \u201cno miracle cure.\u201d\nHowever, we take issue issue with the lead\u2019s definitive tone, which stated that the treatment \u201chelped some patients live for years longer.\u201d That assertion was echoed in the headline. The journal manuscript did not use such language, but referred only to the survival rate being higher than the rate among historical controls.\u201d\u00a0 As the American Cancer Society states, \u201c(Phase I)\u00a0studies are not designed to find out if the new treatment works against cancer.\u201d Their primary focus is on whether the approach is safe. So the \u201chelped some live for years longer\u201d\u00a0language is misleading. More trials with randomized controls are needed to determine whether this treatment actually led to better outcomes.\nThe story quoted a 20-year-old patient who said she was \u201camazed\u201d at her improvement after taking the treatment. However, the story didn\u2019t alert readers that she was one of just two of the 61 to have survived six or more years.\nLastly, the story should have described limitations of using a sample of past patients as a control group \u2014 a practice that might generate more favorable findings than a randomized control trial.", "answer": 0}, {"article": "All rights reserved.\nDoctors at first were leery of it until studies in more groups of women proved its value, and the same may happen with the prostate test, said Dr. Len Lichtenfeld, the American Cancer Society's deputy chief medical officer.\nIndependent experts say such a test is desperately needed but that it's unclear how much information this one adds or whether it will be enough to persuade men with low-risk tumors to forgo treatment, and treat it only if it gets worse.\nHowever, Dr. Kevin McVary, chairman of urology at Southern Illinois University School of Medicine and a spokesman for the Urological Association, said the test must be validated in more men before it can be widely used.\n\"Unless you can be sure your biopsy has hit the most aggressive part that's in the prostate, you can't be sure\" how accurate your risk estimate is, explained Dr. Eric Klein, chief of urology at the Cleveland Clinic, who led early development of the Oncotype prostate cancer test.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story carefully explained:\nIndependent experts say such a test is desperately needed but that it\u2019s unclear how much information this one adds or whether it will be enough to persuade men with low-risk tumors to forgo treatment, and treat it only if it gets worse.\n\u2026\nGenomic Health has not published any results on the prostate test, another thing that makes doctors wary.\n\u2026\nDr. Kevin McVary, chairman of urology at Southern Illinois University School of Medicine and a spokesman for the Urological Association, said the test must be validated in more men before it can be widely used.\n\u201cIt\u2019s not there yet,\u201d he said.\nBut wouldn\u2019t it be most helpful to report what the sensitivity and specificity of the test was?", "answer": 1}, {"article": "The drugs are benzodiazepines, which are widely known by their brand names Xanax and Valium and commonly prescribed to help treat anxiety.\nFinally, since the study looked at correlation (not causation), it\u2019s possible that it missed some other factor driving up overdose deaths among concurrent benzodiazepine and opioid users \u2014 perhaps, for whatever reason, these users may be more likely to misuse their drugs.\nSo it\u2019s not really controversial to conclude that simultaneously using opioids and benzodiazepines dramatically increases the risk of drug overdose \u2014 or, conversely, that stopping the concurrent use of these two drugs could reduce the risk of overdose.\nBut there\u2019s a catch: Such overdoses seem to be very closely tied to the opioid epidemic, with the majority of benzodiazepine overdose deaths involving both benzodiazepines and opioids.\nKeith Humphreys, a drug policy expert at Stanford University and one of the authors of the study, said this reveals an underappreciated policy lever for reducing drug overdoses: making sure patients prescribed to opioids aren\u2019t also prescribed to benzodiazepines, and vice versa.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story does a good job describing the potential weaknesses in the findings:\nThere are some caveats to the study. For one, emergency room visits and inpatient admissions for opioid overdoses likely aren\u2019t a perfect one-to-one proxy for overdoses that didn\u2019t involve a trip to a doctor. The study also only looked at legally prescribed opioid painkillers and benzodiazepines, missing the effects of concurrent use of illegally obtained pills or drugs. And since the research relied on patients who were continuously insured throughout the study period, it\u2019s possible the findings don\u2019t exactly apply to people with spottier coverage. (Although sensitivity analyses in the study for people who had lapses in insurance produced similar results.) Finally, since the study looked at correlation (not causation), it\u2019s possible that it missed some other factor driving up overdose deaths among concurrent benzodiazepine and opioid users \u2014 perhaps, for whatever reason, these users may be more likely to misuse their drugs.\nWe did take issue\u00a0with this sentence: \u201cFor one, emergency room visits and inpatient admissions for opioid overdoses likely aren\u2019t a perfect one-to-one proxy for overdoses that didn\u2019t involve a trip to a doctor.\u201d Isn\u2019t it, instead, that the researchers only measured ER visits and admissions, therefore not capturing overdoses that didn\u2019t involve a trip to a doctor?", "answer": 1}, {"article": "Sure enough, in the week when they ate eggs, volunteers had lower acylated ghrelin and higher PYY3-36 compared with the week when they ate cereal.\nThe folks who carried out this egg industry-funded research were from the Pennington Biomedical Research Center in Baton Rouge, La.\nThis message was brought to you by the American Egg Board.\nThat\u2019s right \u2013 the folks who sell eggs paid for a study that comes to the shocking conclusion that eggs are an ideal breakfast food.\nBoth types of breakfasts had the same number of calories, but the egg breakfasts contained \u201chigher protein quality,\u201d according to an abstract for the study, posted online here.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "This story focused on the funding conflict with the American Egg Board. To be sure, the story would be justified in questioning why the Egg Board was so eager to trumpet these results based on a bare-bones abstract presented at a conference. But we wish the story had asked:\nThe competing WebMD story at least raised some of these questions in its coverage.", "answer": 0}, {"article": "When running was for weirdos\nIn many ways, Sarah is a perfect case study in how to think about the benefits and risks of running versus walking.\nTo find out, I first searched for \"randomized control trials\" and \"systematic reviews\" on running, walking, and exercise at PubMed health (a free search engine for health research) and in Google Scholar.\nThere's even evidence that running can have positive effects on tension, depression, and anger.\nAll this research, while illuminating, didn\u2019t offer up any clear conclusions on whether running or walking was better for you overall.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The writer demonstrates an appreciation of the quality of the evidence, noting that she began by looking for randomized control trials and systematic reviews, which are the highest-quality studies. Not every study to which the story links appears to have been a\u00a0randomized control trial or a systematic review, but all were high-quality studies.", "answer": 1}, {"article": "As the ovaries curb production of the hormones estrogen and progesterone in the years leading up to menopause and afterward, women can experience symptoms ranging from irregular periods and vaginal dryness to mood swings and insomnia.\nWith additional years of follow-up, it also appears that the increased heart attack risk associated with HRT in the initial results from the WHI trials is limited to older women, McNeil added.\nFor women who started hormones in their 60s or 70s, however, there wasn\u2019t a meaningful difference in death rates according to whether they got the treatment or a placebo during the initial years of the study.\n\u201cThe take-home message now is that for the right patient, hormone therapy is safe and effective.\u201d\nTaking a combination of estrogen and progestin is associated with an increased risk of breast cancer, but advances in screening and treatment since the WHI started now mean these tumors are unlikely to be fatal, McNeil said by email.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story does a good job of describing how the study was done\u00a0and establishing the high-quality of evidence from a large randomized trial. ", "answer": 1}, {"article": "\"I called the doctor back in and said, 'We're doing the chemo.'\nAnd the recent data indicating that some women can skip chemotherapy are based on an after-the-fact analysis of selected clinical trials.\nThe drawback of that study, Dr. Glick notes, is that it was not a large prospective randomized clinical trial, the gold standard in medicine.\nIt took two years before the National Cancer Institute and its researchers could even agree on a design for the large new American study that will test the idea that many women might safely forgo chemotherapy.\nThe study is ethical, said Dr. Larry Norton of Memorial Sloan-Kettering Cancer Center in New York, because the only women whose treatment will be decided at random are those in a kind of gray area, not women for whom chemotherapy would be a clear benefit or clearly unnecessary.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "No mention of evidence from Dr. Berry\u2019s analyses, however, the story provides an excellent overview of the changes in the field and the role patients and physicians need to play in evaluating individual risks and benefits of chemotherapy, including determining just how much of a survival benefit a potentially toxic treatment will provide. The story discusses two randomized controlled trials currently enrolling patients. These trials should provide more definitive data on chemotherapy regimens and help physicians and patients make more informed choices about whether chemotherapy might benefit them. ", "answer": 1}, {"article": "Many back patients are afraid certain movements will cause them pain, so they avoid them.\n\"They should also avoid the use of scary, unreassuring labels or diagnoses,\" and not limit movement in therapy, she said.\nWhereas back pain studies involving exercise and drugs have shown changes to the brain's gray matter, the program in this study found no brain changes, Malfliet said.\nPhysical therapists and doctors can guide patients in this process, she added.\nBut this study suggests these methods also can help reduce spinal pain, she said.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "There aren\u2019t many details about the people in the study, including the substantial age range (18 to mid-60s); the sources of the back pain; the way the pain was measured before and after the interventions, and so on. The reader also won\u2019t learn about the surveys and tests (including brain MRIs) used to measure primary and secondary outcomes. And most of all, the reader will have a hard time understanding just what the two arms of the study involved and what the differences are, given that both involved forms of education and physical therapy. While the background for the intervention is discussed in detail, the nature of the study is barely mentioned.", "answer": 0}, {"article": "For more information on the field of anesthesiology, visit the American Society of Anesthesiologists online at asahq.org.\n\u201cWe found that certain women who experience good pain relief from epidural analgesia are less likely to exhibit depressive symptoms in the postpartum period.\u201d\n\nThe researchers controlled for factors already known to increase the risk for postpartum depression, including pre-existing depression and anxiety, as well as post-delivery pain caused by tissue trauma during childbirth.\nAfter accounting for these factors, the study found that in some women, labor pain was still a significant risk factor for postpartum depression symptoms.\n\u201cAlthough we found an association between women who experience less pain during labor and lower risk for postpartum depression, we do not know if effective pain control with epidural analgesia will assure avoidance of the condition,\u201d said Dr. Lim.\nNewswise \u2014 CHICAGO \u2013 Epidural anesthesia may do more than relieve pain during labor; in some women it may decrease the likelihood of postpartum depression, suggests a preliminary study presented at the ANESTHESIOLOGY\u00ae 2016 annual meeting.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "Correlation is not causation, and this release doesn\u2019t go far enough to explain this. The release quotes lead researcher Dr. Grace Lim, who is the director of obstetric anesthesiology at Magee Women\u2019s Hospital of the University of Pittsburgh Medical Center, as saying \u201cWe found that certain women who experience good pain relief from epidural analgesia are less likely to exhibit depressive symptoms in the postpartum period.\u201d\u00a0 However, it also stands to reason that some women \u2014 whether or not they have an epidural or go on to develop post-partum depression \u2014 simply experience less pain.\nThe release does include a brief caveat regarding the association between epidurals and post-partum depression: \u201c\u2026we do not know if effective pain control with epidural analgesia will assure avoidance of the condition.\u201d And, helpfully, it calls the research \u201cearly\u201d and \u201cpreliminary.\u201d\nThe\u00a0release states the study controlled for two major confounding factors: \u201cpre-existing depression and\u00a0anxiety\u201d\u00a0and \u201cpost-delivery pain caused by tissue trauma during childbirth.\u201d But that does not mean women who gave birth weren\u2019t already at risk \u2014 i.e. they may not have been diagnosed. Also, we aren\u2019t told whether the study accounted for\u00a0other risk\u00a0factors\u00a0known to play significant roles in leading to postpartum depression, including: availability of family and social support; employment status and financial well-being; the mother\u2019s physical health; infant behavior (e.g. colic); whether a pregnancy was planned; and other sources of acute stress. The release mentioned some of these in a quote from a study leader but, again, we aren\u2019t told if the study actually controlled for these conditions.", "answer": 0}, {"article": "Currently, lung cancer treatments rely heavily on chemotherapy, but doctors are shifting toward a more customized and precise way of treating each person\u2019s disease in order to improve their chances of survival.\n\u201cAnd while our study is only with 21 patients, the early indications from this study are very positive.\u201d\n\nTaken together, the results could fundamentally change the way lung cancer is treated, significantly improving people\u2019s ability to both hold off lung cancer for longer periods of time, as well as live longer with the disease.\nWhat\u2019s more, say the study\u2019s authors, doctors may also figure out which people are most likely to respond to the two-drug combination of nivolumab (Opdivo) and ipilimumab (Yervoy) and which are not.\nIn addition, \u201ca year after treatment, three times more people on immunotherapy were doing well compared to those who just got chemotherapy.\u201d\n\nThe results could play a role in changing standard treatments for people diagnosed with advanced NSCLC, by making a strong case for starting people immediately on the immunotherapy combination rather than giving them chemotherapy first, as many doctors currently do.\n\u201cTo give you some idea of how significant that is, with chemotherapy we normally see the same degree of response around 20% of the time.\u201d\n\nForde says that the strong response seen in people at the beginning of the disease could suggest that immunotherapies might be useful in re-training the immune system to fight cancer for long periods of time \u2014 possibly even a lifetime.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story starts out strong on this point, by discussing the study design and number of patients in the first trial it discusses, known as\u00a0CheckMate-227; however, it never provided limitations to the data.\nBut less information is given about the second study\u2013how many people? Was it randomized and controlled? What were the limitations?\nBut, the biggest issue is with the third study, in which a handful of patients received an immunotherapy before lung cancer tumor removal.\u00a0It is a pilot study, so the story should have better conveyed the results as preliminary for patients. It did refer to it as a \u201csmall\u201d study, but didn\u2019t explain why that matters.", "answer": 0}, {"article": "It can dominate the lives of patients and their families, leading to excessive overeating, choking, and stomach rupture, along with slowed metabolism and psychiatric disorders.\n\u201cThis is the first demonstration of a clinical benefit against two of the major issues that affect this patient population.\nThomas E. Hughes, chief executive of Zafgen, said the Boston company will use the data to prepare a \u201crisk-mitigation\u201d plan to help persuade the Food and Drug Administration to lift its so-called clinical hold on the late-stage trial, allowing it to resume.\n\u201cThis is a patient population that\u2019s at risk for thrombotic [clotting] issues.\u201d\n\nZafgen said its six-month study involving 107 patients suffering from Prader-Willi syndrome met its two primary goals, known as end points: showing significant weight loss by many patients and a decrease of hyperphagia-related behavior, meaning excessive eating.\nSixty-eight of the enrolled patients completed the study, Kim said, while 27 other patients completed 20 of the trial\u2019s scheduled 26 weeks.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "From the presentation of the results, it is not clear exactly how many patients were included in the final analysis. It is said that the six-month study involved 107 patients who showed significant weight loss and reduction in excessive eating. However, the very next paragraph reveals that only 68 patients completed the full study, while 27 patients completed only 20 of the trial\u2019s scheduled 26 weeks. Furthermore, it is reported that a \u201csmall number other\u00a0patients withdrew early.\u201d This small number, by our calculation, is 107 \u2013 68 \u2013 27 = 12, which is not such a small number considering there were only 107 patients to begin with.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070603/11back.htm was not found on this server.", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story does not accurately characterize the nature of the evidence in either of the two studies it reports. The Dutch study on sciatica and disc surgery was a randomized controlled trial. The second study about treatments for people who had degenerative spondylolisthesis (DS) with spinal stenosis compared outcomes in two different cohorts and is more complicated. As in the Dutch study, some 40% of patients in the DS study who were assigned to nonsurgical care changed their minds and had surgery. Though on the surface this might seem like a mere technicality, it is important. Large numbers of \u201ccrossovers\u201d in a randomized trial can make it very difficult to estimate the true effect of a treatment\u2014something readers might find helpful to know.", "answer": 0}, {"article": "Shares of BioTime Inc, a company that owns nearly 70 percent of Asterias, were little changed at $3.07.\nThe early study tested the benefits of a smaller dose of 2 million stem cells that are tuned to develop into nerves.\nData showed that the severity of the spinal injury was reduced in the first patient and two other patients were able to resume their rehabilitation programs soon after being injected with the stem cells.\nLichtinger said he was confident the data would be positive but was not expecting miracles.\nIts success is a key step toward proving that embryonic stem cell research could cure diseases such as cancer, Parkinson\u2019s and serious health conditions such immune deficiencies, stroke and spinal injuries.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The first sentence of the Reuters report was a bit misleading. Initial data did not indicate that stem cell therapy \u201ccould improve mobility in patients\u201d with spinal cord injuries. Instead, the initial trial indicated this stem cell therapy was safe in low doses, or at two million stem cells. Since this was a phase 1/2a clinical trial, the main purpose was to determine the therapy\u2019s safety. Efficacy was a secondary consideration. With such a tiny sample size of 3 patients, it is impossible to draw any conclusions about the therapy\u2019s effectiveness.\nThe story also could have used some discussion about the limitations of an open-label, single-arm study. In an open-label trial, both researchers and patients know which treatment is being administered. In single-arm or non-randomized trials, everyone enrolled in the study receives the therapy. And in this clinical trial, there was no control group. A comment or two about the natural course of untreated injury would have provided an important context to the story\nThese study designs may be common during phase 1 and 2 testing, but they provide opportunities to introduce bias into the trial. Until scientists conduct a double-blind, randomized clinical trial, it would be premature to draw conclusions on the therapy\u2019s efficacy.", "answer": 0}, {"article": "Our technology keeps the cells in the body under immune surveillance, so immune suppression is not necessary,\" said Sen, who also is executive director of Ohio State's Comprehensive Wound Center.\nIn my lab, we have ongoing research trying to understand the mechanism and do even better.\n\"This is difficult to imagine, but it is achievable, successfully working about 98 percent of the time.\n\"As a matter of fact, we were even surprised how it worked so well.\nWith this technology, we can convert skin cells into elements of any organ with just one touch.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "Appropriate caveats about the very preliminary, murine (rodent-related) nature of this evidence was missing. Curing crippled rodents? Curing mice from strokes? Those are interesting first steps but they are a long way from what any human patient would consider a breakthrough. We need some proof here.", "answer": 0}, {"article": "I wouldn\u2019t wish it on my worst enemy, but I have to go through with it.\u201d\n\nDr. Lowy explored the entire cavity from the diaphragm to the pelvis.\nThe is looking at it, according to people in the field.\nMr. S. had eventually diagnosed as .\n\u201cIt\u2019s maximally invasive,\u201d said Dr. Sugarbaker, who often removes the \u201cspare parts\u201d \u2014 organs a patient can live without, like the spleen, the gall bladder, the ovaries and the uterus.\nBut the appendix was found to be cancerous.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "Includes one expert statement:\u00a0 \u201c\u201cWe\u2019re practicing this technique that has almost no basis in science.\u201d", "answer": 1}, {"article": "However, it's probably not too soon to incorporate a lot of these thing we know are so healthful, lots of fresh fruits and veggies, olive oil.\"\nThey are the first studies to examine the association between the Mediterranean Diet and neurological diseases \u2013 specifically Alzheimer's.\nDr. Senay said another study done in Stockholm, Sweden observed that the decline of patients with a very mild form of Alzheimer's Disease after they began taking supplements that contained two Omega-3 fatty acids.\nThis study, as well as another published earlier this year, were both conducted by Columbia University Medical Center and sponsored by the National Institution of Health (NIH).\n\"Those who most closely adhered to the Mediterranean diet had a 68 percent reduction in the risk of Alzheimer's disease.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story presents some possible evidence of a protective benefit of the Mediterranean diet, but discussion of the study design is incomplete. The story does acknowledge that an intervention trial vs. retrospective study is necessary to improve the evidence for a link between the Mediterranean diet and prevention of cognitive decline and Alzheimer\u2019s disease in old age. ", "answer": 1}, {"article": "Tissue that dies in the brain from stroke is absorbed, leaving a cavity, devoid of blood vessels, neurons or axons, the thin nerve fibers that project from neurons.\n\"Or the new tissue could be improving the performance of the surrounding, unharmed brain tissue.\"\n\"This study indicated that new brain tissue can be regenerated in what was previously just an inactive brain scar after stroke.\"\nThe mice with new neurons showed improved motor behavior, though the exact mechanism wasn't clear.\nThe results suggest that such an approach may someday be a new therapy for stroke in people, said Dr. Tatiana Segura, a former Professor of Chemical and Biomolecular Engineering at UCLA who is now a professor at Duke University.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The news release provides only the briefest synopsis of the study protocol. It mentions the gel provides a scaffolding to support the regrowth of brain tissue and blood vessels. Then it\u2019s implied these tissues are functional since the mice with regrowth \u201cshowed improved motor behavior.\u201d\nBut we\u2019re given no data or insights into the significance of either the regrowth or the observed motor changes.\nLikewise, were the regenerated brain tissue and blood vessels normal? Functional?\nThere\u2019s just not enough evidence to justify the moniker \u201ca new stroke-healing gel.\u201d", "answer": 0}, {"article": "\u201cHeating ducts that have mold and spores in them can make respiratory symptoms worse in the winter when hot air is blowing through them.\nEvery room in your house could be susceptive to some form of an air pollutant, but now there is a new device and app that says it can help you breathe easier by tracking air quality.\nThe app also provides Mayo Clinic \u201cmessage cards\u201d that give relevant information and recommendations for ways to keep your indoor environment healthy.\nThe Awair app is free to download, but each device costs $199 dollars.\n\u201cLow dry humidity in the winter can make asthma worse and children who have dried mucosa can acquire some nasal infections easier,\u201d Dr. Robert G. Lahita, chairman of medicine at Newark Beth Israel Medical Center in New Jersey, told FoxNews.com.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The headline states that this device \u201chelps you breathe easier.\u201d But other than an endorsement from the company that makes it, the story offers no evidence that the device works at all.", "answer": 0}, {"article": "Because this important step is out of the way in advance, it completely changes the patient\u2019s day of surgery experience.\u201d\n\nRadar can target abnormality within 1 mm, sparing more healthy tissue\n\nUnlike mastectomy, which treats breast cancer by removing an entire breast, lumpectomy surgery \u2014 also known as breast-conserving surgery \u2014 is used to remove only the tumor and a small amount of tissue surrounding the tumor.\n\u201cUntil now, a patient would go to the imaging center to have the thin wire precisely placed in the breast.\nI was glad it was done a week before and not the same day as the lumpectomy surgery.\n\u201cThe radar reflector is a replacement for the wire and is essentially a little marker.\n\u201cIt made surgery go smoothly, and I didn\u2019t have any pain before or after.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The news release provides no evidence to support the claims made. This is quite unfortunate since the manufacturer\u2019s website does provide a modest amount of information on the early experience with the system.", "answer": 0}, {"article": "Biopsies may be performed via open surgery on the breast or with a less invasive core-needle biopsy in which a small sample of breast tissue from the affected area is removed through a special needle inserted through the skin.\nIn the study, published in the Annals of Internal Medicine, researchers reviewed 83 studies on the two methods.\nThey say additional studies are needed to find out what factors affect the accuracy of core-needle breast biopsy.\nThe results showed that core needle biopsies were about as accurate as open surgery at detecting cancerous vs. noncancerous breast lesions.\n\"Based on currently available evidence, it appears reasonable to substitute core needle biopsy procedures for open surgical biopsy given the comparable sensitivity and lower complication rates,\" write researcher Wendy Bruening, PhD, of the ECRI Institute Evidence-Based Practices Center in Plymouth Meeting, Pa., and colleagues.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story provides little evidence from the source article in the Annals of Internal Medicine.\u00a0 The story does not provide data comparing false positives or false negatives with either procedure. The story does provide data comparing the rate of complications with each procedure. The story also does not mention the generally low quality of the studies in the meta analysis, but the focus is instead on the quanitiy of studies\u2013 80 studies in this case\u2013\u00a0 and few if any were high quality.", "answer": 0}, {"article": "Blueberries are rich in flavonoids, which possess antioxidant and anti-inflammatory properties.\nThe study excluded anyone who said they consumed more than five portions of fruit and vegetables per day, and all participants were told to stick to their normal diet throughout.\nIn the study, healthy people aged 65-77 who drank concentrated blueberry juice every day showed improvements in cognitive function, blood flow to the brain and activation of the brain while carrying out cognitive tests.\nCompared to the placebo group, those who took the blueberry supplement showed significant increases in brain activity in brain areas related to the tests.\n\"In this study we have shown that with just 12 weeks of consuming 30ml of concentrated blueberry juice every day, brain blood flow, brain activation and some aspects of working memory were improved in this group of healthy older adults.\"\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The study from the get-go wasn\u2019t sufficiently powered (meaning it didn\u2019t have enough study volunteers) to detect changes in cognitive performance. The published report notes that: \u201cCognitive function was assessed, as a secondary outcome, although the study was not sufficiently powered to detect changes in cognitive performance.\u201d\nHow many more people would have been required to provide sufficient power? What limited the researchers from taking the time to recruit them?", "answer": 0}, {"article": ", follow us on Twitter @H_SeniorLife, like us on Facebook or read our blog.\n\"Our study highlights the fact that having a bone density test not only tells women about their risk of fracture, but also their long term risk for cardiovascular disease.\nThey then followed the women for almost 15 years to determine the occurrence of cardiovascular disease within the cohort.\nThey graded the severity of these calcium deposits using scans done for osteoporosis screening.\n\"We found that that the presence of calcifications increased the likelihood of having cardiovascular disease such as heart attacks, and even the likelihood of cardiovascular deaths and mortality in general.\"\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The release does not provide an adequate amount of information to determine the quality of the evidence. The reader is told only that there were 1,000 older women (no defined age group), nothing is mentioned about their baseline risk factors and they were followed for 15 years for \u201cthe occurrence of cardiovascular disease,\u201d which is not defined.\nImportantly, the release does not explain how the information from the scan compares to that provided by already-recommended cardiovascular screenings, or whether it would lead to changes in treatment for anyone who is scanned.", "answer": 0}, {"article": "When I began training last year for my first marathon, my running partner Dave Freedholm, an experienced amateur distance runner, impressed on me the need to vigilantly avoid dehydration. His drink of choice was Accelerade. Like Gatorade, the original sports drink, it's packed with sugars and sodium to provide energy and replace the electrolytes depleted in sweat. But it also contains protein, which he said would help my muscles repair themselves more quickly after the punishing training runs he took me on.\n\nSure enough, I never felt much pain until after the marathon itself, and even then I recovered within a couple of days...", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story adequately describe two recent studies. The story points out that the studies were funded by the drink manufacturers, had small numbers of subjects and were double-blinded.", "answer": 1}, {"article": "The maximum recommended intake of calcium is 2,500 milligrams.\nThe study earlier this year also found that women who took supplements regularly reduced their chance of fracture more than those who didn't.\nThese women showed about a 10 percent chance of fracture, compared with 15 percent.\nIt's important to note that calcium intakes on food labels are based on adult requirements of 1,000 milligrams per day.\nNow, says Senay, a study in the Archives of Internal Medicine shows calcium supplements do reduce the risk of fractures in elderly women, but only among those who take them regularly.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story does provide information about the nature of the study being reported. The story explains that this was a large, controlled trial and that benefits of calcium were found only in the compliant group, not in the overall study sample. The story also explains why these results are different from recent results from the Women\u2019s Health Initiative.", "answer": 1}, {"article": "The amygdala and hypothalamus are regions of the brain that control several memory and emotional functions.\nThe larger sample also would allow them to analyze whether curcumin\u2019s memory-enhancing effects vary according to people\u2019s genetic risk for Alzheimer\u2019s, their age or the extent of their cognitive problems.\nThat study will include some people with mild depression so the scientists can explore whether curcumin also has antidepressant effects.\nThe research, published online Jan. 19 in the American Journal of Geriatric Psychiatry, examined the effects of an easily absorbed curcumin supplement on memory performance in people without dementia, as well as curcumin\u2019s potential impact on the microscopic plaques and tangles in the brains of people with Alzheimer\u2019s disease.\n\u201cExactly how curcumin exerts its effects is not certain, but it may be due to its ability to reduce brain in\ufb02ammation, which has been linked to both Alzheimer\u2019s disease and major depression,\u201d said Dr. Gary Small, director of geriatric psychiatry at UCLA\u2019s Longevity Center and of the geriatric psychiatry division at the Semel Institute for Neuroscience and Human Behavior at UCLA, and the study\u2019s first author.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The release describes the study as \u201cdouble-blind, placebo-controlled study involved 40 adults between the ages of 50 and 90 years who had mild memory complaints. Participants were randomly assigned to receive either a placebo or 90 milligrams of curcumin twice daily for 18 months.\u201d\nLimitations of the study, not directly addressed in the release, are that the changes observed in the amygdala and hypothalamus of the curcumin group are highly subjective and have no established causal relationship with memory or mood. Also, this is an extremely small sample size and the authors did not correct for the multiple comparisons they made. (Learn more about the problems with multiple comparisons in research studies\u00a0here.)\nThe study authors noted in the published paper that the volunteers were not representative of the general population; they were \u201cmotivated, educated, physically healthy subjects concerned about age-related memory problems,\u201d authors wrote.\nFinally, curcumin levels were measured in the blood only; just how much crosses the blood-brain barrier and is actually bioavailable to brain cells is unknown.\nTo its credit the release does note that researchers will be following up with larger studies.", "answer": 0}, {"article": "The World Health Organization says tobacco is the leading preventable cause of death globally, killing more than 5 million people each year from heart disease, cancer and lung disease.\nThe findings were so strong the team now wants to test it in smokers to see if it can keep then from developing tumors.\n\u201cThis important laboratory study, together with prior laboratory and epidemiology research, suggests that metformin may be useful in cancer prevention and treatment,\u201d said Dr. Michael Pollak of McGill University in Montreal, who wrote a review on metformin research in the same journal.\n\u201cAlthough smoking cessation is the most important step for current smokers, over half of lung cancer cases are diagnosed in former smokers, raising the importance of identifying those at highest risk and identifying effective preventive treatments,\u201d Dennis, whose findings were published in the journal Cancer Prevention Research, said in a statement.\nThey said metformin prevented lung tumor growth in mice exposed to a cancer-causing agent found in tobacco smoke, and because it is already widely used in people, it may be worth further study.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story was really weak on this, only mentioning how \"strong\" the findings were.\u00a0 Meantime, in comparison, the HealthDay story advanced into a discussion of possible mechanisms of action, the fact that the mice studied had been genetically engineered to be susceptible to lung tumors, and the fact that a second study was reported in a very small number of humans.\u00a0 \nBig picture:\u00a0 this story didn\u2019t put \"mouse research\" in the headline or in the first sentence and then failed to discuss human research that DID exist in this specific area.\u00a0 By comparison the HealthDay story ended with the quote, \"what\u2019s proven in humans is totally another level.\" ", "answer": 0}, {"article": "\u2022 Cardiovascular disease affects one in six Australians or 4.2 million people.\nIn this UniSA study, published by the American Journal of Clinical Nutrition, researchers compared the health benefits of a MedDiet supplemented with two to three serves of dairy each day, and a generic low-fat diet.\nThe results show that the dairy-supplemented MedDiet (MedDairy) significantly improved blood pressure, heart rate, cholesterol, mood and cognitive function.\n\u201cThis study shows that the new MedDairy works better than a generic low-fat diet, ensuring better health outcomes for people at risk of cardiovascular disease.\u201d\n\nImportantly, the MedDairy diet also meets additional calcium requirements recommended by Australia\u2019s national health bodies.\n\u201cThis study delivers healthier options for Australians by tailoring the nutrients in the MedDiet to meet the needs of a non-Mediterranean population.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The research involved a randomized crossover design but there\u2019s no mention of this in the news release. There\u2019s also no discussion of the small sample of 41 volunteers which limits the generalizability of the findings.\nAdditionally, readers don\u2019t learn what types of dairy products were consumed, such as Greek yogurt and full and reduced fat cheese slices. The release also misreports the number of dairy servings consumed per day. It was not 2-3 servings per day as listed but 3-4 servings per day with participants averaging 3 servings per day, according to the study.\nFinally, the study was just 8 weeks long. Findings from such a short study may be considered surrogate endpoints, not clinical ones. To claim a clinical benefit would require a much longer study.\u00a0\u00a0", "answer": 0}, {"article": "Not everyone agreed with that notion, however.\nPeople who have two or more type 1 antibodies have between a 50 and 100 percent risk of developing type 1 diabetes, according to background information in the study.\nAccording to Knip, the take-home message from the study is that \"it is possible to reduce considerably the initiation of the diabetes disease process in at-risk children in a simple and safe way: weaning to an extensively hydrolyzed formula.\"\n\"I think this is an important study because we need to understand what causes type 1 diabetes,\" said Harlan, who added the caveat: \"In this study, while there is an apparent signal, there are also some causes for withholding complete faith in the conclusion that the formula caused diabetes.\"\nBoth Lee and Harlan stressed that there is currently no definitive evidence to suggest that the use of standard cow's milk formulas leads to an increased incidence of diabetes compared to breastfeeding.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "What is missing here for the reader is a clear estimate of the absolute increase in risk of developing these antibodies. For example, if the risk for infants exposed to hydrolyzed is 1% and the risk for standard formula is 2% this may not be worth the cost. Whereas if the risk for those exposed to hydrolyzed is 5% and for those exposed to standard formula is 10% this may be worth it. Both of these represent a 50% increase in risk, but the absolute differences would have substantially different clinical implications", "answer": 0}, {"article": "An inexpensive drug therapy far surpassed a conventional laser procedure in fixing a leading cause of blindness in babies born prematurely, according to a new study.\n\nThe results of the study, to be published this week in the New England Journal of Medicine, were so significant that the 15 hospitals participating in the research have stopped using lasers in favor of the drug, Avastin, which is injected into the eyes of the affected newborns. Avastin, made by Roche Holding AG's Genentech unit, is designed to be used for treating...", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story provides lots of good details on the study design, including the publication status, size, randomization, multicenter nature, comparator, number lost to follow-up, and a qualitative description of the follow-up period.\nSee the \u201cHarms\u201d criterion for a critically important limitation of the study size.\u00a0A bit more specificity on follow-up wouldn\u2019t have hurt.  A quibble: The article says that the study enrolled \u201cAbout 150\u201d babies, but then it discussed them in groups of 143 and 7. Isn\u2019t that exactly 150?", "answer": 1}, {"article": "Excessive drinking alone is linked to 88,000 deaths each year.\nJohn Kelly, an addiction researcher at Harvard Medical School who was not involved in the study, told me that the study is \u201cgood news, in general,\u201d but pointed out that it\u2019s limited by its methodology: It\u2019s based on an online survey, not the kind of randomized trial that\u2019s typically the gold standard in research.\nAnd since it\u2019s only one study, it\u2019s possible that the results were biased in some other way.\nThere\u2019s a good explanation for that: While the research shows that 12-step treatment can be as effective as professional treatment modalities like cognitive behavioral therapy, the research also shows that the 12 steps don\u2019t work for everyone.\nOne tricky thing with this line of research is you can\u2019t really force people to participate in certain groups \u2014 so studies that randomly assign participants to AA, SMART, LifeRing, or Women for Sobriety may not be easy to do.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "This is a strong point of the story. It notes multiple times that the study is not the last word on this subject and calls attention to specific limitations of this type of study via an independent expert source who tells readers:\nIt\u2019s based on an online survey, not the kind of randomized trial that\u2019s typically the gold standard in research. That may have led to some potentially biased results \u2014 perhaps participants in specific groups were less likely to report bad outcomes, for instance.\nAnd since it\u2019s only one study, it\u2019s possible that the results were biased in some other way. So it\u2019s up to future research to verify the findings.", "answer": 1}, {"article": "The new research provides more evidence of the need for new regional centers of care, in order to minimize the time it takes to transport a patient to hospital capable of providing stent therapy, according to Dr. William J.\n\u201cThe earlier that patients with acute ischemic stroke get to a hospital offering the appropriate treatment, the higher the likelihood is of a good outcome,\u201d said the study\u2019s lead author, Dr. Mayank Goyal of the Hotchkiss Brain Institute at the University of Calgary.\nWhen it comes to a stroke, time is of the essence and according to the National Stroke Association using the FAST approach can help one determine the warning signs.\nResearchers examined data on patients treated with both tissue plasminogen activator (tPA), the standard in stroke treatment, and stent retrievers and found that restoration of blood flow within 2.5 hours of stroke onset was associated with minimal or no disability in 91 percent of patients.\n\u201cThey are destined to be in a nursing home or to be dead and when we re-establish blood flow \u2014 often times right there on the table \u2014 they get better.\u201d\n\nStent retriever therapy is a new procedure experts call the most major advance in stroke treatment in two decades.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The study itself provides an easy-to-understand explanation of how the study was conducted and under what circumstances. Details like this are\u00a0missing from the news story, even basic details like how many people were studied.\nA closer look at the study itself would have revealed, for example, that the paper is looking mainly at the time intervals for each step in the process rather\u00a0than the actual outcome of the patients, which is not directly reported, but only indirectly reported as an adjusted analysis.", "answer": 0}, {"article": ".\n\"After monitoring patients 65 and older for six months, we found medical cannabis treatment significantly relieves pain and improves quality of life for seniors with minimal side effects reported.\"\nWhile the researchers state their findings to date indicate cannabis may decrease dependence on prescription medicines, including opioids, more evidence-based data from this special, aging population is imperative.\nBGU researchers surveyed 2,736 patients 65 years and older who received medical cannabis through \"Tikun Olam,\" the largest Israeli medical cannabis supplier.\nThe new study, published in The European Journal of Internal Medicine, found cannabis therapy is safe and efficacious for elderly patients who are seeking to address cancer symptoms, Parkinson's disease, post-traumatic stress disorder, ulcerative colitis, Crohn's disease, multiple sclerosis, and other medical issues.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "Quality of life was measured by a questionnaire that gave subjects 5 options (very good, good, neutral, bad, very bad).\nPain intensity was measured by the classic 11-point scale (0=no pain; 10= worst pain imaginable)\nPerception of the general effects of cannabis was measure along 7 choices ranging from significant improvement all the way down to significant deterioration.\nBut the reproducibility of the findings from the questionnaires is very limited by small sample size (n= 901), the highly subjective nature of self-reporting, and the inability of the researchers to calculate dosing of the active substance (in this case, the THC in marijuana).\nThe study did not compare cannabis treatment to other therapies. Thus, the reported outcomes are not really comparative. Second, the study population had to be on cannabis for at least 6 months. But we don\u2019t know about the effect in the majority of patients who took it for shorter periods. In effect, the release reports on pre-selected patients who are likely to have done well on the treatment.\nNone of these limitations were mentioned in the news release.\nTo its credit, the release does note at the end that the study should be followed up and \u201cmore evidence-based data from this special, aging population is imperative.\u201d", "answer": 0}, {"article": "In the US, cholesterol tests cost around $80 and usually are covered by health insurance though much lower prices often are negotiated.\nStudy says it could help\n\nWhat if a blood test could reveal that your child is at high risk for early heart disease years in the future, giving you a chance to prevent it now?\nStatins aren\u2019t recommended until around age 10, but certain dietary supplements such as plant sterols and stanols could help younger kids, Urbina said.\nBut many parents balk at the idea of testing children for a disorder associated with middle age, experts say.\nThe study also revealed parents who had the condition but didn\u2019t know it, and had passed it on to their children.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story explains how many babies were tested and how they were tested. But, we didn\u2019t get a sense of how reliable these testing methods are, nor what the study\u2019s limitations were.\nInstead,\u00a0the story implied that the study showed that screening kids will lower their risk, with statements like this: \u201cWhat if a blood test could reveal that your child is at high risk for early heart disease years in the future, giving you a chance to prevent it now?\u201d", "answer": 0}, {"article": "With Cognivue, patients sit before a video screen that shows a series of images, such as a group of dots, that move around and fluctuate in clarity.\nThe test, which has been around since 1975, offers only a broad indication of cognitive abilities and fails to pick up borderline problems, she said.\n\u201cWhat we are all about is making cognitive care part of primary care.\u201d\n\nMore than 5 million Americans have Alzheimer\u2019s disease, the leading cause of dementia.\nBut she said it\u2019s more convenient and less time-consuming to administer.\nBut the alternative involves referring patients for a battery of neuropsychiatric tests that can take hours to complete and cost $1,000 or more.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The evidence that the test is useful is limited to the comments of the inventor and two clinicians who have used the test.\u00a0 We are not provided with any quantitative data to support the anecdotal comments in the story. We assume that the FDA must have examined data as the basis for its approval, but that data isn\u2019t present here.", "answer": 0}, {"article": "\u201cYou have to be at extremely low risk before the risk of statins outweighs their significant, profound benefits,\u201d Gaziano said.\nAnd if even more people were given statins -- if they were given to people with a 3 percent risk of developing heart disease over 10 years -\u2013 another 160,000 heart attacks and strokes would be prevented, they estimated.\n\u201cThere is no longer any question as to whether to offer treatment with statins for patients for primary prevention, and there should now be fewer questions about how to treat and in whom,\u201d Dr. Philip Greenland, an expert in preventive medicine at Northwestern University and a senior editor of the journal, and Dr. Michael Lauer of the National Heart, Lung and Blood Institute wrote in a commentary.\nOne of the recommendations was that statins should be prescribed to anyone with a 7.5 percent risk or higher of developing heart disease over the next 10 years.\nLimiting factors should be a patient's own preference about taking a daily pill, price and the risk of diabetes, they said.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "Other than noting that the study was published in a journal, there is no examination of the quality of the evidence. The Times did a better job in this regard,\u00a0mentioning that the study wasn\u2019t a clinical trial and that the prospective Framingham cohort is almost all white.", "answer": 0}, {"article": "Hot flashes are a sudden rush of heat, followed by facial flushing and sweating, often followed by chills and clamminess.\nIn the newly published study, they set out to determine if the alternative treatment would do the same in women whose symptoms were related to menopause.\nIn an earlier study, Elkins and his Baylor colleagues showed that hypnosis dramatically reduced hot flash and night sweat frequency in breast cancer patients with treatment-related symptoms.\nThe alternative therapy reduced hot flashes by as much as 74% in the study conducted by researchers at Baylor University\u2019s Mind-Body Medicine Research Laboratory and funded by the National Institutes of Health.\nDuring the sessions they received suggestions for mental imagery designed to minimize the intensity of their hot flashes, such as images of a cool place.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The article fails to mention any limitations in the study, such as its small study size and short duration. Furthermore, although the study was randomized, it was not double-blind. And how long did the effects last? Would patients have to undergo hypnosis for the rest of their lives to experience fewer hot flashes?", "answer": 0}, {"article": "In nonblood-based tumors, such as melanoma, only about one-half of patients have T cells in their tumors that can be harvested, and only about one-half of those harvested cells can be grown.\nFor the clinical trial, the Johns Hopkins team enrolled 25 patients with newly diagnosed or relapsed multiple myeloma, although three of the patients relapsed before they could receive the MILs therapy.\nNoonan says the research team has used these data to guide two other ongoing MILs clinical trials.\nThe researchers say the trials also have shed light on new ways to grow the MILs.\n\"What we learned in this small trial is that large numbers of activated MILs can selectively target and kill myeloma cells,\" says Johns Hopkins immunologist Ivan Borrello, M.D., who led the clinical trial.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The release makes a very good effort to objectively describe a technically complicated trial. It defines the trial at least twice as being \u201csmall\u201d and calls it a \u201cpilot,\u201d suggesting that caution is appropriate when considering the results. It effectively explains the process involved in the treatments, including what was learned regarding the growth of cells in the lab after harvesting. It also points to the fact that while tumor-infiltrating lymphocytes (TILs) can only be retrieved from a quarter of the patient candidates for this technique, MILs were obtained from all of the patients in this study, suggesting that they may be a better tool for this therapy.", "answer": 1}, {"article": "Diabetes, high cholesterol, high blood pressure, stroke and being overweight jeopardize vascular health.\nIt is among the top 10 causes of death in America.\nRobert Nagele, PhD, presented his team's most recent findings October 18 at OMED 15 in Orlando.\nPeople found to have preclinical disease can take steps to improve their vascular health, including watching their diet, exercising and managing any weight and blood pressure issues to help stave off or slow disease progression,\" Nagele said.\n\"I can't think of a single patient who wouldn't take steps to prevent the progression of Alzheimer's if they could directly affect their prognosis.\"\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The news release provides no idea of the research results that lead to statements that the test is \u201cclose\u201d or \u201cnearing development.\u201d", "answer": 0}, {"article": "In 2014, prostate cancer was the leading cause of newly diagnosed cancers in men and the second leading cause of cancer death in men.\n\u201cIf by imaging we could predict the tumor grade,\u201d added Robert Reiter, MD, professor of urology at UCLA, \u201cwe may be able to spare some patients from prostate resection and monitor their cancer with imaging.\u201d\n\nCo-authors include senior author Anders M. Dale, Hyung W. Choi, Joshua M. Kuperman, Natalie M. Schenker-Ahmed, Hauke Bartsch, Robert F. Mattrey and William G. Bradley, Department of Radiology, UCSD; J. Kellogg Parsons and Michael A. Liss, Department of Urology, UCSD; Ahmed Shabaik, Department of Pathology, UCSD; Jiaoti Huang, Department of Pathology, UCLA; Daniel J. Margolis and Steven S. Raman, Department of Radiology, UCLA; Leonard S. Marks, Department of Urology, UCLA.\nBy doing both, the ability of imaging to accurately plot a tumor\u2019s location is increased and there is a more refined sense of the tumor\u2019s extent, said Nathan White, PhD, assistant project scientist at UC San Diego, study co-author and co-inventor of the RSI-MRI technique.\nFunding for this research was provided, in part, by the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health, the Department of Defense, Prostate Cancer Research Program, the American Cancer Society and the UC San Diego Clinician Scientist Program.\nThe technique is also valuable in surgical planning and image staging, said David S. Karow, MD, PhD, assistant professor of radiology at UC San Diego and the study\u2019s corresponding author.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "There is nothing in this news release that tells us anything at all about how the new technology was tested or what those tests found. Our perusal of the original study did not turn up much additional information. The article states that the new technology detected\u00a08/9 extracapsular cancers (cancers that extend beyond the prostate capsule), and the old technology only 2/9. The authors did not present a statistical analysis, but by our calculation, the differences are not statistically significant.", "answer": 0}, {"article": "\u201cThe baby will grow and the biodegradable material will disappear,\u201d he said.\n\u201cThat would be one compassionate use of it, a very serious application.\nThe findings, which follow similarly promising 6-month and 9-month data on the plastic device, were described at the annual scientific sessions of the American College of Cardiology in New Orleans.\nIt was cleared by European regulators even though large so-called pivotal trials have not yet been conducted on the product.\n\u201cThe trial\u2019s results would be equivalent to an excellent metallic stent - that type of performance,\u201d said Dr. Patrick Serruys, a cardiologist from Erasmus University Hospital in Rotterdam, who led the study.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story provided only scant explanation of how the study was done and no critical evaluation of the quality of the evidence. It never justifies the first sentence that says the device \u201chas proven safe and effective.\u201d\u00a0 The absence of an independent perspective was felt here as much as anywhere.", "answer": 0}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThe Brain Trauma Indicator was reviewed under the FDA\u2019s De Novo premarket review pathway, a regulatory pathway for some low- to moderate-risk devices that are novel and for which there is no prior legally marketed device.\nThe FDA evaluated data from a multi-center, prospective clinical study of 1,947 individual blood samples from adults with suspected mTBI/concussion and reviewed the product\u2019s performance by comparing mTBI/concussion blood tests results with CT scan results.\nThese findings indicate that the test can reliably predict the absence of intracranial lesions and that health care professionals can incorporate this tool into the standard of care for patients to rule out the need for a CT scan in at least one-third of patients who are suspected of having mTBI.\nThe FDA reviewed and authorized for marketing the Banyan Brain Trauma Indicator in fewer than 6 months as part of its Breakthrough Devices Program.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The release does a good job describing the results of a multi-center prospective clinical study of 1,947 individual blood samples from adults with suspected mTBI/concussion and reviewed the product\u2019s performance by comparing mTBI/concussion blood tests results with CT scan results. But it missed an opportunity to share the trial results in a transparent fashion. The \u201cstudy\u201d appears to draw on data that was already available from a clinical trial. That isn\u2019t the same as conducting a randomized clinical trial on the blood test, and that\u2019s not explained in the news release. There\u2019s no mention of the name of the trial or where it had been published. A glowing quote from the FDA commissioner is no substitute for peer-reviewed trial results. There\u2019s no explanation for how the FDA arrived at the assessment that the test could \u201crule out\u201d CT scans in a third of suspected concussion cases, which is the main purported benefit of this test. ", "answer": 0}, {"article": "Parkinson's disease is a neurological disorder that can cause tremors, stiffness, slowness of movement, trouble balancing, problems walking and difficulty coordinating movement.\nThough other symptoms will show up eventually and help in diagnosing the patient, in the meantime, the patient will be receiving the wrong medicines.\nMeanwhile, doctors are not always correct, Wright said.\nAn accurate blood test, then, would be good news in these situations.\nAccording to Dr. Paul Wright, chairman of neurology at North Shore University Hospital in Manhasset, New York, and Long Island Jewish Medical Center in New Hyde Park, New York, the importance of this study is that it brings to light that there are new biomarker tests that can delineate between these neurological diseases.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The article does a good job of explaining what the study was intended to do and how it was designed. It\u2019s especially good on explaining how blood tests like this should be validated.", "answer": 1}, {"article": "The findings \"are pretty much in line with what all the other studies have shown comparing Atkins and low-fat diets,\" said Bonnie Brehm, assistant professor of nutrition at the University of Cincinnati College of Nursing and co-author of two, independent studies of the Atkins diet.\nBoth the authors and other weight-loss experts were quick to note that the new findings did not answer the question of what is the best way for most people to shed weight.\nReactions to the findings were mixed.\nAll the participants reported eating about 2,000 calories a day when the study began.\nAll also reported having cut their intake -- some by as much as 500 calories per day at two to six months -- but then gradually adding back many of those calories.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story presented the results of a recently published scientific article on a randomized trial comparing four popular weight loss diets.\u00a0 It\u00a0presented estimates of\u00a0the weight loss observed after one year and mentioned changes in other clinical parameters (triglcyerides, blood pressure, HDL cholesterol) without providing precise details about these.\u00a0", "answer": 1}, {"article": "\"But I'd hope we can get past that.\"\nBut a 2012 Cochrane review of randomized clinical trials found there's no evidence that removing wisdom teeth will prevent or reduce crowding of other teeth down the line.\nThe American Association of Oral and Maxillofacial surgeons says, \"There is no pat answer, cookbook recipe, or flow chart that is universally accepted regarding the decision making process\" in these cases.\nThe American Public Health Association has sided with this argument since 2008, when it formally opposed the preventative removal of wisdom teeth.\nA simple surgical extraction for a wisdom tooth that's showing through the gums should run about $230, according to Healthcare Bluebook.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story discusses and links readers to many expert sources for data including a Cochrane review, the American Public Health Association and the American Association of Oral and Maxillofacial Surgeons.\u00a0It notes that the 2012 Cochrane review of randomized clinical trials found there\u2019s no evidence that removing wisdom teeth will prevent or reduce crowding of other teeth down the line. It\u2019s clear from the story that the evidence on this topic isn\u2019t settled and that various expert groups have differing interpretations.\nThe story would have been even stronger had it discussed the position of the American Dental Association, the largest membership association of dentists claiming 157,000 members. A visit to the ADA website\u00a0suggests that the association advocates a \u201cwait and see\u201d approach for wisdom teeth removal.", "answer": 1}, {"article": "\u201cYou have to show that there\u2019s a return on investment.\u201d\nUntil then, Ms. Pisano said, many insurers are denying coverage on the grounds the procedure is experimental.\nSusan Pisano, a spokeswoman for America\u2019s Health Insurance Plans, the industry trade group, said insurers are awaiting the results of an additional five-year clinical trial, required by the F.D.A.\nThe one-time cost of $20,000, they say, is dwarfed by the tens of thousands of dollars in hospital bills and medication costs that a severe asthmatic can easily accumulate in a single year.\n\u201cIt\u2019s not going to get rid of asthma, but it is going to reduce symptoms and hospitalizations and make patients more functional in their daily life.\u201d For now, the procedure is only for severe asthmatics, who \u2014 unlike a vast majority of asthma patients \u2014 cannot keep flare-ups at bay with standard medications, said Dr. Kyle Hogarth, an assistant professor of medicine at the University of Chicago who was involved in clinical studies of the treatment.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "Although it never outright says so, the\u00a0story suggests that the evidence is sufficient for insurers to pay for bronchial thermoplasty. When an insurance industry representative describes the procedure as \u201cexperimental,\u201d the story counters (in its own editorial voice)\u00a0that three 5-year studies of the procedure have already been completed. The implication is that the insurance companies are dragging their feet. That\u2019s certainly one way to view the situation, but it wouldn\u2019t have been difficult to find experts outside the insurance industry who believe the procedure is not yet ready to be rolled out to patients. In this editorial, for example, a researcher who has been funded by the thermoplasty device manufacturer argued that the benefits compared with a sham procedure are small and the long-term safety uncertain. He and a colleague wrote that this \u201cprovocative treatment is not yet ready for prime time but, instead, requires more study.\u201d Another editorialist wrote that the findings of the most recent trial were \u201csomewhat disappointing\u201d and she called for more research to clarify the procedure\u2019s effects.\u00a0We don\u2019t think these legitimate concerns about the procedure\u2019s supporting evidence\u00a0were given an\u00a0appropriate voice in the story.", "answer": 0}, {"article": "Michael Burk found walking increasingly painful last year. Crossing the street and tying his shoes became challenges, and colleagues noticed he was limping at work.\n\nOn a recent morning, Mr. Burk reported to the Hospital for Joint Diseases, part of NYU Langone Medical Center in New York City, for hip-replacement surgery. His surgeon had promised him a better quality of life, and said both the operation and recovery would be quick.", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "True to the spirit of this criterion, we can\u2019t say that the news organization didn\u2019t grasp the quality of the evidence. But we can say that they didn\u2019t frame the story as if it grasped the tradeoffs and the uncertainties involved as the surgery evolves.\nThe story does link to a study as noted above, and it does feature expert voices who call for more studies and who challenge the main premise of the story \u2014 that the anterior approach and same-day procedure are faster and better than the posterior approach. But the text itself offers only anecdotes and doesn\u2019t explore what kind of evidence the linked study offers. And it never makes clear that operating time is only one factor, and not the most important factor, that patients should care about. A\u00a0shorter surgery with an approach that allows the patient to go home the same day will not be seen as a quality result if the surgery does not last as long\u2013for example if it wears out, on average, 5 years sooner.", "answer": 0}, {"article": "Examples of fermented dairy products include cheese, yoghurt, quark, kefir and sour milk.\nWhen the study participants were divided into four groups on the basis of their consumption of fermented dairy products with less than 3.5% fat, the risk of incident coronary heart disease was 26% lower in the highest consumption group compared to the lowest consumption group.\nHowever, the researchers found that a very high consumption on non-fermented dairy products was associated with an increased risk of incident coronary heart disease.\nThe study participants were divided into groups on the basis of how much they ate different dairy products, and the researchers compared the groups with the highest and lowest consumption, while also taking various lifestyle and nutrition factors into consideration.\nTheir dietary habits were assessed at the beginning of the study in 1984-1989, and they were followed up for an average of 20 years.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "There are three major limitations of this study that aren\u2019t mentioned.\nFirst, this is a prospective cohort study that can\u2019t completely control for other health variables in the subjects being responsible for some of the changes observed.\nSecond, the use of a food questionnaire (even with some supervision by nutritionists) is not a completely reliable way to document dairy intake; especially when trying to pinpoint amounts and subtypes of dairy.\nFinally, the cohort studied (Eastern Finnish men, ages 42-60) is a very specific subgroup. This limits the generalizability of the results.\nThe news release addresses none of this.\u00a0 In the published manuscript the authors describe differences in smoking rates and other dietary patterns in the men who consumed more or less of the dairy types.\u00a0 These other differences could have accounted for all of the differences in this observational study.", "answer": 0}, {"article": "While some teenagers want to switch from insulin injections to pump therapy to gain more flexibility in their lives, doctors said device problems such as a blocked tube can lead quickly to dangerous episodes of high blood sugar.\nAt times, the devices malfunctioned, but other times, teens were careless or took risks, the study authors wrote.\nBut they called for more study to address safety concerns in teens and even younger children who use the popular pumps.\nThere were two possible suicide attempts by teens who gave themselves too much insulin, according to the analysis.\nParents should be vigilant in watching their children\u2019s use of the pumps, researchers from the Food and Drug Administration wrote.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "This article includes\u00a0the key findings and conclusions reported in the Pediatrics study.\u00a0 Some of the study methodology, e.g. the 10-year time period of the investigation, was provided.\u00a0 But there is no mention that this was\u00a0a retrospective study and what limitations such a study may have.\u00a0 The story mentions 13 deaths and > 1,500 injuries over 10 years, but fails to give the denominator of subjects involved. In addition, the research study also examined the use of analgesia pump use in adolescents which was not covered in the story.\u00a0 Why not? ", "answer": 0}, {"article": "It\u2019s of phenomenal significance in that regard,\u201d he told Reuters.\n\u201cIt proves the concept that in a patient who has been blind for many years and is unable to see anything, the optic nerves can be re-awakened for them to be able to see again.\nThe implant device, which sits completely within the eye, is a tiny plate, measuring just 3 mm squared and a 10th of a millimeter thick, which has around 1,500 tiny light sensors connected to amplifiers and electrodes.\nZrenner said further trials of the implant should be completed in two to three years and if those proved successful the device could be on the market and available for thousands of patients in about five years\u2019 time.\nEberhart Zrenner, chairman of the University of Tuebingen Eye Hospital in Germany and director of a small company called Retinal Implant AG which is developing the device, said the trial results were a \u201cproof of concept\u201d and would now be taken into further trials in around 25 to 50 patients in Europe.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "There are some caveats tossed into this story, but they can\u2019t overcome the hype. The story says in the lead that\u00a0the implant \u201callowed three blind patients to see shapes and objects within days of treatment\u201d.\u00a0The next sentence says,\u00a0\u201cExperts described the study results as phenomenal\u201d. The story does deserve credit for saying in the lead that only \u201cthree blind patients\u201d saw vision improvement, but the story does little else to describe the limitations of the study or to place it in any context.", "answer": 0}, {"article": "Their waistlines shrank by 1 to 2 inches.\n\"Prior studies have indicated a range of health benefits in mice, but this is the first randomized clinical trial with enough participants to demonstrate that the diet is feasible, effective and safe for humans.\n\"We saw similar outcomes, which provides further evidence that a fasting-mimicking diet has effects on many metabolic and disease markers.\nFor example, baseline fasting glucose levels for participants with high blood sugar levels (putting them at risk for diabetes) dropped into the healthy range, below 99 mg/dl -- but these levels didn't drop among participants who already had healthy levels at the beginning of the study.\nIn effect, the diet reduced the study participants' risks for cancer, diabetes, heart disease and other age-related diseases, according to the findings published Feb. 15 in Science Translational Medicine.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The release clearly exaggerates the evidence and we describe this in detail under the Unjustifiable Language criterion section below.\nThe study on its own has credible and well-described evidence for its limited claim of a change in blood pressure, C-reactive protein and other markers that may\u00a0signal a lowering of risk for heart disease. But the release fails because it claims these prove a reduction in risk of disease.\nStudy author Longo is quoted saying: \u201cLarger FDA studies are necessary to confirm its [the diet] effects on disease prevention and treatment.\u201d In this instance he acknowledges that the small study does not prove a permanent lowering of risk. Yet the release repeats several times that the diet does lower risk.", "answer": 0}, {"article": "Acupuncturists used five different points in the head, face, hand, and leg.\n''Acupuncture could potentially become an alternative treatment to occlusion [patching] therapy for ambylopia [lazy eye], the researchers write.\nDec. 13, 2010 -- Acupuncture treatments to treat one type of lazy eye proved as good as the traditional patching of the eye used to help the eyes work together, according to a new study.\n''These results suggest that the treatment effect of acupuncture is equivalent to that of patching for anisometropic amblyopia in older children,\" Lam writes.\nAmbylopia was evaluated as resolved in nearly 17% of patched eyes but nearly 42% of the acupuncture group.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story did a good job of\u00a0describing what happened in this experiment and pointed out a number of\u00a0key limitations. Importantly, it explained that the children receiving acupuncture\u00a0were told to do an hour a day of vision exercises in addition to the acupuncture \u2014 something HealthDay neglected to call attention to. In addition, it cited the small size of the study; the lack of other\u00a0research on acupuncture for amblyopia;\u00a0and\u00a0the significant time, travel and expense of acupuncture as factors to keep in mind when interpreting the results. We wish it had also called attention to the significant placebo effect that is possible with acupuncture and which may have affected the outcome of the study.", "answer": 1}, {"article": "\"It's clear we need more efficacious drugs with milder side effects.\"\nIn the first year of a two-year trial, 5 of the 31 of those on medication developed full-blown psychosis, compared with 11 of 29 of those who were taking dummy pills.\nFrom 20 to 45 percent of people who score high on the scale go on to develop full-blown psychosis, in which these symptoms become extreme, researchers have found.\nSome left the study without explaining why; others moved; and 10 of those on medication quit the study because they felt the drug was not working, could not make the appointments or did not like the side effects, among other reasons.\n\"Unfortunately, the study's numbers are so small that it cannot be decisive on the key issue, which is whether it's prudent to treat people early when there are uncertainties about the diagnosis and given the effect of stigma and adverse effects,\" said Dr. William Carpenter, director of the Psychiatric Research Center at the University of Maryland, who was not involved in the study.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story mentions the trial design and that eligibility consisted of a screening instrument and evidence of early symptoms of schizophrenia. Fewer patients taking Zyprexa converted to full psychosis during the first year of treatment, but the difference between this group and the placebo group was not statistically significant. What is not mentioned is that the trial was blinded, but there was significant weight gain among the patients who took Zyprexa. As these medications are known to cause weight gain, this may have biased the clinical assessment of these patients. Additonally, many of the patients did not complete the study, so from the 60 initially recruited, only 12 completed the full 2-year trial. Results from such a small number of patients would not be generalizable to a larger population of patients at high risk of developing a psychotic disorder and experiencing early symptoms of schziphrenia, which is mentioned in the story.", "answer": 1}, {"article": "About 35 million Americans have migraines, according to the American Headache Society, and about 20% to 30% of these patients have headaches that are preceded by visual or other sensory warning signs.\nCompared to patients who got sham treatments, more patients treated with the experimental device, known as single-pulse transcranial magnetic stimulation (sTMS), were pain-free two hours later.\nDrugs commonly used in the treatment of severe headaches are generally not considered effective in the aura phase of migraine attacks, and many patients want to treat their migraines without using drugs, neurologist and headache specialist Richard B. Lipton, MD, tells WebMD.\nMarch 3, 2010 -- A handheld device that magnetically zaps pain may be a promising new treatment for patients with a common type of migraine.\n\"Some people don't tolerate the drug treatments very well and others just want to avoid them.\"\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story did an adequate job describing the study and highlighting the rigorous design methods, namely that it was a randomized, sham-controlled, multicenter trial.\u00a0 But the story didn\u2019t reveal whether the benefit was sustained for multiple headaches and repeated use of the device.\u00a0A discussion of why about 2/3 of the originals subjects were not randomized or why another third dropped out after randomization seems like an important omission. \n\u00a0\n\n\nThe story does point out that since this is an industry-sponsored trial, replicating the results with an independent trial is prudent.\u00a0 \nOverall, the story could have zeroed in better on specific limitations and strengths of this report. \n\n", "answer": 0}, {"article": "Allowing more basic emergency medical service (EMS) staff to administer naloxone could reduce drug overdose deaths that involve opioids, according to a Centers for Disease Control and Prevention (CDC) study, \u201cDisparity in Naloxone Administration by Emergency Medical Service Providers and the Burden of Drug Overdose in Rural Communities,\u201d published in the American Journal of Public Health.\nDepartment of Health and Human Services Secretary Sylvia M. Burwell has made addressing opioid abuse, dependence, and overdose a priority and work is underway at multiple HHS agencies on this important issue.\n\u201cNaloxone can be given nasally to a person suspected of overdose, allowing basic EMS staff to administer the drug without injection,\u201d said CDC Senior Health Scientist Mark Faul, Ph.D., M.A.\nA majority of states have adopted national guidelines that prohibit basic EMS staff from administering the drug as an injection.\n\u201cMany of these deaths can be prevented by improving prescribing practices to prevent opioid addiction, expanding the use of medication-assisted treatment, and increasing use of naloxone for suspected overdoses.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "This was an observational study of factors associated with naloxone administration across the country. It wasn\u2019t an experiment designed to tell us whether relaxing restrictions on naloxone administration would have beneficial effects on overdose deaths. It\u2019s problematic to use the publication of a\u00a0study to make a bunch of policy and advocacy statements that are not based on evidence from the study that is the putative subject of the release.\nThe release doesn\u2019t spend much time discussing the evidence. In fact, the release\u00a0sums up the nature of the study in just one sentence: \u201cNational Emergency Medicine Service Information System data for 2012 were reviewed to better understand factors associated with naloxone administration, including demographic data, 911 call information, and details about the scene of an injury or illness as reported by EMS staff.\u201d\nThat sentence begs many questions. How many people were included in the data? How many deaths? How many near misses? How often did naloxone save lives? How often did it cause harm? How accurate are these records? Are there areas \u2014 especially rural areas \u2014 that aren\u2019t covered in the database? The questions could go on. None of them are answered.", "answer": 0}, {"article": "African-American women are more likely than white women to report hot flashes.\nAlthough the benefit was modest, it appeared to be significant enough that women might consider trying it, the researchers said.\nThe study is the first to examine whether there are any racial differences in how well an antidepressant works in alleviating hot flashes.\nIn the new study, Ellen Freeman of the University of Pennsylvania School of Medicine in Philadelphia and colleagues gave 205 women who were either starting to go through menopause who had already gone through menopause either Lexapro or a placebo for eight weeks.\nSince then, many women have been suffering through hot flashes and searching for effective alternatives.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The description of the study was accurate and detailed enough to satisfy this criterion. As with the competing WebMD story, there could have been more emphasis on the short length of the study and the lack of data on longer-term outcomes. Menopausal symptoms can last for years, and an 8-week study doesn\u2019t really tell us much about the durability of the treatment in this context. Also, while it\u2019s useful to know the drug\u2019s effect on frequency and severity of hot flashes, it would have been valuable to have data on the drug\u2019s impact on health-related quality of life.", "answer": 1}, {"article": "Thanks to members Drs.\nThomas Trojian (AMSSM Past Board of Director), Susan Joy (AMSSM Foundation Board Member), Andrew Concoff and John Hatzenbuehler along with Whitney Saulsberry, PharmD and Craig Coleman, PharmD for serving on the expert writing group for this paper.\n\u201cIt is important to look at how a person responds to a medication.\nThe full paper will be published in print in the January 2016 issues of CJSM and BJSM.\nUsing a network meta-analysis we are able to compare the multiple studies done on viscosupplementation and have found that people are more likely to show clinical improvement with viscosupplementation over placebo (saline) and intra-articular steroids.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The quality of the evidence is limited to the few comments related to the \u201cnetwork meta-analysis.\u201d We are not provided with any details on the methods, number of patients followed, what metrics were used to determine efficacy (other than the acronym) or how long people were followed. We\u2019re not told why this is deemed a higher quality therapy for older people, just that it is. We\u2019ll have to wait until the actual article is published in January 2016 to find out.", "answer": 0}, {"article": "\"Close to a million tons of equipment,\" Metz said.\nAt double the cost of standard treatments, many experts say it's being used without proof it's more effective.\nAnd while there's little disputing the value of proton beam for certain rare cancers, increasingly it is being used for more common cancers like prostate.\nBut while the cost is extraordinary \u2026 so are the results for this family.\nthe bigger issue though is, is the increased costs associated with protons worth it to society?\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "Although the story does indicate that there is no good evidence that proton therapy is better than standard radiation, the story could have done a lot more to elaborate on the limitations of the available evidence.", "answer": 0}, {"article": "For more information, visit fredhutch.org or follow Fred Hutch on Facebook, Twitter or YouTube.\nBecause of the data from this clinical trial, avelumab (brand name Bavencio) has become the first systemic therapy approved by the FDA for MCC, and the first treatment of any kind approved for metastatic MCC.\nHis team foundational work on the role of immune cells in MCC paved the way for immunotherapy trials in the disease, including one he leads of another immunotherapy drug with a similar mechanism of action (Merck\u2019s Keytruda), whose results were published last year and changed the field overnight.\nNewswise \u2014 SEATTLE (March 24, 2017) \u2013 The U.S. Food and Drug Administration yesterday granted accelerated approval to the checkpoint inhibitor Bavencio (avelumab) for the treatment of patients with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy.\nUntil now, there were no systemic therapies approved by the Food and Drug Administration for this cancer, and no approved therapies once the cancer had spread.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "We think that patient stories should be used judiciously and balanced with a full representation of the evidence. In this case, the story of one patient is used as a stand-in for all patient experiences in the absence of any measurements of benefits or risks. We don\u2019t think that it is a fair representation of the two-thirds of patients who may see no benefit from the drug, including the fraction who may actually have a serious adverse reaction.\nWhile the\u00a0news release notes that this is the first treatment approved by the FDA for MCC, it does not highlight that this is only a phase II study so there\u2019s no direct evidence that the new treatment is better than the existing treatments.\nBeyond linking to a Lancet Oncology article, the release doesn\u2019t tell us anything about the study upon which the approval was based. At minimum we\u2019d like news releases to tell us how many patients were enrolled in the study and for how long.\nAccording to the published study, 88 patients were enrolled in the trial and received at least one dose of avelumab over the course of the 14-month trial period. Most patients were followed up at 10.4 months. Among the 88 patients,\u00a028 (31.8%) had an \u201cobjective response,\u201d 8 had an \u201cincomplete response\u201d and 20 had \u201cpartial responses\u201d by the end of the study. \u00a0We aren\u2019t provided with data on the average survival for the disease following treatment, but that may be because the 10+-month follow up was of insufficient duration to meaningfully assess the new drug.\nAs mentioned under harms, there were numerous serious side effects.\nPresenting absolute risks and mortality data would have provided important context to the study.", "answer": 0}, {"article": "Inflammation is a sign of damage from cholesterol.\n\u201cIt appears to be safe and to not raise blood pressure,\u201d Shah told CNN, \u201cbut it\u2019s not a slam-dunk.\u201d For one thing, despite improved cholesterol levels, patients did not see less inflammation in their blood vessels.\nBy then, results will also be in on a large study of a similar drug, dalcetrapib, made by Merck\u2019s competitor, Roche.\n\u201cIt\u2019s like a rocket that landed on Jupiter, rather than the moon.\u201d Still, Eckel warned it\u2019s too soon to say whether ancetrapib would actually prevent disease over the long run.\nIf the same benefit were seen in all patients at risk of heart disease \u2013 far from a sure thing \u2013 it would translate to hundreds of thousands of fewer deaths and heart attacks over a five-year period, according to Dr. Christopher Cannon, the lead study author and a cardiologist at Brigham and Women\u2019s Hospital in Boston.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "\n\n\n\nThe story does tell readers that another drug in this class showed initial promise, but was then dropped because it caused more health problems and deaths than it prevented. And while the story describes key details of the trial, t it fails to make clear that the whole point of this trial was to look for major safety problems, not primarily to test effectiveness. Indeed, the title of the journal article in the New England Journal of Medicine is \u201cSafety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease.\u201d Nowhere in the article is there a claim that this trial could demonstrate the drug actually improves the health outcomes of patients.", "answer": 0}, {"article": "Dr. David E. Neal, a professor of surgical oncology at the University of Cambridge in the U.K. and author of an accompanying editorial, believes that, \"PSA testing detects prostate cancer early in its natural history when it causes no symptoms.\nHowever, since the benefit of PSA screening requires at least 10 years to be borne out, it still seems questionable to test PSA for men over 70, the researchers noted.\nStill, the PSA test remains \"a blunt instrument,\" when it comes to determining the aggressiveness of a particular tumor, Neal said.\n\"Our study has a longer follow-up than previous studies, but shows that in those men invited [to the study], the risk of dying is only half of that in the control group.\nOf the men in the screened group diagnosed with prostate cancer, nearly 79 percent were diagnosed because they took part in the study, the researchers noted.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story did a good job of presenting information about certain aspects of the study. \u00a0Information about the nature of the study (i.e. randomized trial) was included. But the article does not indicate that even 20,000 subjects is a small number for a screening trial and that the 44% risk reduction has a wide confidence interval\u2013the true effect could range from 61% to only 18%. \u00a0 These are questions about the quality of the evidence that should have been mentioned. \n", "answer": 0}, {"article": "She exercised.\n\u201cSomething like this could potentially flatten that curve and change the epidemiology of pancreatic cancer.\u201d\n\nStill, Donahue said, the method needs to be \u201cheavily vetted and validated.\nAnd even if it passes muster, it will take some time before a test could be developed to screen for the disease.\nBut, by good fortune, the protein turns up in exosomes only when there is cancer, so its presence could be an early, and testable, marker for the disease.\nIt is a good example of how this disease sneaks up on people and gives no warning.\u201d\n\nA test for pancreatic cancer could save lives, perhaps even Flippo-Morton\u2019s, Raghavan said.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story earns credit for including skeptical comments from Dr. Wolpin about the limited applicability of the results. He notes that\u00a0\u201cIn this study the patients were known to have cancer or not to have cancer. In this kind of sample sensitivity and specificity tend to look good.\u201d\nBut while those comments are on-target, they come at the very end of the story and feel bit like an afterthought to the strong language throughout the rest of the piece, essentially heralding this test as a possible cure for cancer. The very first sentence says, \u201cWith just a drop of blood doctors may one day be able to detect pancreatic cancer in its early stages, before it has become deadly, a new study suggests.\u201d Then later it says, \u201cBut, by good fortune, the protein turns up in exosomes only when there is cancer, so its presence could be an early, and testable, marker for the disease.\u201d The story even suggests that the test could have saved the life of a prominent surgeon. Such enthusiasm is a bit out of balance with the quality of evidence on display here, some of which\u00a0was based on mouse models. This test is far from ready for use in clinical practice.", "answer": 0}, {"article": "Curcumin is an ingredient found in the common spice turmeric.\nDr. Heng reports her experience using curcumin gel on such injuries using three examples of patients treated after burns and scalds, and provides a detailed explanation why topical curcumin may work on such injuries.\nThe author of the study believes that the effectiveness of curcumin gel on the skin - or topical curcumin - is related to its potent anti-inflammatory activity.\nIn this report, use of curcumin after burns and scalds were found to reduce the severity of the injury, lessen pain and inflammation, and improve healing with less than expected scarring, or even no scarring, of the affected skin.\n\"Curcumin gel appears to work much better when used on the skin because the gel preparation allows curcumin to penetrate the skin, inhibit phosphorylase kinase and reduce inflammation,\" explains Dr Heng.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "There are no caveats in the news release about the research type and quality. The published review was a case series, in which three patients were treated with topical curcumin gel.\nCase series are usually low on the hierarchy of evidence-based research, since they are anecdotal reports and employ no control group to compare outcomes. As a result, they have little statistical validity.\nIn this study, all three patients presented with second degree burns, but they were of various ages and followed up for different times. We also don\u2019t know how these patients were treated for their burns apart from curcumin gel application. The news release suggests that they were given standard treatment for their burns, since \u201cDr. Heng uses curcumin gel for burns, scalds and other skin conditions as complementary treatment.\u201d What standard care were these patients given? And were they all the same? How could these patients\u2019 results be attributed to curcumin gel alone? Might the patients have improved with time without the gel?\nSince the news release does not critically evaluate the evidence, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "The results have not previously been published or presented.\nThis presentation outlines the results from two recently completed phase III trials (TESEC-05 and -06).\nThe impact of age and HIV infection on C-Tb, TST and QFT reactivity was assessed in 1090 individuals with symptoms suspect of TB disease, analysis is ongoing and will be included in the presentation.\nThese phase III trial results demonstrate that C-Tb is safe, has comparable diagnostic performance to QFT-GIT and addresses the problem of false positive TST results in BCG vaccinated persons.\nThe test, known as C-Tb, combines the \"field friendliness of the PPD-based tuberculin skin test with the high specificity of interferon gamma release assays, or IGRAs,\" said lead researcher Morten Ruhwald, MD, PhD, head of human immunology at Statens Serum Institut in Denmark, which developed the test.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The release discusses the results of two phase-3 clinical trials comparing the new C-Tb test against existing tests for tuberculosis. It provides specific numerical data comparing the new and existing tests in several categories, and identifies both the number of sites where the trials were held and the number of participants in each trial \u2014 information that might give readers more confidence in the reported findings.", "answer": 1}, {"article": "They're forgetful,\" Ashare said.\nFinally, the researchers asked the study subjects to do their best to not smoke for seven straight days, a time during which the participants still took either galantamine or a placebo.\nBefore the trial began, researchers assessed the smokers' cognitive function to get a baseline.\nFor both drugs, \"we were able to show a reduction in total nicotine self-administered,\" Schmidt said; however, there was a caveat.\nTwo more assessments took place: after the two weeks on the cigarette-drug combination and again after that initial smoke-free day.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The news release gives a fairly clear description of the study parameters. The study, while small with 33 volunteers, involved giving the still-smoking participants either the drug galantamine or a placebo for two weeks and then asked them to refrain from smoking for one week while on either their prescribed galantamine or placebo. The researchers measured cognitive abilities at baseline and after two weeks on the drug to determine if the drug helped reduce side effects people normally encounter while withdrawing off tobacco.\nThe release is clear that much more evidence will be available, including on overall quit rates (the most important and relevant outcome), when the full study is completed. There is really not much of a take-away at this point as the information is so incomplete.", "answer": 1}, {"article": "They found that compared with the placebo, there was a 27% reduced risk of coronary heart disease, a 28% reduced risk of dying from coronary heart disease, and a 25% reduced risk of coronary \u201cevents\u201d such as a heart attack.\n\u201cOur analysis firmly establishes that controlling LDL over time translates to fewer deaths in this population.\u201d\n\nProfessor Sir Nilesh Samani, medical director at the British Heart Foundation, said: \u201cThis research further demonstrates the benefits of statins for people who have high levels of cholesterol in their blood.\nThe 20-year project examined data from 2,560 men taking part in a randomised clinical trial to test the effects of statins versus a placebo.\nAll the men had very high levels of LDL, or \u201cbad\u201d cholesterol, (higher than 4.9mmol/L) but had no evidence of heart disease at the start of the study.\n\u201cThis legitimises current guidelines which recommend treating this population with statins.\u201d\n\nRay said people with lower levels of cholesterol, around 4mmol/L, who otherwise appear healthy, should also be treated with statins.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story lays out the basic results and methods (e.g. a randomized trial on 2,560 men with high cholesterol), though it doesn\u2019t go much beyond that. What were the limitations?", "answer": 0}, {"article": "Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model \u2013 Growth Pharma.\nDUBLIN, Dec. 12, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the CoolSculpting\u00ae treatment is the first and only non-surgical fat reduction technology to be FDA-cleared for improved appearance of lax tissue in conjunction with submental fat, or double chin, treatments.\n\"A 2017 American Society for Dermatologic Surgery (ASDS) survey revealed that 73 percent of patients are bothered by excess fat under the chin.2 We are pleased this patient concern can successfully be addressed by CoolSculpting through a non-invasive approach, and furthermore improve the appearance of lax tissue in the treated area.\"\nYou should not have the CoolSculpting procedure if you suffer from cryoglobulinemia, cold agglutinin disease, or paroxysmal cold hemoglobinuria.\n1 Data On File Allergan, Inc.; Safety and Efficacy of Cryolipolysis for Non-Invasive Reduction of Submental Fat, 2016\n\n3 Data on File Allergan, Inc.; Study to Evaluate Non-Invasive Subcutaneous Fat Reduction in the Submental Area Using Cryolipolysis, 2015\n\nCoolSculpting is a non-surgical, clinically proven treatment that selectively reduces unwanted fat using a patented cooling technology.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "We don\u2019t know much about the study design from the news release \u2014 only that the clinical trial lasted 18 weeks.\nWe find out more about the quality of evidence from the original journal article, patient safety document and ClinicalTrials.gov entry. This was a multicenter, prospective, open label, non\u2010randomized interventional cohort study. All 60 participants underwent the cooling treatment \u2014 most receiving two cooling cycles \u2014 and were followed up for 12 weeks. According to the original journal article, the study\u2019s primary endpoints included the monitoring of adverse events and the identification of at least 80 percent of the pre\u2010treatment images by three blinded independent reviewers. The journal article also mentioned that chin \u201cfat layer thickness\u201d on ultrasound actually increased in eight subjects.\nOne limitation was there was no control or comparison group in the clinical trial, since everyone received the cooling therapy. This was also a small study with only 60 subjects, with an average age of 49.3 years and a mean BMI of 31.8. Investigators acknowledge another limitation \u2014 namely that chin fat reduction wasn\u2019t quantified on a standardized scale, \u201cthus providing an assessment of the relative clinical improvement.\u201d\nWe would have liked more details like these on the study, which is why we give the news release a Not Satisfactory here.", "answer": 0}, {"article": "Women are also more likely to experience a condition known as left bundle branch block, a pattern of disorganized electrical impulses that responds well when the left side of the heart is treated with a pacemaker.\n\u201cWe think this is the first (study) to show this.\u201d\n\nMoss said women have often been overlooked in studies of heart disease, which until recently were dominated by men.\nIn the latest study, Moss and colleagues explore how much better women did, and why.\n\u201cOur finding was unexpected, but extremely important because this is the only heart treatment that is clearly better in women than men,\u201d Dr. Arthur Moss of the University of Rochester Medical Center, whose study appears in the Journal of the American College of Cardiology, said in a statement.\n\u201cWe found there was a dramatic reduction not only in heart failure events, but a very dramatic reduction in death from any cause,\u201d Moss said in a telephone interview.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "Other than providing the name of the trial (MADIT-CRT) and its source of funding (Boston Scientific) the story provided insufficient information to readers to help them evaluate the quality of the evidence.\nIt is not clear what \u2018a 70% reduction in heart failure compared with a 35% decline in men\u2019 actually means. \u00a0The writer probably meant reduction in heart failure related hospitalizations. \u00a0But without this information the statement is not able to be interpreted.\nThe story went on to mention a \u2018dramatic\u2019 reduction in cause of death from any cause. \u00a0While this seems like a potentially good thing \u2013 how big is a \u2018dramatic\u2019 reduction?", "answer": 0}, {"article": "Treatment usually involves surgical removal of the uterus, known as hysterectomy.\n\u201cHowever, if the surgeon is skilled enough to do the hysterectomy without the robot by laparoscopy then the outcomes will be similar.\u201d\n\nNezhat further noted that while robotic assistance can be a good \u201cenabler\u201d for a minimally invasive approach, surgeons should have at least the basic knowledge of regular laparoscopy too, as there may be times when the robotic equipment doesn\u2019t work.\nFurther, the average number of lymph nodes removed was about the same in the robotic and open procedures, suggesting that both approaches result in about equal surgeon accuracy in staging endometrial cancer.\nOn the other hand, the newness of the technology could have deterred surgeons from using it for difficult cases, potentially biasing the results in a positive way for the robotic technique.\nThe robotic equipment provides better three-dimensional vision, increased range of motion and intuitive, downscaled movements, while adding a few thousand more dollars to the procedure\u2019s price tag, the authors note.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story does include several important provisos in its assessment of the study results. However, we don\u2019t think that it adeqautely describes the methodologic issues associated with the meta analysis. In reality the 8 previous studies were conducted elsewhere with diverse patient populations. Since the studies were observational, it is unclear just how comparable the patiet populations were. For example, patients undergoing an open procedure were older. Age and chronic diseases could have led to the differences seen. An important distinction should have been made concerning blood loss. Although the patients who underwent robot-assisted surgery did, on average, have less blood loss, there was no increase in blood transfusions among the three patient groups. Simply noting less blood loss without speaking to the need for transfusion provides readers with a potentially incomplete view.", "answer": 0}, {"article": "OraVerse is a formulation of a decades-old drug, phentolamine mesylate, which is used to treat severe episodes of hypertension.\nIn the clinical trials there were no serious side effects, Novalar said.\nDr. Papas, an adviser to Novalar and an investigator in its clinical trials, said she thought the drug would appeal especially to those receiving cosmetic dentistry \u201cwho like to look good when they leave the dentist\u2019s office.\u201d\n\nNovalar said its surveys showed great interest in the product among consumers and among dentists, some of whom said they would mark up the price of the drug as a source of profit.\nWith about 300 million anesthesia injections given by dentists each year, company executives say the drug could easily achieve sales of hundreds of millions of dollars a year.\nNovalar said the label of OraVerse would also contain the warnings, but note that OraVerse is given in a different manner.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "Claims about the drug\u2019s effects are based on clinical trials that led to FDA approval. But these reports are unpublished and the studies were conducted by the drugmaker at least in part by paid consultants to the company. So readers are forced to accept the company\u2019s point of view.\u00a0 Without access to the source documents or data, the statements cannot be verified. \u00a0 ", "answer": 0}, {"article": "What to do?\nHowever, the study also found that those risk factors -- a small body frame, a history of fractures, or taking medications that could thin bones -- had only a slight effect on a woman's decision to get her bones tested.\nThe result: Osteoporosis screening rates jumped sharply at age 50, despite guidelines suggesting that screening only begin at age 65, unless a woman has certain risk factors.\nMONDAY, May 25, 2015 (HealthDay News) -- Too few women at high risk for osteoporosis are being tested for the bone-depleting condition, while too many women at low-risk are being screened, a new study suggests.\nOver seven years, more than 42 percent of eligible women aged 65 to 74 were not screened, Amarath's team found, nor were nearly 57 percent of those older than 75.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The original journal article describing this observational study notes that the study has several potential limitations, including unmeasured confounding and possible measurement error (e.g. the researchers may not have identified all women who did in fact receive\u00a0DXA screening, which\u00a0would potentially lead to exaggeration of the extent of\u00a0underuse in older women). The results also came from electronic health records of one medical system, which may not be representative of practices more generally.\u00a0The story describes how the observational study was carried out, but makes no mention of these possible limitations. Consulting an independent expert may have uncovered some of this context.", "answer": 0}, {"article": "Why smokers are more susceptible is not known for sure, but some scientists believe it has to do with smoking-caused damage that allows the bacteria to more easily attach to the lungs and windpipe, said Dr. Pekka Nuorti, a medical epidemiologist with the Centers for Disease Control and Prevention.", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story does not provide any quantitative evidence on which the new vaccination recommendations were based; however, there are no publicly-available data provided by the\u00a0CDC or ACIP to report.\u00a0 The story fails to note this lack of evidence, or question experts on this point. The story does note that smokers are four times more likely to develop pneumonia than non-smokers of the same age.\u00a0 ", "answer": 0}, {"article": ".\nThe researchers will continue clinical studies with the OCT device, looking at other types of solid-state tumors.\nThe study found that the OCT device analysis identified the differences between normal and cancerous tissue with 92 percent sensitivity and 92 percent specificity.\n\"For the first time, this study demonstrates the use of OCT for imaging tumor margins within the tumor cavity, in the patient, during surgery,\" Boppart said.\nDiagnostic Photonics, a start-up company Boppart co-founded that also collaborated on the study, is commercializing the OCT probe technology for broader use.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The release did a pretty good job of noting what the study was designed to do, that ongoing clinical studies will be done, and quoting the investigators as saying the study demonstrates specificity and sensitivity, not that it is ready to replace standard practice at this time.", "answer": 1}, {"article": ".\n\"Whether lifestyle factors can improve survival after diagnosis is an important question for women diagnosed with this more aggressive type of breast cancer.\n\"For women with hormone receptor-negative breast cancer, soy food products may potentially have a protective effect.\nTo provide some clarity, Dr. Zhang and her colleagues looked at the relationship between dietary intake of isoflavones and death from any cause in 6235 American and Canadian women diagnosed with breast cancer.\n\"We now have evidence that soy foods not only prevent breast cancer but also benefit women who have breast cancer.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The release doesn\u2019t mention that this is an observational study and that such studies don\u2019t prove cause and effect.\nThe release would have benefited from more details about the 6,235 women whose data make up the study, such as their ages, cancer stage, ethnicity, and race. Some details about the questionnaire/survey tool, and its strengths or weaknesses would also have been helpful for evaluating the evidence.\nIt would also have been good to know whether the women surveyed were hormone receptor negative and if so, did they consume soy before their diagnosis?\u00a0 How much soy did they consume?", "answer": 0}, {"article": "\"What we found was a very coherent pattern of less cervical cancer among people who\u2019ve used the IUD based on thousands of women \u2014 and the pattern wasn't subtle at all, it was stunning,\" Dr. Victoria Cortessis, the study's lead author and associate professor of clinical preventive medicine at the Keck School of Medicine at the University of Southern California, told BuzzFeed Health.\n\nIUDs are small, T-shaped devices that are placed in the uterus to prevent sperm from reaching an egg. They are a highly effective form of birth control and they can offer protection against pregnancy for up to three, five, or ten years.\n\nThe study is the first of its kind to combine and analyze data from multiple studies to look at the issue. \"We went through all of the relevant human epidemiological data on this topic and narrowed it down to 16 high-quality observational studies of over 12,000 women from all over the world,\" Cortessis says.", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The writer was careful to quote the authors of the study about the limitations of the quality of evidence. This was a synthesis of previously existing evidence, all of which were observational studies. Observational studies can demonstrate that two things are associated, but they don\u2019t prove that one causes another. That is, they can suggest correlation, but not causality. That came across clearly.", "answer": 1}, {"article": "Philadelphia, PA, April 18, 2017 - In the past, all forms of metastatic prostate cancer have been considered incurable.\nLonger follow-up is needed to determine whether these patients were in fact cured.\nSuch results could not have been achieved with any single therapy alone.\nThe authors proposed that this end point may serve as a first step toward establishing a curative paradigm.\nWhile the study is only a first step, one-fifth of the patients treated had no detectable disease, with an undetectable prostate-specific-androgen (PSA) and normal blood testosterone, after 20 months.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The release makes clear that this study is \u201conly a first step,\u201d and clearly describes the study \u2014 including the fact that it involved only 20 patients. The release would have been stronger if it had noted the amount of uncertainty inherent in any study involving such a small number of people \u2014 the study had almost as many authors as patients! The release would have been improved had it noted more directly that this is a small, uncontrolled study, with carefully selected patients.", "answer": 1}, {"article": "However, it was hideously expensive.\nBut it might be possible down the road to combine the nanoparticle treatment with another treatment to replace the damaged tissue in more advanced patients, Miller said.\n\u201cWe know that in rheumatoid arthritis, your joints get attacked, but what we don\u2019t know really well is what specific protein in your joints is being attacked.\nWhat\u2019s great about the approach, Miller says, is that it can be used to treat any autoimmune disease.\nThey\u2019re in discussions with the Juvenile Diabetes Research Foundation to test it in people with type-1 diabetes, and the Myelin Repair Foundation to test it in MS patients, Miller said.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story does an excellent job describing the science involved. The descriptions of the different phases of the research and the attempts to perfect this approach are clearly laid out. The story does mention enough times that the research is being conducted in mice and that human trials are years away, but we think it should have steered clear of some of the broader statements about the treatment\u2019s applicability. Like this paragraph:\nWhat\u2019s great about the approach, Miller says, is that it can be used to treat any autoimmune disease. For diabetes, little bits of pancreatic beta cells could be attached to the nanoparticles. For a food allergy, the part of the food that causes the allergic response could be attached. \u201cYou can try to induce tolerance to peanuts or eggs or shellfish or whatever you are allergic to,\u201d he said.", "answer": 1}, {"article": "\u201cTo me, the take-home message is that we don\u2019t have a perfect test, unfortunately,\u201d Dr. Paik said.\nDr. Soonmyung Paik, who presented the second study at the cancer conference, said the problem might lie not in sloppy testing but rather in the cutoff used to determine which women get Herceptin.\nShe said the findings raised questions of whether women who were Her2-negative should be tested again.\nOn the other hand, he said, many women who are Her2-positive do not benefit from Herceptin.\nDr. Paik, who is with the National Surgical Adjuvant Breast and Bowel Project, said that about 40 percent of women had intermediate levels of Her2.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story mentions the known benefit of Herceptin for women classified as Her2/neu positive\u2013that is a reduced risk of recurrence of about 50%.\u00a0 The story mentions that double the number of women may benefit from Herceptin, but provides no further evidence of long-term benefit or any data comparing Her2/neu negative women with those diagnosed as Her2/neu positive. \nThe story also did not warn readers about reaching conclusions from unpublished data presented at a scientific meeting.\u00a0 See our primer on this topic.\u00a0 ", "answer": 0}, {"article": "Infections are also a problem when doctors put tubes into the body.\n\u201cPreventing one infection will pay for thousands of these screenings,\u201d Dr. Henri Verbrugh of Erasmus, a coauthor of the study, said in a telephone interview.\nThe new study, published in the New England Journal of Medicine, used a rapid test to identify which patients, most of whom were scheduled to undergo surgery, had the bacteria in at least one nostril.\nAlthough his team did not evaluate enough patients to study the problem directly, \u201cWe feel this technology is capable of preventing those types of infections as well,\u201d Verbrugh said.\nThe research team, led by Dr. Lonneke Bode of Erasmus University Medical Center in Rotterdam, estimated that 250 patients would need to be screened to prevent one infection.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The article mentions the large number of subjects, placebo control group, and the peer-reviewed presentation of the data. It implies treatment randomization.\u00a0 \nThe story could have provided a bit more detail on the methods for this study, and more importantly for the second study.\u00a0The accompanying editorial is important in its assessment and should have been discussed more completely in the story. \u00a0The comments in the story relative to the editorial appear to miss the central point: of the two interventions, the use of chlorhexidine-alcohol appears to be preferable for the majority of patients. \nNonetheless, we\u2019ll give the story the benefit of the doubt on this criterion. ", "answer": 1}, {"article": "Wolters Kluwer N.V. (AEX: WKL) is a global leader in information services and solutions for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors.\nThey identified a total of 24 breasts reconstructed by DTI in 19 patients, all with at least 30 days' follow-up and most with one year of follow-up\n\nPatient characteristics and outcomes were compared to those of 109 breasts with TEI reconstruction in 98 patients.\nDr. Moreira adds, \"In appropriately selected cases, DTI reconstruction is a viable alternative to staged techniques requiring multiple surgeries.\"\nThe women undergoing DTI reconstruction were older (73.5 versus 69.2 years) and had a higher body mass index, compared to the TEI group.\nThe researchers believe the DTI technique may expand the options for older women, who are less likely to undergo breast reconstruction.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The news release does well in reminding us this is a retrospective chart review of just one hospital\u2019s experience. The size of the study \u2014 comparing 24 breasts reconstructed by DTI in just 19 patients, with 109 breasts with expander-implant approach in 98 patients \u2014 also limits the generalizability of these findings. With just over 100 patients the study is quite small.\nWe appreciate mention of the fact that DTI is not an appropriate choice for all women (breast size, shape, and other factors come into play).\nThe study mentioned that many of the DTI reconstructions necessitated the use of acellular dermal matrix (a soft tissue substitute that is derived from donated human skin tissue) which has to be considered with regards to risk profile of the patient and whether this is a suitable procedure.", "answer": 1}, {"article": "Another person said of their pet birds: \"If I didn't have my pets I think I would be on my own.\nHe feels this study is important because, although there's a lot of work looking at the benefits of trained therapy animals, they can be expensive and out of the reach of many patients.\nBrooks says, \"Many felt deep emotional connections with their pet that weren't available from friends and family.\"\nSixty percent of the people who considered pets to be a part of their social networks placed them in the central, most important circle \u2014 the same place many people put close family and social workers.\nMany people with serious mental illness live at home and have limited contact with the health care system, says Helen Brooks, a mental health researcher at University of Manchester in the United Kingdom and the lead author on the study, which was published Friday in the journal BMC Psychiatry.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story should have emphasized that\u00a0this was a purely observational study of a small group of people, which means that it is difficult \u2014 if not impossible \u2014 to ascertain the value of pet ownership as a therapeutic practice based on these results.", "answer": 0}, {"article": "That was not statistically significant.\nJanuvia, an oral medication known chemically as sitagliptin that helps lower blood sugar levels, had sales of about $4 billion in 2014, plus another $1.8 billion for the related combination product Janumet\n\nOn the study\u2019s main focus, after about three years 11.4 percent of Januvia patients had experienced cardiovascular death, non-fatal heart attack, non-fatal stroke or hospitalization for unstable angina versus 11.6 percent in the placebo group.\n\u201cWe can be reassured we can use this drug for glucose lowering without affecting the already high cardiovascular risk in people with type 2 diabetes,\u201d said Professor Rury Holman, the study\u2019s lead investigator, who presented the data at the American Diabetes Association meeting in Boston.\nThe Tecos heart safety study was conducted by an independent academic research collaboration between the University of Oxford Diabetes Trials Unit and the Duke University Clinical Research Institute.\nMerck in April said the study, called Tecos, of 14,724 patients with type 2 diabetes and a history of heart disease demonstrated that adding Januvia to usual care did not increase major heart problems any more than adding a placebo, removing a cloud that has been holding back sales of the medicine and the company\u2019s share price.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The study itself was a good design and the story\u2019s description is consistent with the quality of the evidence. So we\u2019ll award a Satisfactory rating, although the story could have been a little clearer about where this evidence was coming from. The story talks about the drug company presenting information, and then information being presented at a conference, and then some data being published in a journal. There\u2019s a big difference between comments made at a conference or in a company press release and findings that were subjected to peer review and published in a journal. We think the reporter had all those facts at hand but that, on deadline, they did not come out clearly in the final piece.", "answer": 1}, {"article": "\"There are many gaps in the evidence,\" Reiss said.\n\"This is a very preliminary study with a small number of subjects and the results are far from conclusive,\" said Dr. Allison Reiss, head of the Inflammation Section at Winthrop-University Hospital in Mineola, N.Y.\n\nShe believes the current study lacks information on possible confounding factors -- things such as \"coexisting illnesses, medications, hydration state, tobacco use and multiple other variables\" that could influence what's found in the saliva samples.\n\"It is uncertain whether the strength and consistency of the relationship between these metabolites [in saliva] and Alzheimer's risk will be maintained in a large multicenter study.\"\nExperts agreed that the findings held promise, but much more research will be needed.\n\"Saliva is easily obtained, safe and affordable, and has promising potential for predicting and tracking cognitive decline, but we're in the very early stages of this work and much more research is needed,\" study author Shraddha Sapkota, a neuroscience graduate student at the University of Alberta in Canada, said in a news release from the Alzheimer's Association.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story does a very nice job pointing to potential weaknesses in the study: \u201d . . . the current study lacks information on possible confounding factors \u2014 things such as \u2018coexisting illnesses, medications, hydration state, tobacco use and multiple other variables\u2019 that could influence what\u2019s found in the saliva samples.\u201d\u00a0\u00a0A second source says, \u201cThere are many gaps in the evidence. It is uncertain whether the strength and consistency of the relationship between these metabolites [in saliva] and Alzheimer\u2019s risk will be maintained in a large multicenter study.\u201d\u00a0 These caveats come half-way through the story and are substantive enough to meet our standard.", "answer": 1}, {"article": "\"Clinical chemistry score versus high-sensitivity cardiac troponin I and T tests alone to identify patients at low or high risk for myocardial infarction or death at presentation to the emergency department\" is published August 20, 2018.\nIn this international study, researchers from Canada, Australia, New Zealand and Germany combined common laboratory blood tests available at many hospitals around the world to create a single laboratory score, or clinical chemistry score, to diagnose heart attack.\nA negative (or low-risk) clinical chemistry score at emergency department presentation missed only one of these events compared with up to 25 missed heart attacks/death when using a high-sensitivity cardiac troponin test alone.\nA positive (or high-risk) clinical chemistry score also identified about 75% of patients at high risk of heart attack or death when positive compared with a low of 40% detected when the high-sensitivity cardiac troponin test alone was positive.\nThe researchers validated the clinical chemistry score as a predictor of heart attack or death within 30 days using data on 4245 patients from emergency department studies in the four countries.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The reader will encounter useful detail about the number of patients, the employment of data from patients whose heart attack outcomes were already determined, the global nature of the effort, and the relatively short-term nature of the design.\u00a0 It would have been useful, however, to have described the three tests that were combined to create the single predictive score.\nAlso, the accuracy of the predictive score depends on which cutoff the investigators use (scores ranged from 0 to 5). Rather than reporting statistics such as sensitivity and specificity to compare tests, it would be preferable to report the area under the receiver operating characteristic (ROC) curve \u2014 a tool researchers use to evaluate and compare the performance of diagnostic tests. However, this was not done in the study. \u00a0They also calculated separate scores based on different high-sensitivity troponin assays.\u00a0 This was not addressed in the news release.", "answer": 0}, {"article": "It's very exciting.\"\nAlthough the experiment involved mice, Melton and other researchers were optimistic that the approach would work in people.\nMelton and other researchers cautioned that many years of research lay ahead to prove whether the development would translate into cures.\nThe experiments, detailed online yesterday in the journal Nature, raise the prospect that patients suffering from not only diabetes but also heart disease, strokes and many other ailments could eventually have some of their cells reprogrammed to cure their afflictions without the need for drugs, transplants or other therapies.\n\"It's kind of an extreme makeover of a cell,\" said Douglas A. Melton, co-director of the Harvard Stem Cell Institute, who led the research.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The results of the study reported on have not been replicated. \u00a0The study was conducted in mice without an intact immune system in a laboratory model of induced diabetes. \u00a0These are two significant factors to consider when thinking about the applicability of the results to humans. \u00a0Further \u2013 as this was a proof of concept experiment, there was no longer term analysis to determine whether there were significant side effects associated with the treatment or whether the treatment had durability. While viral vectors may hold promise, there are considerable difficulties in the application in humans. These points could not have been emphasized enough \u2013 and were not \u2013 not when references to cures and holy grails were included. ", "answer": 0}, {"article": "As with each of our next generation OTC drug products, we intend to license HSRx 2121 to a leading marketing entity that has the resources and expertise to maximize sales, here and abroad,\" Parise said.\n\"Our acne treatment product has enormous commercial potential, evidenced by the significant licensee interest it has attracted.\nThe HSRx product demonstrated superior treatment performance throughout the entire clinical study.\n\"We demonstrated that with HSRx 2121.\"\nInformation is available at \u200eHSRxGroup.com.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "Nice try describing this as a \u2018head-to-head\u2019 comparison and a \u201crandomized controlled trial.\u201d Alas, there is more we don\u2019t know (and need to know!) than what is revealed here.", "answer": 0}, {"article": "We've had a lot of migrants from European nations, so they're fair-skinned ... and we do have a very intense sun here,\" Ziman said.\nFor potential sufferers in remote areas, away from skin specialists, diagnosis can be especially tricky, he said, making a simple blood test an easy alternative to identify those at risk.\n\"We need to know how accurate it is, if it can save lives, and how it could work in practice.\nIn turn people should talk to a health professional about any \"unusual or lasting changes to a mole, freckle or normal patch of skin.\"\nHowever, she stressed the fact this new test has not undergone clinical trials.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story provides a modest amount of information on the study methods and carefully describes the results. The comments of Dr. Moffat place the research in proper context,\u00a0\u201cWe need to know how accurate it is, if it can save lives, and how it could work in practice. So, although a blood test to find skin cancer earlier is certainly exciting, research in this field still has hurdles to overcome\u2026\u201d\nHowever, one important point to make about this level of research \u2014 the scientists were using blood samples from confirmed melanoma patients. Will the blood test\u2019s performance hold up when used widely and only among people with unknown cancer status?", "answer": 0}, {"article": "Obese children and those with diabetes often suffer from fatty liver, a condition normally associated with alcohol abuse but increasingly common among non-drinkers who gain excessive amounts of weight.\nNow, in a paper published Tuesday, he and his colleagues believe they have come up with the definitive evidence that sugar, as Lustig says, \u201cis toxic.\u201d\n\nIn most lab studies, the doses of sugar that scientists test are quite high; they want to see what the effect is quickly and, depending on the research, they may not have time to wait to study the more gradual effects that might emerge.\n\u201cWe know that a healthy diet and weight loss cause good metabolic changes, and although this study tries to attribute its effects to low fructose, in fact it is impossible to do that because of the study design.\u201d\n\nSome experts are concerned for other reasons.\nBut that the rise of the chronic diseases was actually linked to higher sugar consumption is a challenge.\nThis study does hint however, at what might be happening.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story does a fine job of explaining how the study was done and why the evidence it provides is meaningful. It explains that compared with previous research, which was observational in nature and couldn\u2019t prove cause and effect, the new study suggests that cutting out sugar may be causing the beneficial metabolic changes observed. We do have a problem with the story\u2019s framing, however, which frontloads discussion about how important the findings are, while burying discussion of limitations far down in the text. Experts point out some problems with the study, but we think the story could have gone further \u2014 explaining for example that the study was small and time-limited and that it had no control group. Though the story feels slightly unbalanced, we\u2019ll acknowledge that it did make an attempt to critically evaluate the findings \u2014 hence the Satisfactory rating.", "answer": 1}, {"article": "Pneumonia is a leading cause of death for elderly patients, with over 90 percent of pneumonia-related deaths among those 65 and older.\nDisclosures: The basis for this analysis, The Multicenter Osteopathic Pneumonia Study in the Elderly (MOPSE) clinical trial, was funded by a consortium of foundations including the Foundation for Osteopathic Health Services.\nDifferences between treatment groups were evaluated for subgroups of participants based on their age, Pneumonia Severity Index and type of pneumonia.\nBy intention-to-treat analysis of the older subgroup, in-hospital mortality rates were 11 percent lower to the conventional-care only group.\nThe study results published in The Journal of the American Osteopathic Association.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "Here is the category with perhaps the biggest deficiencies. The release is based on a study of subgroup analyses from another already published study and that really needed to have been highlighted in the release. The\u00a0primary outcomes study (mentioned in the introduction of the current paper) found no difference in intention-to-treat analyses (ITT) but some differences in per-protocol ones. (ITT analysis means all patients who were enrolled and randomly allocated to treatment are included in the analysis. Per-protocol analysis is a comparison of treatment groups that includes only those patients who completed the treatment originally allocated.)\nThe authors of the study go to some lengths to discuss the limitations and weaknesses of their findings, explicitly noting that \u201cpossible explanations\u201d for their positive results could include a \u201cphysiologic response to attention and touch,\u201d but also \u201cearly mobilization\u201d created by the need to position the patients for manipulation and also \u201canticipatory belief in the treatment\u201d (a kind of placebo effect). The release also does not offer any explanation as to what mechanisms (physiologic, psychological, etc.) might be responsible for the reported benefits. Nor does it give any description of what the manipulation therapy is composed of. The researchers clearly call for additional research to sort out the \u201cniche\u201d applications of adjunctive osteopathic manipulation, and which patients at highest risk would most benefit. The release, however, quotes the study author as saying\u00a0only that \u201cthis study should encourage physicians to use their osteopathic techniques when treating older patients with pneumonia,\u201d a blanket assertion not supported by the data.\nThe table highlights that no statistically significant differences were found in any intention-to-treat analyses \u2014 the most rigorous ones in a randomized trial. Only in per-protocol analyses do some statistically significant differences emerge. Even there the results don\u2019t fully make sense. Length of stay is lower with OMT in younger patients than those with more severe disease (PSA class IV). This would in some ways seem contradictory.", "answer": 0}, {"article": "New York Eye and Ear Infirmary of Mount Sinai is ranked No.\nThis is the first study to demonstrate that among advanced cancer patients admitted to an inpatient oncology service, standardized use of triggers for palliative care consultation is associated with substantial improvement on multiple quality measures.\n\u201cOur results highlight the need to adopt this practice at acute care hospitals across the nation,\u201d said Dr. Smith.\nPatients were eligible for this prospective cohort study if they met one or more eligibility criteria: advanced solid tumor cancer, prior hospitalization within 30 days, hospitalization for more than 7 days, or active symptoms.\n\u201cPalliative care involvement helps patients understand their prognosis, establish goals of care, and formulate discharge plans in line with those goals, and this study is the first to confirm the impact of using standardized criteria and automatic palliative care consultation on quality of cancer care.\u201d\n\nCo-authors of the study include Kerin Adelson, MD, Division of Hematology/Oncology at Yale University School of Medicine.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "Although the news release includes\u00a0a description of the inclusion criteria for the study and the content of the palliative care consultation, we are given no information about how many patients were involved, what period of time the study took place, or what defined \u201cearly\u201d referral in comparison to the status quo. There\u2019s also no mention that this was an observational study. Observational studies can\u2019t prove cause and effect \u2014 something that was suggested in the headline. Without a brief recap of those issues, readers can\u2019t assess the quality of the evidence.\nThe study listed several limitations that were not included in the release. Among them:", "answer": 0}, {"article": "But they found that the number of children born to a mother did not affect the results.\nA Swedish study suggests yet another health advantage of breast-feeding, this time for the mother: it reduces the risk of rheumatoid arthritis.\nThe community-based approach and the fact that data on breast-feeding was collected before the onset of disease give the study strength.\nAfter controlling for factors including smoking and education level, they found that women who breast-fed for 1 to 12 months reduced their risk of arthritis by 25 percent, and that those who breast-fed for more than a year cut their risk in half.\n\u201cBut even if you breast-feed for a month or two, it makes a difference.\u201d\n\nAlthough the mechanism is not clear, the scientists write that the protective effect may come from long-term changes in the mother\u2019s immune system induced by breast-feeding.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "\nThe news brief describes the methods of the new research in enough detail for readers to accurately infer that it was a case-control study, with results adjusted for factors that might affect the incidence of RA. The story mentions some of the pros and cons of the study\u2019s design as well\u2013the advantages of a \"large community-based approach\" and the fact that \"it is difficult to separate the effect of breast-feeding from childbirth itself.\" However, the story does not mention other limitations inherent in the study\u2019s design that could also undermine the results. Is it possible that the study simply overlooked some other factor(s) that might account for the reduction in RA incidence among Swedish women who breast-feed? Can women accurately recall today the breast-feeding habits of children born decades earlier? Was the study large enough? The new research is suggestive, not definitive\u2014but the news story does not make this sufficiently clear. (See also \"Quantification of Benefits\u2026\" below.)\n", "answer": 0}, {"article": "Traditionally, dentists were taught that the only way to deal with decay was to drill it out.\nThat's still important in some cases, Featherstone says, but without fixing the underlying problem of bad bacteria, patients just keep coming back for more fillings.\nWhen Featherstone put his patients on personal treatment plans, he found the strategy worked.\nBut there are other theories about how fluoride works.\nStriking as these results seem, the concept isn't new.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story portrays the evidence for fluoride\u00a0treatments as clear and convincing, when there are actually just a few studies, and a lot of expert opinion. That\u2019s not to say the experts quoted in the story are wrong, but the story elevates beliefs to the level of evidence-based conclusions.", "answer": 0}, {"article": "Lactoferrin supplementation also enhances the expression of salivary immune proteins, which may help reduce oxidative stress and resulting side effects.\n\"The prevailing symptom described by patients undergoing chemotherapy is a persistent metallic flavor or aftertaste, with or without food intake.\nTheir most recent study builds on the previous body of work through the application of lactoferrin supplements in treating taste and smell abnormalities.\nTheir findings could bring relief to millions of patients undergoing cancer treatment.\nThis research could help us develop TSA-targeted biomarkers and strategies for improving quality of life during chemotherapy.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "Several problems here that aren\u2019t mentioned in the release:\nNot addressing these limitations is a major weakness of this release and, therefore, a huge disservice to readers.", "answer": 0}, {"article": "Breast MRI currently is used to screen women at high risk of breast cancer and as a diagnostic adjunct to mammography.\nThe new approach is not intended to replace current contrast-enhanced breast MRI protocols in general, Dr. Bickelhaupt emphasized, but to expand the spectrum of options available for answering specific clinical questions.\nShould the results hold in larger trials, the model has potential advantages in the clinic beyond its ability to reduce unnecessary biopsies in women with BI-RADS 4 lesions.\nIn an independent test set of 127 women, the radiomics analysis reduced false-positive findings by 70 percent, while detecting 60 of 61 malignant lesions, or 98 percent.\nThe software algorithm makes the assessment reader-independent, ensuring that its accuracy is maintained across different imaging facilities.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "This news release is based on a retrospective study in which a software algorithm was created based on 222 women at two independent study sites who had suspicious mammography findings. The algorithm was then pilot-tested on another 127 cases retrospectively, and found to be effective. Given the very preliminary nature of these findings, the news release is appropriately careful not to over claim benefits. The release does assert that the new technique might cut down on the number of false positive findings, and therefore on unnecessary biopsies. However, it also states that definitive information on that awaits large-scale clinical trials.", "answer": 0}, {"article": "The Ache: Common cholesterol-lowering drugs called statins can have unpleasant side effects, including muscle aches and weakness.\n\nThe Claim: An extract from a bitter, fragrant citrus fruit called bergamot, commonly known as a flavoring in Earl Grey tea, can lower cholesterol with minimal side effects, some scientists say. It also boosts good cholesterol, reduces fatty deposits in the liver and lowers blood sugar, they add.", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "We aren\u2019t told much about how the study was conducted. For example, was it randomized and blinded? Was there a placebo control group?\nThose deficiencies aside, the story did an admirable job of explaining the limitations of existing research and putting the current study in context. Examples:\nOn balance, we\u2019ll rate this satisfactory.", "answer": 1}, {"article": "Master said each participant was asked to carry an accelerometer to record movements and an iPod Touch loaded with an app that would ping them prompts at intervals during each day to report any symptoms they were feeling. They also completed activity questionnaires and summaries. In addition, they wore a device called an ActiGraph to monitor sleep.", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story does state that the study was a pilot and that more research is needed. However, this opening line is a misrepresentation of the research findings and overshadows the more cautionary details: \u201cHave a child healing from a head injury? There\u2019s an app for that, and it may help doctors to improve concussion care.\u201d\nThere is no app publicly available for children healing from a head injury. Only this small group of researchers has access to the tool used in the study. This was a feasibility study to see if the technology worked. It\u00a0remains to be seen if it does anything other than objectively keep track of symptoms.", "answer": 0}, {"article": "Estrogen stimulates the growth of ER+ tumors.\nThe observation was based on a national study launched at 118 hospitals across the United States.\nThe investigation was funded by the American College of Surgeons Oncology Group and led by Dr. Julie A. Margenthaler, an assistant professor of surgery and a breast surgeon at the Siteman Cancer Center at Washington University in St. Louis.\nThe most common form of breast cancer, ER+ accounts for about three-quarters of all breast cancer cases in the United States, the authors noted.\n\"These results will encourage a change in practice across the country so that more women can benefit from the currently underutilized approach of administering estrogen-lowering agents before surgery.\"\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The\u00a0story included no cautionary statements\u00a0about limitations of this study\u00a0or how it should be interpreted. We can think of a couple:\u00a0", "answer": 0}, {"article": "We're sorry, but we seem to have lost this page.", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "Stating that something \"is superior\" and \"is considerably better\" is not quantifying potential benefits. The study itself spends little time on the numbers, but the numbers are there. And the reporter could have asked the authors to go through the numbers. There is no evidence presented that a strategy that starts with MRI\u00a0has better outcomes than a strategy started with a CT. The guideline expert implies that it is obvious. The other doctors question that, but never explicitly in terms of outcomes. That\u2019s where this story really falls short.", "answer": 0}, {"article": "Digital rectal exams can tell a specialist that the prostate is getting bigger, but that happens with normal aging as well as with cancer.\nIf you had precursors such as high grade PIN (prostatic intraepithelial neoplasia) your score was about 38 to 40 and men who had cancer scored about 50 to 55.\u201d\n\nThe test had a specificity of 78 percent, meaning that 78 percent of the men who had cancer indicated by the test actually did.\nThis compares to just 21 percent for PSA alone, the researchers told a meeting of the American Urological Association in San Francisco.\nThe test had a sensitivity of 49 percent, meaning it correctly identified 49 percent of cancers.\nThe Progensa test looks for a genetic material called PCA3.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "\u00a0The information in the story comes from a study presented at the recent meeting of the American Urological Association. \u00a0The story described the sensitivity and specificity of this assay. It indicated the number of men with elevated PSA levels that were studied as well as the percentage that were found to have cancer, though it did not indicate anything about the stage of the cancer. \u00a0\nBut two key points were missing: ", "answer": 0}, {"article": "About the American Urological Association: The 111th Annual Meeting of the American Urological Association takes place May 6 \u2013 10 at the San Diego Convention Center in San Diego, CA.\nFollowing a 13-week efficacy phase, men continued to receive their assigned treatment for up to 52 weeks.\nThe research will be highlighted by study authors during a special press conference to be moderated by Tobias S. K\u00f6hler, MD, MPH, FACS, AUA spokesperson and associate professor of Surgery at Southern Illinois University on May 8, 2016 at 7:30 a.m. PT in the San Diego Convention Center.\nOf the 315 men, 210 were randomized to LPCN 1021 and 105 were randomized to active control.\nThroughout a 52-week study period, a total of 315 hypogonadal men were randomized either to LPCN 1021 or T gel (active control).\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "The release explains that this was a randomized trial based on 315 patients It would have been stronger had it given some more details about the methodology or potential limitations of the study that might help readers evaluate the evidence. It would be helpful to know how many volunteers completed each stage of the study \u00a0Also, the study found\u00a0that average testosterone levels were high in the study group but\u00a0doesn\u2019t mention what the level was in the control group.", "answer": 1}, {"article": "The researchers found a 63 percent response rate in women who received the depression-specific acupuncture, while the response rate was 44.3 percent in the control acupuncture and massage groups.\nAnd, she cautioned, suicidal thoughts are never normal and are a sign that you should seek help.\nBut, she added, because this is the first study of its kind, and the acupuncture protocol used was specifically designed for this study, \"you always need replication of the findings.\"\nThe bottom line, she said, is to talk with your doctor to find the right combination of treatments that can help you.\nDr. Shari Lusskin, director of reproductive psychiatry at the New York University Langone Medical Center, echoed that sentiment.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story does a good job of describing the current study and pointing out its limitations, most importantly, that it was a small study and the first to evaluate this specific form of acupuncture.", "answer": 1}, {"article": "\u201cMy nightmare was that nothing would be different from the placebo group, and there would be nothing of interest to talk about,\u201d he says.\nWe need more studies to see if it really does have benefit and then it could be turned into more effective drugs that can better target Alzheimer\u2019s.\u201d\n\nCorrection: The original version of this story misstated that all the participants were men.\nI think resveratrol is an engaging target that\u2019s very interesting and could be pharmacologically manipulated to develop a treatment.\u201d\n\nMORE: Red Wine Not That Healthy After All, Study Shows\n\nThe resveratrol group showed no change in the levels of a protein that builds up in the brains of Alzheimer\u2019s patients.\nIn what the authors describe as the largest and longest study of resveratrol in people with mild to moderate Alzheimer\u2019s disease, there\u2019s encouraging news that the component, which is found in red wine, grapes and dark chocolate, may keep the disease from progressing.\nThe amounts of resveratrol in the purified doses that the participants took were extremely high and beyond those found on the market currently \u2014 around what would be contained in about 1,000 bottles of red wine.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story does note the size of the study and the maximum dosage that patients received. However, the story doesn\u2019t provide much in the way of critical evaluation of the results. For example, while the story says that \u201cmen who were treated [with resveratrol] showed slight improvements in their ability to maintain certain daily activities on their own, such as dressing and bathing themselves,\u201d it doesn\u2019t mention the fact that the study included five tests that measured patient\u2019s mental processes \u2014 and found slight improvements in only one of them. There was no difference between the resveratrol group and the placebo group on the other four tests.\nSimilarly, the study\u00a0looked at many different measures in the spinal fluid and plasma, as well as many different brain volume measures. And when looking at so many different outcomes, the authors were bound to come out with one or two positive results by chance. So-called \u201ccorrection for multiple comparisons\u201d is designed to address this problem, but wasn\u2019t performed in this study as far as we could see.\nLastly, the point of a phase 2 study is to look at safety, not benefits, but the story never communicated this key limitation or explained the purpose of this type of study. As the paper itself notes: \u201cThis phase 2 study has limitations\u2026.The altered biomarker trajectories must be interpreted with caution. Although they suggest [central nervous system] effects, they do not indicate benefit. A larger study is required to determine whether resveratrol may be beneficial.\u201d\nInclusion of an independent perspective would likely have brought attention to many of these concerns.", "answer": 0}, {"article": "A large, new study may be reassuring to women considering mastectomies because of a history of breast cancer in their families.\n\nStanford University researchers affirmed that women with mothers and sisters who carry one of the BRCA gene mutations but who aren't carriers themselves don't have an especially heightened risk of breast cancer.", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story provides\u00a0the necessary\u00a0details about the\u00a0research and explains one of the reasons why\u00a0the current population-based study\u00a0is considered more reliable than\u00a0previous clinic-based studies which found increased risk in first-degree relatives of non-BRCA carriers.", "answer": 1}, {"article": "\"There were times when I would yell at myself: 'I can't do this.\nRebecca Branstetter, psychologist who blogs at Notes from the School Psychologist, says this dyslexia brain scan could provide useful information, but it doesn't highlight environmental factors -- such as the quality of instruction in the child's classroom -- that could contribute to reading problems.\nAnother important limitation in the study is that some children in the study did receive tutoring or reading interventions, to which they were not randomly assigned.\nThis was another small study -- 20 dyslexic volunteers and 21 participants without the condition -- testing how people identify shapes, navigate a virtual environment, and do other tasks involving spatial reasoning.\nIf made widely available, this kind of brain scan could be an important complement to the assessments -- based on reading and behavior -- already available for diagnosing dyslexia, Hoeft said.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "\n\n\n\nThis story fails to point out that the \u201cchildren\u201d studied were not beginning readers, but teenagers who were already identified as having dyslexia and may have been involved in special reading programs for many years. It also fails to mention several of the caveats and limitations that the researchers noted in their journal article, including the possibility that misclassification of the participants based on their initial testing could affect the results. In other words, rather than actually improving during the study, it is possible some of the teens were actually better readers from the beginning, but just scored low on the baseline tests.\nNevertheless, we rate the story as satisfactory because it appropriately describes this study as helping researchers to understand the disease, rather than evaluating the clinical usefulness of brain scans. Also, one paragraph deep in the story highlights the preliminary nature of the research; specifically that the study included only 25 participants with dyslexia, \u201cwhich is too small a sample size to prove anything.\u201d It also notes that the study did not look at whether different varieties or reading instruction or other interventions might have had some effect and it includes a comment from an independent expert about the lack of data on instruction or other factors that could influence reading ability. The story would have been better if the alert to the preliminary nature of the study had been near the top, rather than buried near the end.", "answer": 1}, {"article": "But the F.D.A.\nDr. Min said in an e-mail message that foam sclerotherapy was \u201cvery safe,\u201d but that \u201cit is associated with higher risks than liquid sclerotherapy.\u201d Foam injections have been blamed as the cause of blood clots in leg veins, he wrote, adding that one known stroke \u201cmay have been caused by foam sclerotherapy.\u201d\n\nBut foam sclerotherapy has been a big relief for some patients.\nBy contrast, he said by e-mail, Asclera \u201cis very safe for skin.\u201d\n\nAn injector\u2019s experience matters, because if the injection misses the vein, (or open sores) can occur.\nBut doctors say they should: these veins are not just a cosmetic problem, but can also lead to aches, pain, and heaviness from blood pooling in the legs.\nOften the concentrations of polidocanol from compounding pharmacies were \u201cwrong\u201d and had \u201clots of contaminants\u201d that could damage the skin where injected, according to Dr. Robert A. Weiss, a dermatologist who directs the Laser, Skin and Vein Institute.\n", "question": "Does the story seem to grasp the quality of the evidence? ", "explanation": "The story doesn\u2019t spend much time discussing\u00a0the complexities of the medical evidence,\u00a0but in its defense, it does make sure to provide specifics regarding which treatments are\u00a0FDA-approved and which are being used off-label. This is in and of itself\u00a0a key indicator of the strength of the\u00a0data supporting different treatments. Still, the story goes a bit off course when it\u00a0compares the effectiveness of different treatments without\u00a0citing any\u00a0data.\u00a0It quotes an expert who says that\u00a0newer, more expensive\u00a0radio-frequency and\u00a0laser treatments are\u00a0\"a heck of a lot better than surgery\u201d for treatment of underlying\u00a0varicose veins. But we\u00a0would expect such an\u00a0assessment from someone who developed\u00a0a laser treatment for varicose veins, as this expert apparently did. What would be more compelling\u00a0is some reference to studies\u00a0showing that these new treatments improve outcomes compared with conventional surgery\u2013but no such information was provided. In fact, recent reviews suggest that while these newer treatments may work as well as surgery in the short term, current studies haven\u2019t followed patients long enough to determine which is more effective over the long term.\u00a0 ", "answer": 0}, {"article": "Dry eye syndrome is a multifactorial disease of the tear film and ocular surface that produces symptoms of ocular discomfort, eyesight disorders, and tear film instability with potential damage to the ocular surface.\nIn this context, the phase III \"Helix\" study is being carried out in more than 30 hospitals in Spain, Germany, Estonia, Portugal, Slovakia and Italy, in 300 patients to evaluate the efficacy of this compound in the treatment of the sign and symptoms of dry eye syndrome.\nSylentis, Pharmaceutical Company belonging to the PharmaMar Group, has presented results from the clinical studies carried out with tivanisiran for the treatment of dry eye syndrome and that has enabled the start-up of the Phase III \"Helix\" clinical trial.\nAmong these, the abstract \"Tivanisiran a new treatment for Dry Eye Disease, that improved signs and symptoms in clinical trials\" (Posterboard number: 925 - B0103) is highlighted, the compound improving the ocular inflammatory parameters, tear quality and a reduction in ocular pain associated with dry eye disease is also underlined1.\nWe currently have a robust therapeutic program in ophthalmology with two candidates under development in Phase II and III studies for glaucoma (bamosiran) and ocular pain (SYL1001) , respectively.\n", "question": "Does the news release seem to grasp the quality of the evidence? ", "explanation": "There is no evidence included in the release, despite the headline that says the drugmaker \u201cannounces the results of tivanisiran for dry eye syndrome.\u201d The release only notes that the drug completed both phase I and phase 2 trials, (for safety and optimum dosage) and that a phase 3 trial is starting.\nThe release doesn\u2019t point readers to any of the earlier trials. It should be noted that these results were reported at a medical conference and have not been peer-reviewed or published in a medical journal.", "answer": 0}]